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The integrity of our genome is constantly threatened by endogenous and exogenous sources of DNA 
damage. The successful repair of DNA lesions is necessary for cellular survival and prevention of 
disease such as cancer. Therefore, complex molecular pathways have evolved to allow for accurate 
and timely DNA repair. It is now well-established that mammalian CtIP (CtBP-Interacting Protein) has 
an important function in DNA Double-Strand Break repair, by promoting the resection of DNA ends in 
preparation for homologous recombination (HR) and micro-homology mediated end joining (MMEJ). 
However, the biochemical basis of CtIP’s critical role in DNA double-strand break repair remains poorly 
understood.  
The aim of this work is to improve our understanding of CtIP’s function in maintaining genomic 
stability. In my thesis I describe the structural and biophysical characterisation of human CtIP and its 
two evolutionarily conserved N- and C-domains that are critical for CtIP function. Sufficient quantities 
of recombinant CtIP were expressed and purified for in vitro analysis. A combination of biophysical 
approaches, including analytical ultra-centrifugation, size-exclusion chromatography and cryo EM, 
were used to probe the oligomeric nature of CtIP. All techniques showed the presence of high 
molecular weight oligomeric CtIP species. 
The N-terminal region of CtIP has been previously shown to be essential for its role in DNA end 
resection, HR and MMEJ. Using X-ray crystallography in combination with small-angle X-ray scattering 
I demonstrate that an extended region of the CtIP N-terminus spanning amino acids 31 to 136 forms 
an elongated parallel helical dimer with coiled-coil segments flanking a central zinc-binding motif. In 
combination with previous crystallographic analysis of the N-terminal tetramerisation motif of CtIP, 
my new structural information allows modelling the overall architecture of the CtIP NTD.  
I have explored the ability of CtIP to bind DNA, via electrophoretic mobility shift assays and 
fluorescence polarisation, to determine the affinity and minimum binding site of its interaction with 
double-strand DNA. Using alanine scanning mutagenesis, I have investigated the zinc-binding ability 
of putative metal-coordination residues within the C-terminal domain. Furthermore, I provide 
evidence for the presence of a coiled-coil region N-terminally juxtaposed to the CtIP-CTD, which might 
mediate its dimerization.  
My findings advance our current knowledge of the biochemical and structural properties of human 
CtIP. They represent a useful contribution to our current efforts to improve our limited understanding 
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Chapter 1, Introduction. 
1.1 DNA and genome stability 
Nucleic acids are the molecular carriers of genetic information. All life forms depend on nucleic acids, 
as the information encoded by their sequence of bases: guanine, adenine, cytosine and thymine, is 
fundamental to an organism’s existence. Not only do they encode the organism’s hereditary 
information, but they encode all the functional and structural characteristics of the cell. Therefore, 
eukaryotic cells devote a vast amount of resources to maintain the integrity of their genomes against 
the ever-present threat of genotoxic agents and processes.  
Deoxyribonucleic acid (DNA) is a highly stable biological macromolecule, which makes it a well suited 
as chemical medium for storage of genetic information. The closely related polymer of ribonucleic acid 
(RNA) is more susceptible to decomposition. This vulnerability can be found where high mutation rates 
are beneficial as, for example, in the small genomes of RNA viruses. Both DNA and RNA are 
constructed with basic building blocks, the nucleotides. The human genome consists of approximately 
3,200,000,000 nucleotides of chromosomal DNA, which undergo an estimate of 100,000 spontaneous 




1.2 Causes, types and risks of DNA damage 
Unwanted damage to the chemical structure of nucleic acids have been a constant threat to faithful 
transmission of genomic information since the very early life forms developed on earth (Kitadai and 
Maruyama, 2018). A DNA lesion is an alteration to the chemical structure of the DNA, affecting a base 
or a nucleotide, or causing a single- or double- strand break (SSB or DSB) in the phosphodiester 
backbone. These lesions or ‘DNA damage’ can have either endogenous or exogenous sources.  
Endogenous DNA damage can occur in many ways such as through spontaneous hydrolysis of the 
purine and pyrimidine bases, replication errors inserting incorrect bases, oxidative metabolism and 
non-enzymatic methylation. Common examples of DNA damage include deamination of cytosine to 
give uracil that, if left un-repaired, would pair with adenine causing a C to T transition, and oxidative 
metabolism that produces reactive oxygen species (ROS) which can yield oxidized bases such as 8-
oxoguanine and damage to the phosphodiester backbone (Hoeijmakers, 2009; Jackson and Bartek, 
2009; Norbury and Hickson, 2001; Valko et al., 2006).  
Exogenous DNA damage can be produced by agents such as genotoxic chemicals or high-energy 
radiation. Solar ultraviolet (UV) radiation is one of the most prevalent forms of environmental DNA 
damaging agents. The UV radiation spectrum ranges from 190-400nm, with the more dangerous UV 
radiation (<280nm) absorbed by the ozone layer; however UV A (315-400nm) and UV-B (280-315nm) 
radiation can produce 10,000 photoproducts such as cyclo-butane pyrimidine dimers per cell per day 
(Hoeijmakers, 2009). In addition, UV radiation can indirectly cause DNA damage through the 
production of ROS within cells (Jackson and Bartek, 2009). Ionizing radiation (IR), such as X-rays, 
generates various forms of DNA damage, for example DNA-protein adducts, base damage, SSB and 
DSB. Among these damage events a DSB is the most detrimental lesion due to the creation of 
unprotected DNA ends. Chemical agents causing exogenous DNA damage can be both the cause and 
treatment of cancers through mutation of coding DNA. For example, polycyclic aromatic hydrocarbons 
and nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone found in tobacco smoke form DNA-
adducts that predispose to lung cancer (Hecht, 1999). However, chemotherapy agents, such as 
anthracyclines can cause apoptosis through excessive DNA damage to treat lung cancers (Cheung-Ong 
et al., 2013; Ciccia and Elledge, 2011). 
Cells have evolved efficient mechanisms to repair DNA and maintain genomic integrity. Failure of 
these mechanisms can lead to detrimental consequences such as various forms of cancer as well as 
developmental and neurodegenerative disease. Furthermore, predisposition to DNA damage can be 
inherited via one of the rare genome stability syndromes, such as Nijmegen breakage syndrome, 
ataxia telangiectasia, Fanconi anemia, Bloom Syndrome, and Werner syndrome (Knoch et al., 2012). 
3 
 
These genetic conditions have proven extremely useful model systems to elucidate the molecular 
mechanisms that preserve genomic integrity in the cell. 
 
1.3 The DNA damage response  
In response to DNA damage, multiple repair mechanisms have evolved that help maintain genome 
integrity and assist in the faithful replication of DNA. A vast network of protein-protein interactions 
and modifications has emerged which sense DNA damage and transduce this information 
appropriately, resulting in the activation of a complex series of lesion type-dependent pathways that 
are collectively known as the DNA Damage Response (DDR). This cellular DDR can lead to changes in 
gene transcription, upregulation of the necessary proteins for repair, cell cycle arrest, or as a last resort 
senescence or apoptosis to ensure damage is not inherited (Ciccia and Elledge, 2011; Jackson and 
Bartek, 2009; Polo and Jackson, 2011). 
 
1.3.1 The eukaryotic cell cycle 
Alongside day to day tasks of routine metabolism the cell must duplicate its genome at an appropriate 
time during its cell cycle and prior to cell division. This process includes a multitude of pathways 
necessary for successful replication of the genome and division into two daughter cells (Tyson and 
Novak, 2008). The cell cycle can be divided into four distinctive phases: gap phase G1, synthesis phase 
S, gap phase G2 and Mitosis M phase. Replication of the genome occurs in S phase with cell division 
occurring in M phase. The two gap phases G1 and G2 allow sufficient time for preparation of the next 
phase in the cell cycle. Cells require a period of growth to ensure they are metabolically active before 
they can pass the G1-S phase checkpoint (also known as restriction point) and start DNA synthesis. 
Throughout S-phase cells are replicating their DNA so that each chromosome gives rise to two sister 
chromatids that are held together by cohesion factors. Following S-phase, a further gap phase G2 
ensures the cells have enough time to complete DNA synthesis and repair of each chromosome and 
are ready for cell division. As all sister chromosomes are available in G2 Homologous Recombination 
can now take place to repair complex breaks.  Once cells enter M phase chromosomes are bound via 
kinetochores to spindles at opposite poles and become aligned along the metaphase plate. Following 
correct segregation new nuclei begin to form at opposite sides of the original cell and cells can undergo 
cytokinesis to form two daughter cells, each with an exact copy of the parental cell’s DNA. 
This entire process is tightly controlled by restriction checkpoints at various stages of the cell cycle. 
The G1-S phase checkpoint is arguably the most critical as it separates the post-M from the pre-S 
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interval. Passing this checkpoint is necessary to continue to replicate. At this point cells can either 
commit to a further round of replication entering S-phase, or can withdraw from the cell cycle into G0 
phase whereby they do not replicate their DNA and become senescent (Zetterberg et al., 1995). Cell-
cycle checkpoints are highly conserved among eukaryotes and depend on the activity of cyclin-
dependent protein kinases (CDKs) in cooperation with their binding partner cyclin. The abundance of 
CDKs remains constant throughout the cell cycle. However, two main processes have evolved for 
regulation of CDK activity: binding to different cyclin partners to target different protein substrates 
and post-translational phosphorylation to control activity. The levels of cyclin expression are 
dependent on the cell stage, with their rate of transcription and degradation controlling the 
abundance. This process allows activation of different cyclin CDK complexes to mediate the cell cycle 
stage. For example, the Cyclin E CDK2 complex is activated for entering S-phase, however this is 
inhibited during M-phase with Cyclin B CDK1 activated to control mitosis (John et al., 2001; Murray, 
2004). Further counteracting proteins are involved in controlling the activity of CDKs; Wee1-like 
kinases cause inhibitory phosphorylation on a CDK’s activation loop, while Cdc25 can dephosphorylate 
and reverse the inhibitory effect. Further control is through the CDK-activating kinase (CAK), which on 
phosphorylation allows full CDK activity (Coleman and Dunphy, 1994; Morgan, 1995).  
 
 
In yeast S. cerevisiae and S. pombe, where a lot of the original CDK research was performed, only one 
CDK is present to control the cell cycle checkpoints. In contrast, humans have at least 10 members of 
the CDK family: CDK1, 2, 4 and 6 are known to be involved in cell cycle control with 4 different cyclins 
Figure 1.3.1: The Eukaryotic cell cycle. The Eukaryotic cell cycle contains four phases, G1, S, G2 
and M. Progression through the cell cycle is governed by the checkpoint controls in normal 
cells. Cells can exit the cell cycle into G0 or by becoming senescent.  
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A, B, D and E (figure 1.3.1) (Cooper, 2000; Meyerson et al., 1992). Further control of CDK activity comes 
from proteins which inhibit cyclin-CDK complexes and in some cases activate others (Besson et al., 
2008). The cyclin-CDK complexes are also a target for cancer treatment as checkpoint inhibition can 
lead to apoptosis, which will be discussed later in this section. 
 
1.3.2 DNA-damage induction of cell cycle checkpoints 
DNA damage can elicit a rapid and sensitive response to slow or even arrest cell cycle progression. 
Checkpoints are therefore a constant surveillance mechanism for stress and DNA damage, as incorrect 
decision making and repair can potentially lead to uncontrolled cell proliferation and cell death, 
especially in the context of the most genotoxic lesions, DSB. While many lesion-specific responses for 
DNA repair exist, they all activate common checkpoint pathways with the goal to maintain CDK 
activation until the lesion is removed. This response can be detailed by four components: the sensors 
(such as ATM and ATR), mediators which amplify the detection (such as BRCA1, 53BP1 and MDC1), 
the transducers (such as Chk1 and Chk2) and the effectors (such as p53 and Cdc25) (Barnum and 
O’Connell, 2014; Sancar et al., 2004). The simple checkpoint activation pathway leads from sensors 
detecting DNA damage and abnormalities that need repairing through mediators to relay the signal to 
the transducers. Transducers can then regulate the effectors that directly control and inhibit the cell 
cycle progression to allow sufficient time for repair of the DNA lesion. These pathway stages, however, 
can be attributed to a single protein acting at several levels: for example ATM can act as a sensor, 
mediator and transducer of DNA damage with multiple roles within a checkpoint response (Barnum 
and O’Connell, 2014; Sancar et al., 2004).   
 
1.3.3 ATM and ATR activation by DNA damage 
Protein complexes exist to transduce alterations in the DNA in the initial stages of sensing DNA 
damage (Harper and Elledge, 2007). Of these, Ataxia-Telangiectasia Mutated (ATM) and ATM and 
Rad3 Related (ATR) are two of the most studied early sensors/mediators of the DNA damage. They 
belong to the family of phosphatidylinositol-3 kinase-related serine/threonine kinases (PIKK) which 
also includes mammalian target of rapamycin (MTOR), suppressor of morphogenesis in genitalia 
(SMG1) and DNA-dependent protein kinase catalytic subunit (DNA-PKcs). Functions of the PIKK family 
span a wide range of pathways including cell survival and metabolism (Weber and Ryan, 2015); the 
function of ATM and ATR within the DNA damage response will be discussed here.  
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In humans, the Ataxia telangiectasia (AT) syndrome led to the discovery of the protein ATM (AT 
mutated), with AT patients showing symptoms of immunodeficiency, cancer predisposition, 
neurodegeneration and genome instability, which are strongly linked ATM to genomic maintenance. 
Cells that lack ATM fail to respond to DNA damage induced by IR, with documented absence of 
checkpoint activation (Bakkenist and Kastan, 2003). ATR was first identified via analysis of the human 
genome database by sequence similarity with ATM and S. pombe Rad3 (Cimprich et al., 1996). In 
contrast to ATM, gene disruption of ATR has been shown to be embryonically lethal in mice with 
partial loss of function causing severe phenotypes, indicating non-redundant activities of ATM and 
ATR (Brown and Baltimore, 2000; de Klein et al., 2000; O’Driscoll and Jeggo, 2006). 
ATM is well known as the pivotal activator of the DNA damage response on detection of a DSB, 
orchestrating a global response including checkpoint activation, DNA repair, senescence, apoptosis 
and changes to chromatin structure and transcription (Shiloh and Ziv, 2013). With such a wide range 
of responses, the activity of ATM must be tightly regulated to abate spurious activation. In un-
perturbed cells ATM remains in an inactive state, trans-dimerised via its kinase domain. Upon DNA 
damage caused by IR, ATM is at the forefront of the detection with rapid recruitment and activation 
upon DSB formation (Giunta et al., 2010; Lee and Paull, 2005). Although originally this highlighted ATM 
as a sensor of DNA damage, more recent evidence shows that the MRN complex (Mre11, Rad50, and 
Nbs1) and Ku (Ku70-Ku80) are the sensors of the DSB subsequently recruiting ATM for activation, 
providing another level of ATM regulation  (Blackford and Jackson, 2017).  
Although this area is still widely debated, a complex interplay between sensors and activation has 
become apparent. Mice knockout studies using the Cre/LoxP recombination system have shown 
compensation between the MRN and Ku70/Ku80 recruitment pathways with activation of ATM in the 
absence of MRN or Ku70/Ku80 (Hartlerode et al., 2016). ATM has also been shown to have MRN/DSB 
independent methods of activation in response to oxidative stress or chromosome changes (Blackford 
and Jackson, 2017).  
The exact method in which recruitment activates ATM is however yet to be fully understood. It has 
been shown that intramolecular phosphorylation of ATM disrupts the dimer allowing activation 
(Bakkenist and Kastan, 2003). In vitro kinase assays have also shown activation of ATM by MRN using 
purified components, stimulating the kinase activity towards its substrates (Lee and Paull, 2005), with 
the potential for a positive feedback loop to reinforce ATM activation (Kaidi and Jackson, 2013). 
After recruitment and activation, ATM acts upon its numerous targets including BRCA1 (Cortez et al., 
1999), CtIP (Li et al., 2000), and itself (Bakkenist and Kastan, 2003) to bring about cellular changes. The 
first target at a DSB damage site is the C-terminal tail of the histone variant H2AX; the phosphorylated 
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H2AX binds MDC1 (mediator of DNA damage checkpoint protein-1) leading to further MRN 
recruitment (Lloyd et al., 2009). A cascade of recruitment follows with MRN bringing further ATM to 
amplify the formation of γ-H2AX (Harper and Elledge, 2007). This amplifies the signal ensuring 
recruitment and maintenance of proteins such as MRN, BRCA1 and 53BP1 at the damage site (Stucki 
and Jackson, 2006). This activation is summarised in figure 1.3.3. More recently, the activation of ATM 
by MRN has been shown to phosphorylate the MRN complex to control the extent of break resection 
and formation of ssDNA (Kijas et al., 2015; Lavin et al., 2015). Notably ATM also phosphorylates kinases 
such as Chk2 (Matsuoka et al., 1998) and MAPK (Mitogen activated protein kinase) (Vanesa Lafarga et 
al., 2009) to act on yet more substrates (Shiloh and Ziv, 2013).  
One such substrate is the tumour suppressor protein p53. p53 Can be indirectly activated through the 
MAPK pathway as well as through ATM phosphorylation of MDM2 (Mouse Double Mutant -2) and p53 
co-factors (Blackford and Jackson, 2017; Shiloh and Ziv, 2013). At the same time, ATM can 
phosphorylate p53 on multiple sites to stabilise the protein by resistance to MDM2 degradation 
(Ashcroft et al., 1999; Banin et al., 1998; Canman et al., 1998). Together, all these actions of ATM 
orchestrate global cell changes to activate cell-cycle arrest and allow time for DNA repair. 
In contrast to ATM, ATR acts as the pivotal kinase during replication stress and is activated by a much 
larger variety of genotoxic stress, primarily UV radiation and replication inhibitors (Ward et al., 2004). 
ATR has been shown to be recruited to extended tracks of ssDNA, which occur from nucleolytic 
processing of various forms of DNA damage including DSBs or by uncoupling of the helicase-
polymerase complex at replication forks (Byun et al., 2005). Both of these events cause rapid coating 
of the ssDNA by Replication protein A (RPA) which then recruits ATR via its ATR interacting protein 
(ATRIP) subunit (Zou and Elledge, 2003). Studies using Xenopus egg extracts have shown that the 
depletion of RPA completely inhibits the chromatin association of ATR; ATRIP was  also shown 
necessary for controlled recruitment of ATR to RPA (Zou and Elledge, 2003). However, recruitment of 
ATR is insufficient for optimal activation, with further proteins being necessary, such as TopBP1 
(topoisomerase binding protein 1) which is a crucial activator of ATR (Kumagai et al., 2006). As with 
ATR, loss of TopBP1 or inability to activate ATR has been shown to be lethal in mammalian cells (Jeon 
et al., 2011; Zhou et al., 2013). The interaction between ATR-ATRIP and TopBP1 is also necessary to 
supress new origin firing (Sokka et al., 2018). Potentially overlapping mechanisms exist for recruitment 
of TopBP1 to ATR that implicate factors such as MRN and Bloom syndrome protein (BLM) (Blackford 
et al., 2015; Duursma et al., 2013). Thus, a prominent pathway for recruitment of TopBP1 and 
activation of ATR consists of the RPA-ssDNA binding, interaction with the RAD17-RFC (replication 
factor C) clamp loader complex (Zou and Elledge, 2003) and the 9-1-1 (RAD9-HUS1-RAD1) 
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heterotrimer (Delacroix et al., 2007); TopBP1 is then recruited through sequential binding and 
interactions with the C-terminal tail of RAD9, leading eventually to activation of ATR (figure 1.3.3).   
Like ATM, ATR has many phosphorylation targets. Some of the targets overlap, such as MRN which 
acts both up- and down-stream of ATR activation. For example, DNA-end resection by MRN causes 
recruitment of RPA leading to ATR activation; however, replication fork stalling following UV 
treatment causes ATR-mediated MRN phosphorylation to down regulate DNA replication (Olson et al., 
2007). On activation, a key ATR function is to phosphorylate and activate the protein kinase Chk1, as 
shown to occur in Xenopus egg extract studies through the mediator protein Claspin (Kumagai et al., 
2004). As demonstrated by mutational analysis, Chk1 is an essential kinase required for the G2/M 
checkpoint passage (Kumagai et al., 2004). On activation, Chk1 promotes proteasomal degradation of 
CDC25, a protein responsible for removing inhibitory phosphorylation events on CDKs. Thus, reducing 
CDK activity slows down or arrests cell-cycle progression, allowing time for DNA repair (Bartek et al., 
2004), as well as inhibiting further late-origin replication firing and increasing the pool of nucleotides 
available for replication (Blackford and Jackson, 2017). Although many of the signalling events in the 
DDR rely on phosphorylation, other post-translational modifications also play a key role such as 
sumoylation, ubiquitination, acetylation, and methylation (Harper and Elledge, 2007; Polo and 
Jackson, 2011).  
With ATM and ATR’s pivotal roles in the DNA damage response, it is not surprising that a lot of research 
is underway focusing on ATM and ATR as possible targets for cancer treatment. Targeting and 
inhibiting the transduction signalling would inhibit propagation of the repair signal, therefore 
sensitizing cells to DNA damaging agents such as IR in combination therapy. Pre-clinical experiments 
suggest that inhibition of both proteins can selectivity sensitise cancer cells to radiation or 





Figure 1.3.3: Schematic representation of ATM and ATR activation. Blue represents the sensor, 
green represents either ATM or ATR-ATRIP, with pink representing the mediator of activation. 
Yellow arrows indicate phosphorylation events with phosphates in red. 
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1.3.4 The ATM/ATR checkpoint signalling cascade 
Interplay between the DDR and cell cycle machinery results in distinctive signalling in response to DSBs 
in different stages of the cell cycle for checkpoint activation and recovery back into the cell cycle. Once 
activated, ATM and ATR phosphorylate a multitude of proteins including those with roles as 
checkpoint mediators such as BRCA1, 53BP1, MDC1 and claspin. Direct or indirect phosphorylation of 
the checkpoint transducers Chk1 and Chk2 by ATM and ATR respectively is followed by a further 
cascade of events, with effectors such as CDC25 and p53 leading to cell cycle arrest (figure 1.3.4) 
(Blackford and Jackson, 2017; Sancar et al., 2004). Details surrounding the G1-S, intra S and G2-M 
phase checkpoint activation by ATM/ATR will be briefly described in the following section. 
 
Figure 1.3.4: ATM and ATR activated checkpoint pathways. 
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1.3.4.1 G1-S phase checkpoint  
In the context of DSBs, ATM is the activator of the G1-S checkpoint. During the G1 phase the main 
repair pathway is Non-Homologous End Joining (NHEJ) which has insufficient DNA-end resection to 
activate ATR (Cortez et al., 2001; Jazayeri et al., 2006). Conversely, small-molecule inhibition of ATR 
has been shown to allow early entry into S-phase with DNA damage present, implying that ATR still 
has an important function in G1-S checkpoint (Bøe et al., 2018). After detection of DNA damage, Chk1 
and Chk2 phosphorylate the CDC25A phosphatase, which through binding to 14-3-3 is sequestered to 
the cytoplasm and unable to activate Cyclin E- CDK2 and therefore maintains cells in G1-phase (Chen 
et al., 2003). 
Activation of ATM/ATR, Chk1/Chk2 leads to phosphorylation and stabilisation of p53, which in turn 
lead to transcription of a wide variety of targets including p21, a CDK inhibitor protein (Harper et al., 
1995; Wade Harper et al., 1993). P21 inhibits the S-phase promoting Cyclin E-CDK2 thus maintaining 
G1 arrest, along with inhibition of cyclin D-CDK4/6 preventing phosphorylation of Retinoblastoma 
(RB). Both targets are crucial to progression into S-phase. Un-phosphorylated RB remains bound to 
the E2F transcription factor preventing transcription of S-phase genes for the G1-S phase transition 
(Sancar et al., 2004). This process has been reported to oscillate in waves of ATM, p53 and p21 
activation until the DSB is resolved, allowing the cell a simple pathway for progression and removal of 
the cell cycle arrest on DNA repair (Batchelor et al., 2009). Conversely, when the DNA damage is too 
severe ATM activation of the MAP kinase family leads to a slower transcriptional response; this allows 
stabilisation of p21’s mRNA to sustain the cell cycle arrest (V. Lafarga et al., 2009; Reinhardt et al., 
2007).   
1.3.4.2 S-phase checkpoint  
While ATM checkpoint activation occurs in S-phase the main checkpoint activator is ATR. Once 
replication has been initiated by CDK2, a DSB can trigger activation of ATR through end resection of 
the DNA during Homologous Recombination (HR) repair. As mentioned earlier, resection of DNA 
exposes ssDNA, which through RPA activates ATR, mediating enhanced downstream checkpoint 
signalling to allow time for HR repair. Genotoxic stress can also arise from other forms of DNA damage 
causing replication forks to stall, thus also activating ATR, with the need to inhibit further origin firing. 
Alongside the actions of ATR to further stabilise p53 and the p21 pathway a further protein is involved, 
the Wee1 kinase. Wee1 is phosphorylated by Chk1 and Chk2; phosphorylation activates the kinase to 
phosphorylate CDK2 and inhibit its activity (Beck et al., 2010). During S-phase p21 acts at DSBs. 
However, due to its role in origin licencing it is degraded at the replication fork by the proliferating cell 
nuclear antigen (PCNA) associated CRL4cdt2 ubiquitin ligase to inhibit detrimental re-replication (Y. Kim 
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et al., 2008). ATR also targets the Fanconi Anaemia (FA) pathway, responsible for inter-strand crosslink 
repair, by phosphorylating proteins FANCI and promoting FANCD2 mono- ubiquitination, which are 
key steps in the pathway activation (Ishiai et al., 2008). 
1.3.4.3 G2-M phase checkpoint 
The G2-M checkpoint is crucial for preventing cells from entering mitosis in the presence of damaged 
DNA. In M-phase the DDR is potently inhibited (Shaltiel et al., 2015). DNA damage sustained in this 
phase activates ATM but the signal is not transmitted to activate Chk2 (Giunta et al., 2010). Therefore, 
cells must ensure entrance into M-phase is delayed in the presence of DNA damage. The Wee1-
dependant pathway of CDK inactivation remains important in G2 phase alongside a second kinase 
MIK1 which acts on the same site in CDK1 enforcing the inactive state (Baber-Furnari et al., 2000; Hirai 
et al., 2009). Similar to the previous two checkpoints, via ATR and ATM, Chk1 and Chk2 phosphorylate 
CDC25C leading to its exclusion from the nucleus and inability to dephosphorylate Cyclin B-CDK1 
(Graves et al., 2001; Lopez-Girona et al., 1999). The actions of p21’s present in G1 can now also be 
reinstated as replication has completed, and transcriptional control of p21 through ATM and the MAP 
kinase pathway can again cause sustained arrest (Bunz et al., 1998). In G2 phase, p53 can also play a 
further role through transcriptional expression of GADD45 (growth arrest and DNA damage-inducible 
gene 45α), which disassociates the cyclin B-CDK1 complex. In G1 the action of GADD45 does not cause 
arrest due to inefficient inhibition of the cyclin E-CDK2 complex (Jin et al., 2000; Zhan et al., 1999). In 
further contrast to G1, DSBs can now be faithfully repaired by HR due to the presence of the sister 
chromatid. Therefore ATR is activated in G2 and can maintain cell cycle arrest (Brown and Baltimore, 
2003). Inhibition of HR repair proteins BRCA1 and PALB2 cause premature M-phase entrance, 
highlighting the importance of HR and ATR activation for G2 arrest (Menzel et al., 2011). Knockdown 
of mediator proteins such as 53BP1 and MDC1 also show a similar response as ATM activation at DSBs 
is not sustained (Shibata et al., 2010). Recovery from cell cycle arrest is a fine balance to avoid DNA 
damage persistence while avoiding senescence or apoptosis. Late activation of G2 arrest can also 





1.3.4.4 BRCA1 and CtIP in checkpoint pathways 
Alongside proteins such as Chk1, Chk2 and p53 many other proteins are activated in the G1-S, S and 
G2-M DNA damage checkpoints. BRCA1 is an example of a protein phosphorylated at several sites by 
ATM, Chk2 and ATR, which leads to a cellular checkpoint response (Roy et al., 2011). In particular Chk2 
phosphorylation of BRCA1 is required for the CtIP/MRN/BRCA1 complex formation to activate the 
G2/M checkpoint (Greenberg et al., 2006). Downstream of H2AX phosphorylation by ATM, BRCA1 has 
also been reported to be retained at chromatin resulting in the activation of Chk1 and the G2-M 
checkpoint (Huen et al., 2010). Studies have also shown the BRCA1/CtIP complex is necessary for ATR 
activation downstream of ATM, likely due to the role of CtIP in DNA-end resection (Sartori et al., 2007; 
Yu et al., 2006). BACH1 binds to the same site on BRCA1 as CtIP with the two interactions being 
mutually exclusive, forming the BRCA1 BARD1-BACH1-TopBP1 complex. This second complex has been 
shown to play a checkpoint regulatory role critical for the S-phase checkpoint activation (Greenberg 
et al., 2006). On IR or UV treatment the CtIP-BRCA1 interaction is necessary for the ATR/ATM 
dependant phosphorylation of Chk2, p53 and Nbs1, and downstream activation of P21 and GADD45 
(Foray et al., 2003; Li et al., 2000, 1999). BRCA1 has also been shown to induce apoptosis by playing a 
role in regulation of anti-apoptotic and pro-apoptotic factors in response to DNA damage:  
upregulation of BRCA1 facilitates stress-induced apoptosis in cancer cell lines and increases 





1.3.5 DNA damage induced apoptosis and its therapeutic potential 
DNA repair defects, alongside irreparable, or intolerable DNA lesions threaten the genome stability of 
an organism. Programmed cell death, termed apoptosis, can be induced by DNA damage or natural 
processes to mitigate the effects of these events throughout the cell cycle. The main process of 
apoptosis involves activation of caspase (cysteine aspartyl protease) 3 leading to irreversible DNA 
fragmentation and apoptotic body formation (Elmore, 2007; Norbury and Hickson, 2001). Caspase 3 
can be activated by external signalling through DEATH receptors or through an internal shift between 
pro- vs anti-apoptotic factors leading to the release of cytochrome C from the mitochondria and 
caspase 3 activation (Elmore, 2007; Fulda and Debatin, 2006; Wajant, 2002; Wang and El-Deiry, 2003).  
The DDR is directly linked to apoptosis through p53 (Reinhardt and Schumacher, 2012). Sustained p53 
activation directly activates transcription of pro-apoptotic genes while suppressing anti-apoptotic 
protein activity (De Zio et al., 2013; Elmore, 2007). Apoptosis can also occur through Chk2 via two 
pathways: E2F-1 transcriptional regulation of apoptotic factors and phosphorylation of PML 
(promyelocytic leukaemia) to promote pro-apoptotic activity (Stevens et al., 2003; Yang et al., 2002). 
Activation of p21 and p16 by p53 can also cause senescence. Senescence is a more permanent form 
of cell cycle arrest which also protects the organism during genotoxic stress (Althubiti et al., 2014). 
The balance of apoptosis is a key factor in many human conditions including autoimmune disorders, 
neurodegenerative diseases and many types of cancer. However, the ability to modulate apoptosis 
has great therapeutic potential. Inhibition of the cell cycle checkpoints can lead to cells progressing to 
mitosis with damaged DNA causing mitotic catastrophe and cell death, selectively targeting replicating 
cells (Bouwman and Jonkers, 2012; Curtin, 2012). Inhibition of the cyclin-CDK complex is therefore a 
target for cancer treatment. In 1992, Flavopiridol was the first wide range CDK inhibitor shown to act 
as an anti-cancer agent, however with toxic side effects (Sausville, 2002; Visconti et al., 2016). More 
recently, selectivity for CDK4/6 to cause G1-phase arrest has been achieved with palbociclib, approved 
for the treatment of advanced breast cancer (Finn et al., 2015; Pernas et al., 2018). 
Chemotherapeutic modulation of DNA repair pathways can also lead to apoptosis. Synthetic lethality 
can be employed when cancer cells are deficient in a DNA repair pathway. This is apparent by the 
sensitivity of BRCA-deficient tumour cell lines to PARP (poly ADP-ribose polymerase) inhibition, 
specifically targeting tumour cells to apoptosis, while the cells with intact BRCA1/2 pathways can 
repair the DNA damage (Audeh et al., 2010). Knowledge of how the different pathways act, interact 
and overlap can lead to further advances within the chemotherapeutic field and our understanding of 
human disorders. Research into DNA repair is therefore vital with the current understandings of the 
pathways discussed within the next sections of this thesis.    
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1.4 DNA Repair pathways  
The first experimental evidence of what was DNA repair emerged in 1949 from observations made by 
Albert Kelner, who at the time was using UV radiation to generate mutations in bacteria. Kelner noted 
highly increased rates of survival when the irradiated bacteria were exposed to visible light (Kelner, 
1949). At the same time, Renato Dulbecco discovered the phenomenon of photoreactivation in 
bacteriophage (Dulbecco, 1949). The correct interpretation of Kelner and Dulbecco’s findings as a 
biochemical pathway for the repair of DNA photoproducts had to wait for the recognition of the DNA 
double helix as the chemical basis of genetic heredity in 1953, and the subsequent isolation of 
photolyase, the enzyme that catalyses photoreactivation in 1958 (Rupert et al., 1958). In 1974, Francis 
Crick wrote: “We totally missed the possible role of enzymes in repair, although, due to Claud Rupert's 
early very elegant work on photoreactivation, I later came to realize that DNA is so precious that 
probably many distinct repair mechanisms would exist.” (Crick, 1974). By the 1960s, DNA repair had 
become an important and established field of research in molecular and cellular biology (Friedberg, 
2008).  
There are many different pathways of DNA repair, which are specific for the different types of DNA 
damage. In 2015, Tomas Lindahl, Aziz Sancar and Paul Modrich shared the Nobel Prize for Chemistry 
for their discoveries of Base Excision Repair (BER), Nucleotide Excision Repair (NER), and Mismatch 
Repair (MMR) respectively, which form the main pathways for repair of single-strand DNA lesions. 
Whereas DNA repair by direct reversal requires a single enzyme, NER, BER and MMR have multiple 
steps involving excision of the damaged region, insertion of new nucleotide(s) and ligation to complete 
the repair process (Clancy, 2008; Friedberg, 2008). Although the underlying mechanistic principles are 
similar and involve a sequential cascade of enzymatic steps, separate sets of proteins are at play in 





1.4.1 Direct Reversal 
The first historical evidence of DNA repair can be explained by the repair mechanism of enzymatic 
photo-reactivation (EPR) which is also believed to be the first DNA repair mechanism to have evolved 
(Friedberg et al., 2005). Cyclobutane pyrimidine dimers are known to be one of the most common 
effects of UV radiation and have the potential to block both replication and transcription of DNA. They 
can however be repaired by DNA photolyases which utilise the energy of blue light to split the 
cyclobutane ring, thus directly reversing the DNA damage.  
Another example of direct reversal is repair of alkylation affecting either the aromatic base or DNA 
backbone. The first example of base alkylation is N3-methyladenine which can block replication and is  
removed directly by 3-methyladenine-DNA-glycosylases restoring the natural adenine base (Borja-
Cacho and Matthews, 2008). Another example is that of O6-methylguanine which incorrectly pairs 
during replication with thymine rather than cytosine and is therefore mutagenic. This lesion can be 
exploited in chemotherapy using the drug Temozlomide to generate O6-methylguanine in replicating 
cells; only a single round of treatment can be performed due to drug resistance from enhanced activity 
of O6-methylguanine-DNA-methyltransferase (MGMT) which directly reverses these lesions (Abbott 




1.4.2 Base Excision Repair 
Base modifications are one of the most common forms of DNA lesion, accounting for thousands of 
DNA damage events per human cell per day (Hoeijmakers, 2009). Base Excision Repair (BER) has 
evolved to cope with the high level of spontaneous DNA damage from oxidation, deamination and 
alkylation. Although there is little distortion to the structure of the DNA helix, the damage can be 
recognised by DNA glycosylases that cleave the N-glycosidic bond between the damaged base and the 
ribose of the sugar-phosphate backbone, leaving an apurinic/apyrimidinic (AP) site for further 
processing. At least 11 distinct mammalian DNA glycosylases are known, each recognising a subset of 
base lesions with partial overlap between the enzymes. After generation of an AP site the repair can 
be completed by one of two pathways: Short-Patch (also known as single-nucleotide) BER or Long-
Patch BER; the latter replaces between 2 to 13 nucleotides (Fromme and Verdine, 2004; Kim and 




Figure 1.4.2: A schematic drawing of the Short-patch and Long-Patch Base Excision Repair (BER) 
pathways for repair of DNA base lesions. 
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Short patch BER is generally the dominant pathway in replicating and non-replicating cells. Long patch 
BER mainly takes place post-replication in proliferating cells utilising the proteins of DNA replication 
for processing after the generation of the AP site. The main step in short patch BER is cleavage of the 
phosphodiester bond 5’ to the AP site by AP endonuclease APE1, which generates a strand break with 
a 3’-hydroxyl and 5’ sugar phosphate end (5’dRp). DNA polymerase (Pol) β can then add one correct 
nucleotide to the nick while its phosphodiesterase activity (dRpase) removes the 5’dRP to generate a 
5’ phosphate end required for ligation. DNA ligase III-XRCC1 seals the break and completes the process 
(Krokan and Bjoras, 2013; Svilar et al., 2011). In Long patch BER the same initial process takes place, 
however Pol δ/ε replaces Pol β to displace several nucleotides extending the repair patch. This 
generates a flap with a 5’-sugar phosphate which can be removed by the FEN1 endonuclease. 
Following removal of the flap, DNA ligase I seals the break to complete the process (figure 1.4.2). Other 
proteins also have roles in BER to signal the DNA damage and to edit the ends of the nucleotide gap 
(Krokan and Bjoras, 2013; Memisoglu and Samson, 2000). PARP also plays a role in initial recruitment 
of BER proteins to damaged DNA by creating a scaffold for protein binding; inhibition of this pathway 
results in processing by the slower homologous recombination mediated pathways (Javle and Curtin, 
2011).  
 
1.4.3 Nucleotide Excision Repair 
Nucleotide Excision Repair (NER) detects and removes bulky helix-distorting adducts by targeting 
altered DNA backbone conformations (Kim and Wilson III, 2012). The process was originally discovered 
through the process of bacteria repair of cyclobutene pyrimidine dimers (Hanawalt, 1994; Setlow, 
1966), with a preference to repair transcribed genes compared to non-transcribed genes (Mellon et 
al., 1986). Our understanding of NER has been ever advancing through study of such conditions as 
Cockayne syndrome and Xerodema Pigmentosum (Hoeijmakers, 2009). From probing these 
conditions, looking at both transcribed and non-transcribed regions of DNA, two sub-pathways of NER 
were determined: Global Genome NER (GG-NER) and Transcription Coupled NER (TC-NER). Defects in 
these pathway lead to a variety of diseases from UV radiation sensitivity to severe premature aging 
(Marteijn et al., 2014).  
The sensing of DNA lesions for the two sub-pathways involves a different subset of proteins. For GG-
NER the damage sensor XPC (in complex with HHR23B) constantly probes the DNA for helix-distorting 
lesions (Sugasawa et al., 1996). In TC-NER damage is directly recognised by the stalling of RNA pol II 
during transcription elongation. Transient interactions with NER proteins allow quick recognition and 
increased binding affinity of proteins such as Cockayne Syndrome Protein (CSB) to RNA pol II (Marteijn 
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et al., 2014). The subsequent 
recruitment of RPA, XPA and 
the 11 subunit Transcription 
initiation factor IIH (TFIIH) 
complex forms the pre-
incision complex 1 (PIC1) 
which is the same in both 
pathways. The TFIIH helicase 
activity further unwinds the 
DNA allowing for recruitment 
of XPG which displaces XPC to 
form pre-incision complex 2 
(PIC2). XPG can then verify 
the existence of lesions by 
binding to chemically altered 
nucleotides. Once verified, 
pre-incision complex 3 (PIC3) 
is formed by recruitment of 
the XPF-ERCC1 nuclease 
which is directed to the 
damaged stand by RPA to 
create an incision 5’ to the 
lesion. After this “point of no 
return”, XPG is activated 
cleaving 3’ to the lesion and 
creating a 22-30 nucleotide 
long strand. The gap can then 
be filled by DNA Pol ε/δ and 
PCNA before ligation by DNA 
ligase 1 (Adebanke F. 
Fagbemi. et al., 2011; de Boer 
and Hoeijmakers, 2000; Orelli et al., 2010; Sugasawa et al., 2009). Some NER factors are known to be 
involved in other processes such as TFIIH in transcription, XPF-ECC1 in recombination and RPA in 
replication and recombination. The two pathways are summarised in figure 1.4.3. 
Figure 1.4.3: A schematic diagram of DNA base lesion repair by 
Global Genome Nucleotide Excision Repair (GG-NER) and 
Transcription Coupled Nucleotide Excision Repair (TC-NER). 
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1.4.4 Replication fidelity and Mismatch Repair (MMR) 
Preservation of genetic information during normal cell proliferation relies on low mutation rates in 
DNA replication. High fidelity DNA polymerases maintain genomic integrity by ensuring that only the 
correct Watson-Crick base pairing occurs between the templated base and the nucleotide in its active 
site. Studies on Pol δ show only one incorrect base pair per 107 to 108 nucleotides inserted (Bębenek 
and Ziuzia-Graczyk, 2018; Ganai and Johansson, 2016); however given the size (3.2x109 nucleotides) 
of the human genome multiple errors still occur. Part of this high fidelity is achieved through 
proofreading by Pol δ and Pol ε, which remove incorrectly inserted bases using their 3’ to 5’ 
exonuclease activity (Schmitt et al., 2009). Errors which escape this process are repaired by the highly 
conserved MMR, while mutations in the MMR pathway can lead to Hereditary Non-Polyposis 
Colorectal cancer (HNPCC) (Steinke et al., 2013).  
In MMR, the cell must distinguish between the two strands to ensure removal of the mismatch from 
only the daughter strand. In bacteria strand discrimination exploits the transient hemi-methylation 
which lags behind the replication fork. For humans however the mechanism has been less clear and is 
likely to rely on nicks within the newly synthesised DNA (Hsieh and Zhang, 2017). Nicks are present on 
the lagging strand prior to ligation of okazaki fragments however this implies nicks are present on 
leading and lagging strands to direct the MMR machinery to the daughter strand. Orientation specific 
loading of PNCA has been reported on the leading strand providing evidence to support this method 
of detection (Pluciennik et al., 2010). Following mismatch detection, the excision machinery is 
recruited including EXO1 and RPA triggering strand degradation. RPA coats single stranded DNA prior 
to Pol δ recruitment for re-synthesis and the remaining nick sealed by DNA ligase I (Li, 2007; Thornby 
Bak et al., 2014).  
1.4.5 Repair of interstrand crosslinks 
DNA interstrand crosslinks (ICL) have the potential to cause replication and transcription stalling 
through blockage of DNA separation. Some chemotherapeutic drugs introduce ICL to promote cell 
death; agents such as cisplatin that introduce ICLs were one of the earliest and still widely used 
chemotherapeutics. However, cisplatin causes only 5% interstrand crosslinks, and over 90% 
intrastrand crosslinks, which can be repaired but are a source of further DNA damage leading to cancer 
(Deans and West, 2011; Muniandy et al., 2011). Fanconi Anaemia (FA) is a rare genetic disorder with 
high sensitivity to ICLs and its study has provided insight into the repair of these lesions, which requires 
a coordinated response involving proteins from NER, HR and the FA complex.  
Initial ICL recognition is by the FANCM-FAAP23 complex which becomes part of the core FA complex. 
The formation of the FA complex can then coordinate changes in the fork such as regression and single 
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DSB formation to stabilise an intermediate structure. Recruitment of the XPF-ERCC1 complex can then 
create a gapped structure for lesion bypass polymerases to add nucleotides across the ICL. The excised 
DNA, still bound by the crosslink, can then be further processed and removed by NER. The whole fork 
can then be repaired by HR allowing replication to proceed; FANCD2 has been shown to interact with 
CtIP to help channel the DSBs intermediate into the HR pathway (Unno et al., 2014).  
1.4.6 Tolerance to DNA damage 
Even with the many DNA repair pathways at the cell’s disposal, DNA damage is a random process and 
can interfere with ongoing cellular processes before being repaired (Friedberg, 2008). In the case of 
DNA replication, a blocked replication fork can lead to cell death. Thus, cells have evolved tolerance 
pathways such as Translesion DNA Synthesis (TLS) to bypass the damaged site. During TLS, when the 
replication machinery stalls at a DNA lesion the replicative DNA polymerase is exchanged for a 
specialised Y-family TLS polymerase, such as Pol eta, kappa and zeta (Goodman and Woodgate, 2013). 
These polymerases have an active site capable of accommodating distorted or damaged templates, 
allowing additional nucleotides to be added to the newly synthesised strand opposing the lesion (Sale 
et al., 2012). This lesion bypass by TLS allows fork progression and abates cell death, but at the expense 
of an increased mutagenic load, as TLS polymerases are low-fidelity. Control mechanisms therefore 




1.5 Double strand break repair 
A Double Strand Break (DSB) is one of the most detrimental forms of DNA damage. Even a single DSB 
causes a major threat to the genome integrity by creating two uncapped chromosomal ends. Without 
repair chromosomal loss is possible, as the ends are accessible to nucleases, which can lead to cell 
death. Inaccurate repair can also be detrimental as large translocations or gene fusions can cause cell 
transformation and cancer (Jackson and Bartek, 2009; Salesse and Verfaillie, 2002).  
DSBs can be caused by endogenous or exogenous sources (O’Driscoll and Jeggo, 2006). Endogenous 
DSBs can be a deliberate action in the execution of a cellular programme of genetic rearrangement. 
For example, during meiosis where DSBs are generated for the process of recombination between 
homologous chromosomes (Baudat and De Massy, 2007; Edlinger and Schlögelhofer, 2011). 
Development of immunity also relies on a controlled DSBs through V(D)J recombination and 
immunoglobulin heavy chain switching. In these processes segments of DNA in the immunoglobulin 
and T-cell receptor loci are shuffled and re-ligated to generate genetic diversity within the immune 
system (O’Driscoll and Jeggo, 2006; Schatz and Swanson, 2011).  
Exogenous sources of DNA damage such as IR can also produce complex DSBs with multiple clustered 
sites of DNA damage. These can be produced either by generation of ROS that attack the 
phosphodiester backbone or by directly supplying the energy to break a bond. In many cases these 
events can be two SSBs on the complementary strands in close proximity to each other, which causes 
a DSB. Further DNA damage caused by IR such as protein adducts can increase the complexity of the 
break (Durante and Loeffler, 2010; Schipler and Iliakis, 2013; Ward et al., 1987). Failure of normal 
cellular processes, however, can also be a source of endogenous DSBs in an uncontrolled manor. As 
repair is not initiated in M-phase, prolonged mitosis from checkpoint failure can lead to an increased 
build-up of exogenous DNA damage. Physical pulling in opposite directions of the sister chromatids 
can also lead to further DSB formation (Ganem and Pellman, 2012). The replication fork can also lead 
to the formation of DSBs. On encountering a nick nascent strand synthesis can be discontinued leading 
to a DSB, replication fork stalling can also lead to the formation of DSB through collision of two forks  
(Aguilera and Gómez-González, 2008; Alexander and Orr-weaver, 2016). Furthermore, the non-
translated ssDNA during transcription can form secondary structures that can impede fork progression 
and cause DNA breaks. Replication of DNA fragile sites can also cause secondary structures to be 
cleaved generating a DSB, with the replication fork meeting a SSB or fork stalling also leading to the 
formation of a DSB (Aguilera and Gómez-González, 2008). 
Repair of a DSB is necessary to protect the cell against detrimental effects. Cells have therefore 




Canonical NHEJ is a DSB repair mechanism without the need for resection and homology of the DNA. 
In NHEJ, the DSB ends are therefore directly re-joined with little or no base pairing at the damaged 
site. Although this can result in inaccurate repair, NHEJ is a major pathway of DSB repair in mammalian 
cells, whereas in lower eukaryotes such as S. cerevisiae recombination-mediated pathways 
predominate (Davis and Chen, 2013; Hefferin and Tomkinson, 2005).    
The initial stage of NHEJ is recognition by binding of the Ku protein, a heterodimer of two highly 
abundant subunits within the cell Ku70 and Ku80. Ku quickly and tightly binds to DNA ends without 
sequence specificity forming a ring structure around the DNA. This has been further demonstrated by 
both crystal and electron microscopy structures of Ku in complex with dsDNA (Davis and Chen, 2013; 
Fell and Schild-Poulter, 2015; Spagnolo et al., 2006; Walker et al., 2001). These structures showed no 
obvious difference between a Ku DNA-bound and unbound state meaning after DSB repair it is likely 
that Ku remains trapped on the DNA (Rivera-Calzada et al., 2007). Removal of Ku was subsequently 
shown to be by protein ubiquitination and degradation by the E3 ubiquitin ligase RING finger protein 
8 (RNF8) (Feng and Chen, 2012). Ku has also been reported to be involved in bridging the broken DNA 
ends. Knockdown of Ku80 showed an increased distance between the ends with Ku70 also shown to 
be involved in bridging interactions (Davis and Chen, 2013; Ribes-Zamora et al., 2007; Soutoglou et al., 
2007). 
Following binding of Ku further proteins are recruited such as the DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs), X-ray cross complementing protein 4 (XRCC4), XRCC4-like factor (XLF) 
and DNA Ligase IV (Davis and Chen, 2013). Initial recruitment of DNA-PKcs ensures the Ku complex is 
at the tip of the DSB, with DNA-PKcs involved in bridging across the gap allowing auto phosphorylation 
and formation of the active holoenzyme with Ku. Further recruitment of XRCC4-DNA ligase IV complex 
is achieved through interactions with the Ku-DNA-PKcs complex with XRCC4 binding to Ku70 
specifically (Chang et al., 2017; Davis and Chen, 2013). The XRCC4-DNA ligase IV complex can then 
complete the break ligation in an ATP-dependant manner; the protein XLF was identified to prompt 
this reaction (Ahnesorg et al., 2006; Dahm, 2008). More recently PAXX (PAralog of XRCC4 and XLF) has 
been identified as a further core NHEJ factor for mediation of XRCC4-DNA Ligase IV ligation to 
complete NHEJ (Ochi et al., 2015). This pathway is summarised in figure 1.5.1. 
While the proteins described above have critical roles in the NHEJ pathway there is considerable 
flexibility in the proteins recruited for repair. Complex DSB ends can be produced by IR with a subset 
being processed by NHEJ. These however require further processing through kinases/phosphatases 
such as the mammalian polynucleotide kinase/phosphatase (PNKP) (Chappell et al., 2002), nucleases 
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such as Mre11 (Foster et al., 2011) and Artemis (Ma et al., 2002), Werner syndrome protein (WRN) a 
nuclease and helicase (Karmakar et al., 2002), the RECQ1 helicase (Parvathaneni et al., 2013), 
phosphodiesterases such as tyrosyl DNA phosphodiesterase 2 (TDP2) (Gómez-Herreros et al., 2013) 
and DNA polymerases such as Pol µ and Pol γ (Ma et al., 2004; Mahajan et al., 2002). For example, 
incompatible 5’ overhangs require processing by Artemis in complex with DNA-PKcs for removal of 
the overhanging DNA, blunt end ligation can then be stimulated by PAXX and XLF leading to a deletion 
of information (Chang et al., 2017). All these factors process the DSB end to enable re-ligation of a 
variety of complex DSBs. This processing can result in a diverse range of products including insertions, 
deletions and translocations. However, this potentially error prone NHEJ repair is preferred to the 
potential loss of chromosome without DSB repair.  
 
  
Figure 1.5.1: Schematic 
representation of Non-




Micro homology mediated end joining (MMEJ) is an alternate, mutagenic, NHEJ DSB repair pathway 
and always results in deletions, potentially causing chromosome translocations to quickly repair DSBs. 
The MMEJ pathway is relied upon when NHEJ or HR are compromised while other mechanisms 
channel breaks away from MMEJ (Reczek et al., 2016). Due to the mutagenic property this pathway 
was thought to be a last resort to avoid apoptotic events (Sfeir and Symington, 2015). However, timely 
DSB repair is important for genomic integrity with evidence supporting a role for MMEJ within the cell 
in the presence of active HR and NHEJ pathways (Truong et al., 2013). CtIP has been established to 
play a role in MMEJ through DNA-end resection at a DSB. This resection inhibits the binding of Ku, 
therefore the break can no longer be processed by canonical NHEJ, in the absence of long range 
resection HR also is unable to process the break leading to MMEJ (Wang and Xu, 2017).  
  
 
Figure 1.5.2: Schematic representation of micro-homology mediated end joining. Green 
represents a region of micro-homology necessary for MMEJ. 
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MMEJ is distinguished from NEHJ by the use of a 5-25 base pair micro-homology sequence between 
the broken ends independent of Ku. This resection stage is shared with HR, however it is BLM-, Exo1- 
and Rad51-independent, separating MHEJ from the HR pathway leading to a deletion (Truong et al., 
2013; Wang and Xu, 2017). MMEJ is still an emerging pathway within DNA repair, however the key 
step of initial Mre11/CtIP dependent resection was solidified early in its discovery (Bennardo et al., 
2008). Following end resection by CtIP and Mre11 the micro-homology region is annealed by an 
unknown mechanism, this process has been shown to be countered by binding of RPA (Wang and Xu, 
2017). Annealing leads to formation of an intermediate with a 3’ flap and gaps either side of the break 
site (figure 1.5.2). These 3’ flaps must then be removed by XPF/ERCC1 to allow a promiscuous DNA 
polymerase pol θ to fill the gaps (Mateos-Gomez et al., 2015; Seol et al., 2018). PARP1 along with 
XRCC1 DNA ligase III/I have been implemented in this stage and the subsequent ligation however the 
precise mechanism is unclear (Audebert et al., 2006; Seol et al., 2018; Simsek et al., 2011).  
Although MMEJ is mutagenic it has been seen that inactivation through inhibition of Pol θ results in 
vast chromosome deletions, showing its necessity for genome protection (Yousefzadeh et al., 2014). 
This role of Pol θ is crucial in DSB repair in a HR deficient background, with reports of Pol θ dependency 
in tumours that lack the HR repair pathway (Ceccaldi et al., 2015). Initiation of MMEJ is focused on 
CtIP converging cellular signals. This includes phosphorylation by polo-like kinase 1 (PLK1) expressed 
in S through to M phase. Action of PLK1 has been shown to inhibit CtIP/Mre11 resection sufficient for 
HR and channel the break into MMEJ; this action accelerates DNA repair through the quicker MMEJ 
and allows the G2/M transition in cells recovering from DNA damage (H. Wang et al., 2018). With CtIP 
playing a pivotal in the MMEJ pathway, inhibition of this action could be route to a further cancer 
treatment allowing cells to enter M-phase with DNA damage and cause mitotic catastrophe when 
other pathways are compromised. Nevertheless, further study into both CtIP and MMEJ is necessary 







In contrast to NHEJ and MMEJ faithful DNA repair is achieved through the process of Homologous 
Recombination (HR). This pathway involves a series of processes which use an undamaged 
homologous DNA template to lead to successful repair. HR maintains genomic stability through 
accurate repair of DSBs alongside recovery of replication forks, and contributes to tolerance of DNA 
damage (Krejci et al., 2012). HR is also critical to maintenance of telomeres and during chromosome 
segregation in meiosis 1 (where NHEJ cannot act) through the formation of crossovers (Li and Heyer, 
2008; San Filippo et al., 2008). Therefore HR must be under tight control as unchecked recombination 
can lead to gross chromosome rearrangements, loss of heterozygosity and cell death (Kaniecki et al., 
2018).  
Research into recombination started as early as 1964 when Robin Holliday published the “Holliday 
model” of recombination at meiosis in fungi, providing the early molecular basis for gene conversion 
and crossover (Holliday, 1964). This model highlighted the fact that the action occurs post replication 
with DNA breaks allowing single strands to anneal to the complementary sequence to form a structure 
linking the two chromatids. This point is known as the Holliday Junction (HJ), which on resolution 
results in either a crossover or non-crossover product (Holliday, 1964). Further iterative models built 
on this such as the Meselson-Radding model showing the process was initiated through a single DSB 
(Meselson and Radding, 1975). Further studies on yeast meiosis in 1983 led to the classic Double 
Strand Break repair (DSBR) model. According to this model, the DSB ends were resected in the 5’-3’ 
direction with the 3’ tail active in strand invasion, on crossover this gave equal amounts of crossover 
and non-crossover products (Szostak et al., 1983). Studies in Drosophila melanogaster revealed the 
synthesis-dependent strand annealing (SDSA) model for mitotic recombination and a preference for 
non-crossover events (Nassif et al., 1994).  
HR can now be divided into three stages: presynapsis, synapsis and post-synapsis with proteins such 
as the Rad51 recombinase functioning in all three stages. We now know that the resected 3’ ssDNA is 
rapidly coated by RPA to protect it from nuclease degradation, eliminate secondary DNA structure and 
activate the ATR pathway. This RPA coating is subsequently exchanged for the Rad51 recombinase 
through the mediator protein BRCA2 (Davies et al., 2001). This Rad51 nucleoprotein filament can then 
undergo strand invasion to search for a homologous sequence. During DSBR on base paring with the 
homologous sequence DNA synthesis at the 3’ end results in a displacement loop (D-Loop), while the 
nascent strand pairs with the other 3’ tail. Both 3’ ends are extended by DNA synthesis to form a 
double HJ intermediate. Resolution then forms both crossover and non-crossover products. In 
contrast, in SDSA only one of the break ends is paired with the homologous DNA and extended, the 
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DNA is then displaced and annealed to the unpaired end to form non-crossover products 
(Kowalczykowski, 2015; Morrical, 2016) (figure 1.5.3). These and further biochemical studies using 
single molecule microscopy have helped define the molecules and pathways that are involved in 
recombination known today (Kaniecki et al., 2018).   
 
Figure 1.5.3: Schematic 




1.5.3.1 HR Machinery  
In contrast to NHEJ, many of the proteins that are involved in HR were first discovered in the budding 
yeast S. cerevisiae. The classical procedure of mutant isolation by sensitivity to DNA damaging agents 
and complementation of the mutant phenotype identified the RAD52 epistasis group(Petrini et al., 
1997). The structures and functions of the group members were found to be highly conserved with 
homologues found in the human system such as: Mre11, Rad50, Nbs1, Rad52 and the Rad51 
paralogues (Rad51b, Rad51c, Rad51D, XRCC2 and XRCC3) (San Filippo et al., 2008). Many other factors 
such as RPA and the breast cancer susceptibility proteins BRCA1 & BRCA2 were identified to play 
crucial roles in HR in vertebrates. Further research in S. cerevisiae discovered Sae2, which was later 
revealed to be the homologue of CtIP (Sartori et al., 2007). Each of these proteins have specific 
functions within HR with assembly of the presynaptic filament being the rate determining step (San 
Filippo et al., 2008). 
 
1.5.3.2 MRN, presynaptic filament formation 
The initial stage in all DSB repair mechanisms is identification of a DSB. Although originally thought to 
be the role of ATM, the Mre11, Rad50, Nbs1 (MRN) complex has been attributed to break sensing and 
recognition for initiation of HR. Its influence however is not limited here, with the MRN complex also 







Figure 1.5.3.2-1: Schematic representation of the MRN complex proteins Mre11, Rad50 and 
Nbs1. Flexible regions are shown by solid arrows. Dashed arrows represent disordered segments. 
Adapted from Lafrance-Vanasse et al., 2015. 
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The Mre11 subunit of the MRN complex is a highly conserved protein composed of an N-terminal 
phosphoesterase domain, which possesses manganese-dependent nuclease activity in vitro, and two 
distinct C-terminal DNA binding domains (D’Amours and Jackson, 2002). Isolated Mre11 has been 
shown to form stable dimers in solution possessing intrinsic DNA binding activity and enzymatic endo- 
and exo-nuclease activity against both ssDNA and dsDNA substrates, with the ability to act on 5’ 
overhangs, 3’ flaps and 3’ branches (De Jager et al., 2001a; Lamarche et al., 2010; Mimitou and 
Symington, 2009). Determination of an archaeal Mre11 dimeric structure led to distinction between 
endo- and exo- nuclease activities of Mre11, with single point mutations selectively inhibiting activity 
respectively (Williams et al., 2008). Conversely, the Mre11 subunit lacks the 5’ – 3’ exonuclease activity 
thought to be required for generation of 3’ tails with its 3’ to 5’ activity shown to be necessary for the 
action (Lamarche et al., 2010; Paull and Gellert, 1998).  
In vivo, the Mre11 protein exists in an Mre112Rad502 heterotetrameric core complex with each Mre11 
molecule binding to a single Rad50. The Rad50 subunit belongs to the conserved family of the 
structural maintenance of chromosomes (SMC) possessing both structural and sequence homology. 
Rad50 has been shown to form an antiparallel coiled coil through crystallography studies in archaea 
folding back at a conserved Cys-X-X-Cys (CXXC) motif. This was shown to form an interlocking hook 
upon coordination of a Zn2+ ion to mediate dimerisation of Rad50 (Hopfner et al., 2002; Lamarche et 
al., 2010). The sequence homology to the SMC proteins exists at the N and C-termini with Walker A 
and B motifs present respectively; these stably associate to form an ATP-binding cassette (ABC)-type 
ATPase domain with DNA binding affinity to dsDNA termini (De Jager et al., 2001b).  
Collectively the domains of Rad50 have illuminated the function at the break site in the MR core 
complex. Deletion of the coils and zinc binding independently have been shown to impair the DNA 
binding affinity and ATPase activity, showing the coiled-coils link the Rad50 catalytic heads together 
for action with Mre11 (Deshpande et al., 2014; Hopfner et al., 2002; Lee et al., 2013; Paull and 
Deshpande, 2014). The ATP-related activities of Rad50 are also essential for its role in DNA repair with 
mutations in the Walker A motif akin to Rad50 deletion (Moncalian et al., 2004). Specific changes in 
the Rad50 coils on ATP binding and hydrolysis change the angle from 90-120° to alter the orientation 
of Mre11 and accessibility of the nuclease domain to the DNA (Deshpande et al., 2014; Lammens et 
al., 2011; Lee et al., 2013; Lim et al., 2011; Williams et al., 2011). Analysis of the ATP binding has also 
shown that the ATP-bound closed state promotes Rad50 DNA binding, tethering of the DNA ends, and 
ATM activation, but prevents Mre11 nucleolytic activation (Lamarche et al., 2010). With ATP-
hydrolysis by both Rad50 active sites necessary for Mre11 activation (Deshpande et al., 2017). 
Shortening the length of the coils (removing 300 amino acids) has no effect on HR while it does affect 
telomere maintenance, meiotic DSB formation and surprisingly NHEJ, indicating two roles for the 
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Rad50 coiled-coil domain in inter- and intra-chromosome bridging (Hohl et al., 2010). In the current 
model, a dual conformation of Rad50 has been shown. A long straight ridged Rad50 within the MR 
complex is involved in DNA tethering activities, while a looped Rad50 structure is involved in DSB 
repair (Lafrance-Vanasse et al., 2015). 
The third subunit of the MRN complex, Nbs1 (Xrs2 in yeast), binds to this core complex via Mre11 to 
form the MRN complex in a 2:2:2 stoichiometry (Lamarche et al., 2010). Nbs1 was originally identified 
as the mutated protein in Nijmegen breakage syndrome, a rare autosomal-recessive disease with 
hypersensitivity to IR, immune disorders, microcephaly, growth retardation and cancer predisposition 
(Chrzanowska et al., 2012). Nbs1 lacks enzymatic activity but can be viewed as both a sensor and an 
effector due to its Mre11 interaction and ability to recruit other proteins, with links to ATM signalling 
and modulation of Mre11 nuclease activity binding both through its C-terminal domain (Crown et al., 
2013; Lee and Paull, 2004, 2005; Park et al., 2011). At the N-terminal domain of Nbs1 a FHA and two 
BRCT motifs mediate phospho-dependent protein-protein interactions such as with CtIP (figure 
1.5.3.2-2)(Lloyd et al., 2009; Williams et al., 2009), MDC1 (Lloyd et al., 2009b; Spycher et al., 2008), 
WRN (Kobayashi et al., 2010) and ATR (Olson et al., 2007). From structural determination of Nbs1 in 
complex with a S. pombe Ctp1 (CtIP homologue) peptide long range conformational changes in the N-
terminal of Nbs1 were seen having the potential to regulate the BRCT1 & 2 sites to modulate repair 
pathway choice by CtIP (Williams et al., 2009). Further evidence for the importance of Nbs1 phospho-
specific interactions comes from mutation of the FHA domain causing high sensitivity to IR, 
camptothecin and hydroxyurea known to cause DSBs repaired by MRN highlighting Nbs1’s key role 
within the complex (Lloyd et al., 2009; Williams et al., 2009). 
 
  
Figure 1.5.3.2-2: Architecture of the 
Mre11-Rad50-Nbs1 complex with Nbs1 
bound to CtIP. Where possible space fill 
models are represented with colours for 
Nbs1 and Mre11 the same as in figure 
1.5.3.2-1. Rad50 is represented as a 
dimer consisting of one monomer in 
orange, one monomer in yellow. ATM 
binding is represented by an arrow to 
Nbs1 and Mre11. Dashed lines represent 
disorders protein linkers. Adapted from 




Following detection of the DSB and DNA binding by Mre11-Rad50, ATM signalling is activated for 
downstream DSB signalling and necessary checkpoint control. MRN 3’ -5’ nuclease activity has long 
been known to be necessary for the subsequent generation of 3’ tails. Recently it has been reported 
that the MRN complex moves 100-200 base pairs away from the end of the DNA after initial detection 
of the break (Shibata et al., 2014). This was shown to be independent of Rad50 ATPase activity, 
although it relied on the Rad50 head domain for 1D diffusion along the DNA (Myler et al., 2017). Post 
diffusion, CtIP/ Sae2 have been shown in nuclease assays for humans and S. cerevisiae to stimulate 
the endonuclease activity of Mre11, cutting the 5’ strand 3’ to the break site (Anand et al., 2016; 
Cannavo and Cejka, 2014). Activity in human CtIP is dependent on the conserved threonine 847 (T847) 
CDK phosphorylation site and interaction with Nbs1 (Anand et al., 2016; Sartori et al., 2007). However, 
the change in architecture within the MRN complex on phosphorylation of CtIP T847 is yet to be 
determined. From this point Mre11 5’-3’ exonuclease activity resects the DNA strand back towards 
the DSB end (Cannavo and Cejka, 2014; Garcia et al., 2011; Shibata et al., 2014). While in the opposing 
direction the BLM helicase along with Exo1 or DNA2 nucleases carry out the long range 5’-3’ resection 
(Gravel et al., 2008; Zhu et al., 2008). This has been shown to be MRN nick-generation dependent (W. 
Wang et al., 2018) (figure 1.5.3.2-3). MMEJ is inhibited by the long-range resection and binding of RPA 








Figure 1.5.3.2-3. Model of MRN functions in DSB repair. Colours are the same as in previous 
figures in this section A) Initial detection is by 3D collision with the DSB. B) In HR the complex 
relies on Rad50 head domain in 1D diffusion to move close to the DSB end. C) 
Phosphorylated CtIP bound to Nbs1 induces unknown changes in MRN leading to a complex 
capable of endonuclease activities to generate a nick 3’ to the 5’ DSB end. D) MRN 3’ -5’ 
exonuclease activity resects DNA back to the DSB end, while BLM with Exo1/Dna2 resects in 
the 5’ to 3’ direction. E) In both NHEJ and HR DNA tethering activates of MRN can be utilised. 
Adapted from Lafrance-Vanasse et al. 2015, with single molecule fluorescence from Myler et 
al., 2017.   
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1.5.4 Regulation of DSB repair pathways  
As discussed in Sections 1.4 and 1.5 there is a large array of DNA repair pathways that have evolved 
to tolerate and repair a variety of different lesions. In the case of DSB repair, regulation between the 
choice of HR, NHEJ and MMEJ pathways is vital. One method that necessitates HR is the presence of 
the sister chromatid: limiting HR to G2 and S phase of the cell cycle. In contrast, both NHEJ and MMEJ 
can operate throughout the cell cycle, however are often mutagenic. Many other methods of 
regulation exist to control these pathways, for example the availability of HR factors such as Rad51 
which has been shown absent in mouse G1 phase (Yamamoto et al., 1996), along with CtIP and BRCA1 
which have very low expression at the protein level in G1 (Yu and Baer, 2000).  
Although NHEJ is active throughout the cell cycle, it must also be controlled to ensure HR can mediate 
repair where necessary. Recent studies show that many of the chromosome abnormalities and repair 
defects in Fanconi Anaemia are a result of inappropriate action of NHEJ in S-phase (Adamo et al., 
2010). The 53BP1 and BRCA1 proteins are emerging as pivotal regulators of DSB repair by NHEJ and 
HR respectively with many genetic studies highlighting their roles in this decision. 53BP1 disruption 
has been shown to channel breaks into HR, with 53BP1 mutation rescuing lethality of BRCA1 deficiency 
in mice (Cao et al., 2009), likely by relieving end-resection inhibition at DSBs through RIF1 (Bunting et 
al., 2010; Jasin and Rothstein, 2013; Xu et al., 2015; Zimmermann et al., 2013). The exact method by 
which BRCA1 and 53BP1 counteract each other at the biochemical level to choose between NHEJ and 
HR remains unclear (Chapman et al., 2012). The helicases, BLM and WRN have also been shown to 
play a role in this decision between canonical NHEJ and HR by modulating the binding of Mre11/CtIP 
to the DSB (Grabarz et al., 2013; Shamanna et al., 2016). More recently ubiquitinated BLM has been 
shown to be recruited by MRN to DSB sites to modulate both NHEJ and HR repair in a cell-cycle 
dependant manner (Tripathi et al., 2018).  
Several mechanisms have evolved to reverse the HR reaction through anti-recombinase activities 
during S-phase to ensure HR is activated at the correct time and location. This can be acted upon at 
various stages of the process to counteract toxic HR intermediates and to alter the crossover outcome 
of repair. One method has been shown by yeast a UvrD-like helicase Srs2, which acts to dismantle 
Rad51-ssDNA filaments to prevent inappropriate HR at active replication forks (Marini and Krejci, 
2010). Orthologous to Srs2, PARI has been shown to act in vitro by binding and disrupting Rad51 
filaments interacting with PCNA which is present at replication forks (Moldovan et al., 2012). Further 
control of HR post resection and formation of the presynaptic filament exist to control the pathway of 
recombination and ensure homologous sequence alignment (Heyer et al., 2010).  
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Despite these mechanisms when NHEJ and HR are simultaneously available the choice between the 
two pathways remains. Experiments in human cell lines showed that NHEJ is much faster than HR 
taking place in 30 minutes verses several hours for HR (Mao et al., 2008), highlighting the importance 
of this decision. In G1 phase the strong DNA binding affinity of Ku outcompetes HR repair factors, 
whereas experiments overexpressing Ku in G2 show a reduction in the recruitment of Mre11 (Fell and 
Schild-Poulter, 2015). The decision between the repair pathway can also depend on the complexity of 
the break, low complexity DSBs are repaired by NHEJ while more complex DSBs with protein adducts 
or clusters of breaks are repaired by HR (Hada and Georgakilas, 2008; Shibata et al., 2011). Evidence 
now exists towards a cellular model whereby canonical NHEJ acts first in an attempt to repair the 
break, with activation of resection when NHEJ cannot repair the break during S-G2 phase (Her and 
Bunting, 2018; Shahar et al., 2012). The emerging 3’ endonuclease CtIP/MRN nick model of DSB repair 
strongly supports this process, suggesting a pathway for overcoming the strong affinity of Ku at DNA 
ends. With this, resection by Mre11 has been shown to take place at Ku-bound DNA ends or other 
DNA-end adducts, requiring ATM phosphorylation of CtIP and Mre11 nuclease activity (Chanut et al., 
2016; Myler et al., 2017).  
DSB DNA-end resection is a key commitment step for homology directed repair (HDR). Therefore, 
many converging signals act upon CtIP to control and limit DNA-end resection. One method mentioned 
previously is that of CDK phosphorylation of CtIP at T847, necessary for its action with MRN and 
therefore is restricted to S/G2 phases of the cell cycle (Huertas and Jackson, 2009). A further 
phosphorylation event is that of PLK1 which phosphorylates CtIP at multiple serine residues at the C-
terminus (Serine 723 in particular), this has been shown to reduce BLM recruitment and therefore 
help channel resected DNA into MMEJ (H. Wang et al., 2018). A second regulation focused on CtIP is 
that of its neddylation by RNF111/UBE2M, this can affect the choice between NHEJ and HR, and can 
also regulate the extent of resection and sub-HR-pathway choice (Jimeno et al., 2015). Many other 
phosphorylation, sumoylation, ubiquitination and isomerization events act on CtIP to regulate its 
action at the DSB and will be discussed in the next section. How many of these events change the 





1.6 CtIP (CtBP-interacting protein)  
CtIP was originally identified in 1998 through its interactions with two proteins: C-terminus binding 
protein of adenovirus E1A (CtBP) and Retinoblastoma (RB) giving it the names CtBP Interacting Protein 
(CtIP) and RB binding protein 8 (RBBP8 or Rim) respectively (Fusco et al., 1998; Ute Schaeper et al., 
1998). Shortly after its discovery, interactions of CtIP and BRCA1 were also reported (Wong et al., 
1998). In the subsequent years the name “CtIP” has been more commonly used, with functions in 
transcriptional regulation, cell cycle checkpoint control, genome stability, tumour suppression and 
more recently methods of DSB repair identified (Wu and Lee, 2006). 
The human CtIP gene is located at chromosome 18q11.2 and encodes an 897 amino acid protein. 
Many interaction motifs within CtIP have been characterised such as the RB binding motif (LECEE), 
CtBP binding motif (PLDLS), the MRN binding sites and further direct interaction motifs detailed in the 





Figure 1.6-1: Schematic representation of direct interaction motifs on human CtIP. 
Interacting partners are shown in orange and purple. 
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Aside from direct interaction many phosphorylation sites are present in CtIP with some mediating 
interaction in a phosphorylation-specific manner. Sites on CtIP include ATM phosphorylation at serine 
664/745 and threonine 859. Many CDK phosphorylation sites are also present with the importance of 
serine 327 and T847 well established in CtIP function. Further sites are also detailed in this thesis and 





Structurally only short regions have been determined such as the tetramerisation domain from 
residues 18-52 (Davies et al., 2015) and a short region containing a small beta strand that interacts 
with LMO4 shown in figure 1.6-3.  
 
 Figure 1.6-3: Schematic representation of determined CtIP structures within the literature. 
Structure images for the CtIP-nNTD and LMO4 were extracted from papers by Davies et al 2015 
and Stokes et al 2013. 
Figure 1.6-2: Schematic representation of phosphorylation sites on human CtIP. Kinases are 
shown in red, binding partners in orange. MAP kinase has also been shown to phosphorylate 
Serine 276 for PIN1 binding to S276 & S315. Residues S233, T245, S276, T315 and S347 have all 





1.6.1 CtIP and homologous recombination 
Although CtIP was originally associated with transcriptional regulation, Sartori et al. revealed the role 
of human CtIP in DNA end-resection prior to ATR signalling pathway activation (Sartori et al., 2007). 
Here evidence for CtIP’s involvement in DSB repair came from 1-hour siRNA depletion of CtIP in U2OS 
cells, the results showed hypersensitivity to camptothecin and etoposide which cause replication-
dependent DSBs. The effects of short CtIP depletion were abrogated by inhibiting replication using 
aphidicolin. As DSBs generated in S-phase by camptothecin are repaired by HR, it suggests a role for 
CtIP to promote HR at DSBs. As mentioned previously, on detection of a DSB ATM phosphorylates 
H2AX with ATR activating Chk1 after ssDNA generation. Camptothecin treatment of cells caused 
phosphorylation of H2AX (γH2AX) and hyper-phosphorylation of CtIP, however depletion of CtIP did 
not affect the formation of γH2AX. This indicates that depletion of CtIP still allowed the drugs to cause 
DSBs and they were still detected by ATM. Conversely, recruitment of ATR and phosphorylation of 
Chk1 were drastically reduced on CtIP SiRNA treatment indicating CtIP played a role in generation of 
the ssDNA required for their downstream activation. Analysis of ssDNA tracks showed co-localisation 
of CtIP with RPA, however on CtIP depletion RPA was absent from the break foci. Anti-BrdU staining 
for ssDNA confirmed that on depletion of CtIP and camptothecin treatment ssDNA was not formed 
(Sartori et al., 2007). These data established that CtIP promoted ssDNA formation at a DSB site. Further 
co-immunoprecipitation experiments showed CtIP could interact with the MRN complex while direct 
interactions were confirmed using purified regions of CtIP which could retrieve MRN from HeLa cell 
extracts (Sartori et al., 2007). The MRN CtIP interaction was further confirmed by an independent 
study by Yuan & Chen (Yuan and Chen, 2009). In addition, the ground-breaking research published by 
Sartori et al. demonstrated activation of the MRN endonuclease activity by CtIP in the presence of 
magnesium with an increase in activity in the presence of manganese. CtIP alone exhibited no 
nuclease activity when purified from HEK293 cells (Sartori et al., 2007). Specific involvement of the C-
terminal domain in DSB repair through truncation of CtIP was also reported. Here removal of the last 
108 CtIP residues inhibited Chk1 phosphorylation and recruitment of RPA without affecting the cell 
cycle (Sartori et al., 2007). 
From this point forward CtIP’s role in DSB repair has been further established in generation of ssDNA 
in complex with MRN. An independent study in 2008 showed interactions of the CtIP N&C-termini 
with Nbs1 which was significantly strengthened in the presence of Rad50 and Mre11 (Chen et al., 
2008). These results were followed in 2009 reproducing CtIP depletion affecting the HR processes 
downstream of RPA recruitment but not affecting γH2AX formation. Chromatin immunoprecipitation 
(ChIP) experiments reported by You et al. located CtIP to within 100bp of a DSB end with the same 
results for Nbs1 and Ku70, all three of these required a broken end and would not associate with a 
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circular plasmid (You et al., 2009). In the same year the CDK sites serine 327 and T847 were reported 
to promote interaction with BRCA1, deciding between DSB repair pathways and activation of HR 
respectively (Huertas and Jackson, 2009; Yun and Hiom, 2009). In 2010 the action of CtIP at the DSB 
site in alignment with its role as a multivalent adapter protein was found to be a controlling factor in 
initiation of HR repair. Activation of the MRN complex end resection was only seen on integration of 
checkpoint and cell cycle signals by CtIP (You and Bailis, 2010). Further regulation of CtIP by 
phosphorylation, sumoylation, ubiquitination and proline isomerization were subsequently 
discovered in the years to follow and will be covered later in this section.  
The discovery of CtIP’s involvement in resection is not limited to vertebrates with many functional 
homologues characterised in other eukaryotic species including Arabidopsis thaliana and 
Caenorhabditis elegans through to the Saccharomyces cerevisiae homologue Sae2 and the 
saccharomyces pombe homologue Ctp1 (Clerici et al., 2005; Limbo et al., 2007; Uanschou et al., 2007). 
The C-terminus of CtIP is homologous through to S. cerevisiae Sae2. Limited sequence similarity exists 
within the disordered region of the protein, however homology within the N-terminal tetramerisation 
domain does exist in Ctp1 and in other species (Andres et al., 2015; Sartori et al., 2007; Uanschou et 
al., 2007). Analysis of Sae2 null S. cerevisiae showed accumulation of un-resected DSBs, reduced 
synapsis formation and absence of sporulation which resembles Mre11 nuclease-dead mutations 
(Moreau et al., 1999; Prinz et al., 1997). Ctp1 has also been placed at the DSB junction being required 
for MRN DNA-end resection and subsequent RPA coating (Limbo et al., 2007). The name “Sae2” 
originated from the absence of sporulation being recovered in a Spo11 null background (Sae2 is an 
acronym for Sporulation in the absence of Spo11). Spo11 is known as a type II topoisomerase-like DNA 
transesterase which is meiotic specific; in a Sae2 null background spo11 remains covalently attached 
to DNA with Sae2 activity required for the removal (Prinz et al., 1997). Ctp1 has also been reported to 
play a role in removal of topoisomerases from the 5’ and 3’ DSB break ends with Rad32 (S. Pombe 
Mre11). Here Ctp1 preferably removes 5’ linked Top2 while protecting 3’ linked Top1 suggesting a role 
in 3’ end protection (Hartsuiker et al., 2009). 
Alongside the critical role in DSB repair evidence also exists that CtIP plays a crucial role in ICR 
upstream of a DSB, interacting with the FA protein FANCD2. Residues 166-273 of CtIP have been 
shown to be sufficient for the FANCD2-CtIP interaction recruiting it to the damaged chromatin. Here, 
the interaction tethers CtIP at the stalled or collapsed replication fork to encourage restart by HR. This 
interaction supresses the action of NHEJ at the fork which is a less favourable pathway for fork restart. 
Studies in CtIP depleted cells with aphidicolin treatment (to stall replication forks) showed that CtIP 
not only has roles in replication fork restart but also in repression of new origin firing (Duquette et al., 
2012; Murina et al., 2014; Unno et al., 2014; Yeo et al., 2014).  
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1.6.2 Regulation of CtIP 
With the great power of CtIP acting in a multitude of pathways comes a great responsibility to ensure 
it is under tight regulation. Abundance of CtIP protein is controlled through its promotor activity and 
at the post-transcriptional level; specific functions of CtIP are also regulated by modifications such as 
phosphorylation and sumoylation, and by binding different interaction partners. CtIP protein levels 
are limited in G1 phase, however expression is up-regulated during late G1 phase. Consistent with its 
role in transcriptional regulation CtIP has been shown to control its own gene expression to maintain 
protein levels throughout S-phase (Wu and Lee, 2006).  
During S and G2 phase of the cell cycle CtIP can be phosphorylated by CDK’s, with 12 potential sites in 
human CtIP (Ferretti et al., 2013); remarkably phosphorylation of a single CDK site, T847, is required 
to promote resection. Mutation studies of the highly conserved T847 showed impaired RPA 
recruitment when substituting to alanine which was not the case when mutating to a phosphomimetic 
glutamic acid residue. In both cases, however, DSB repair efficiency was affected causing 
hypersensitivity to DSB-generating agents suggesting a fine level of control through the CDK site 
(Huertas and Jackson, 2009). Similar studies using Sae2, showed residue Serine 267 was equivalent 
and also required for DNA resection with a phosphomimetic allowing resection in the absence of CDK 
(Huertas et al., 2008). More recently phosphorylation of CtIP at T847 has been shown to be the key 
step in activation of MRN endonuclease activity to initiate DNA cleavage on the 5’ strand. This then 
allows activation of MRN’s 3’-5’ exonuclease activity and generation of a 3’ overhang in the presence 
of a protein block, the same has also been seen for Sae2 however without the need for 
phosphorylation (Anand et al., 2016; Cannavo and Cejka, 2014).  
The actions of the T847 site have also been shown to be independent of the interaction with BRCA1, 
which interacts through a further CDK site at serine 327 (Polato et al., 2014). The role of the serine 
327 CDK site for this interaction is still under debate, however evidence shows that the 
phosphorylation directs cells towards HR rather than MMEJ showing a role in switching the repair 
pathway for DSBs (Polato et al., 2014; Yun and Hiom, 2009). CtIP’s role in MMEJ and the switch 
between the pathways by BRCA1 could present an effective target for breast cancer treatment that 
display MMEJ-dependent chromosomal rearrangements (Reczek et al., 2016). More recently advances 
in single molecule studies of resection tracks have given a better understanding of the BRCA1-CtIP 
interaction in the context of DNA end resection. Cruz-Garcia et al. showed that when using a serine 
327 to alanine mutant protein the rate of resection was reduced with conclusions from their paper 
indicating a role of BRCA1 to modulate the speed of resection (Cruz-García et al., 2014). 
Phosphorylation of CtIP can also be mediated by other kinases such as PKM2 (T126), this has been 
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reported to increase DSB repair efficiency and improve resistance to genotoxic treatments (Sizemore 
et al., 2018). Phosphorylation by PLK1 at the C-terminus (S723), as well as DNA damage-inducible PLK3 
phosphorylation at T847 and S327 in G1 phase, has been shown to regulate CtIP and direct the 
pathway choice towards MMEJ (Barton et al., 2014; H. Wang et al., 2018) highlighting the role of CtIP 
as an orchestrator of cellular events.  
CDK-mediated phosphorylation of CtIP has been shown to be a prerequisite for ATM-mediated 
phosphorylation of CtIP and subsequent recruitment of BLM and Exo1 to the DSB site (Wang et al., 
2013). After DNA damage CtIP is phosphorylated by ATM on serine residues 664 and 745, however 
the function of this is unclear. One possibility is that this causes a conformational change that exposes 
a DNA binding region in the middle of CtIP. Live-cell imaging of laser-line micro irradiation of U2OS 
cells showed ATM kinase activity was necessary for recruitment of a CtIP minimal damage recruitment 
motif (509-557) (You et al., 2009). Conversely, the region 505-546 has also been shown to interact 
with PCNA, which binds to DNA and initiates MMR as discussed previously (Gu and Chen, 2014). As 
the first study used camptothecin, where the damage caused is repaired by MMR, the interaction of 
this region to DNA is more likely to be through PCNA (Fedier et al., 2001). ATM phosphorylation is still 
potentially necessary to expose this region as its requirement in topotecan (camptothecin analogue) 
induced replication associated DSB’s has been shown (Köcher et al., 2013).  
Sumoylation has been shown for Sae2 to increase solubility of the protein as a further control 
mechanism; without this modification the repair function of Sae2 is impaired (Sarangi et al., 2015). In 
human CtIP, sumoylation occurs on lysine 896 by the SUMO E3 ligase CBX4. Depletion studies of CBX4 
confirmed impaired DNA end processing without the sumoylation, which blocked HR and decreased 
genome stability (Soria-Bretones et al., 2017). A further layer of CtIP regulation is that of acetylation 
(Rajendran et al., 2013). Under unperturbed conditions CtIP was shown to be acetylated which was 
abrogated on DNA damage. CtIP Acetylation was shown to inhibit DNA end resection, with activation 
of end resection on deacetylation, however the publication has now been retracted (Kaidi et al., 2010). 
Controlling CtIP by degradation is another mechanism to regulate its activity through protein levels. 
The Sartori group has identified a pathway proposed to fine-tune DNA end resection using the Cullin3-
KLHL15 ubiquitin ligase and the Prolyl Isomerase PIN1. In the case of PIN1 the interaction is with two 
CDK sites serine 276 and threonine 315 which on phosphorylation promote CtIP isomerization. This 
action then leads to ubiquitination and proteasome degradation. In the quest to find the protein that 
ubiquitilates CtIP in this pathway interactions with the Cullin3-KLHL15 complex were discovered. Here 
the KLHL15 protein binds to a short region in the C-terminus of CtIP relying on the side chain aromatic 
ring of tyrosine 842 rather than its phosphorylation. This interaction which is stabilised by action of 
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PIN1 then causes polyubiquitination of CtIP by Cullin3-KLHL15 for subsequent degradation by the 
proteasome (Ferretti et al., 2016; Steger et al., 2013). Further control of CtIP by protein degradation 
is through its conserved patch between amino acids 464 and 472 which contain the recently reported 
consensus KEN box sequence D/N-K-E-N-x-x-P. This targets CtIP for degradation through the 
anaphase-promoting complex/cyclosome-Cdh1 (APC/C(Cdh1)) with studies showing this occurs during 
mitotic exit and during control of DSB repair (Lafranchi et al., 2014). A further E3 ligase SiAH1 has been 
shown to bind CtIP, SiAH1 is induced by p21 and p53 during apoptosis and tumour suppression. The 
association of SiAH1 with CtIP has been shown to cause CtIP degradation through the ubiquitin 
proteasome pathway with SiAH1 having a critical role in breast and prostate cancers (Germani et al., 
2003; Knauer et al., 2015). 
It is likely that convergence of different signals on CtIP changes the outcome of its interactions and 
the structure of CtIP. Evidence to support this comes from research by the Charpentier group working 
on Cas9 to encourage gene integration by HR using the CRISPR Cas9 system. Here they discovered a 
preference to HDR when Cas9 was fused to CtIP. Further study into the domains of CtIP showed a 
region spanning 1-296 sufficient for HDR activation. Within this region 3 out of the 6 CDK sites involved 
in Nbs1 binding were shown to be necessary for the enhancement (serine 233, threonine 245, serine 
276) (Wang et al., 2013). In contrast to a full-length fusion, CtIP residues 1-296 fusion to Cas9 gave a 
different pattern of insertion deletions showing that the further domains of CtIP change the function  
(Charpentier et al., 2018). Two key points of interest come from these experiments. Firstly, not all the 
Nsb1 phosphorylation sites were necessary, indicating distinctive regulation and effects of each Nbs1 
binding site. Secondly, the C-terminal half of CtIP containing T847 was dispensable for the actions, 
meaning CtIP must affect MRN without the proposed T847 endonuclease activity activation of MRN 
(Anand et al., 2016).  
Although this fusion and function is manmade, it brings about many questions as to the known and 
unknown functions of domains within CtIP and what they mean within a wider cellular context. Further 
study into the structure and action of the CtIP domains and the modifications brought about by the 
CDK phosphorylation events are therefore necessary, especially in the context of its interaction with 
MRN. 
 
1.6.3 Transcriptional regulation by CtIP 
Further roles in transcription have been established since identification of CtIP through its CtBP 
interaction. As mentioned previously, CtIP regulates its own transcription. During late G1 phase CtIP 
is recruited to its own promoter to associate with RB to release E2F, CtIP then remains at the promotor 
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site to activate its own transcription by binding to the transcription machinery TFIIB and TATA binding 
protein (TBP) (Koipally and Georgopoulos, 2002). This action of CtIP also activates transcription of 
other E2F controlled genes such as Cyclin D1 which are essential to enable cell cycle progression from 
G1 to S phase (Liu and Lee, 2006; Wu and Lee, 2006). More recently, sustained E2F-dependant 
transcription with increased cellular levels of CtIP has been shown to be a key mechanism in 
preventing replication-stress-induced DNA damage (Bertoli et al., 2016). 
The interaction of CtIP and BRCA1 also facilitates transcriptional regulation. For example, both CtIP 
and BRCA1 are required to form a complex with LMO4 which represses BRCA1-mediated 
transcriptional activation through inhibition of BRCA1 binding to other proteins (Sum et al., 2002). CtIP 
also regulates gene transcription through its binding to other transcription factors. For instance, 
binding to CtBP can in turn recruit further proteins involved in promoter targeting and chromatin 
remodelling (U. Schaeper et al., 1998). The same is also true for the CtIP-RB interaction connecting 
CtIP through RB to the Krupple zinc finger protein Ikaros for transcription repression (Koipally and 
Georgopoulos, 2002).  
On DNA damage, CtIP has also been shown to play a transcriptional role initiating the production of 
CDK inhibitor P21, with CtIP binding to the p21 promotor to drive expression (Liu et al., 2014). At the 
same time, DNA damage activation of ATM leads to phosphorylation of CtIP on serine 664 and 745, it 
is thought that this can also regulate the expression of ATM as well as help activate cell checkpoint 
control (Liu and Lee, 2005). The phosphorylation of CtIP by ATM has also been shown to cause 
disassociation of BRCA1 from CtIP which allows transcription of the GADD45 gene upon IR (Li et al., 
2000), this activates p53 through the MAP Kinase pathway for cell cycle control (Salvador et al., 2013). 
The Notch signalling pathway can determine cell fate of various cell lineages. Binding of ligand to the 
receptor leads to release of the Notch intracellular domain which can activate transcription, however, 
without ligand the Notch controlled genes are supressed by the RBP-Jk/SHARP corepressor complex. 
Research by Ozwald et al. identified interactions between SHARP C-terminal and CtIP which were 
sufficient to supress CtIP mediated transcription prior to Notch signalling. The Notch target gene Hey1 
was also shown to be regulated by CtIP/CtBP with CtBP-depressed embryonic fibroblasts showing a 
strong reduction in Hey1 (Oswald et al., 2005). Deficiency in Hey1 known to cause death after 
embryonic day 9.5 showing the crucial role of CtIP transcriptional control in development (Fischer et 
al., 2004). 
Further evidence exists for CtIP’s involvement repair of DSBs in the context of topoisomerase and 
transcription. GAT3, a transcription factor critical for mammary gland development, has been shown 
to bind to the CtIP promotor to trigger transcription when topoisomerase II is stalled by etoposide and 
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DSB are formed (Zhang et al., 2017). CtIP has also been shown to interact with TopBP1 in a damage 
dependant manner while interacting the Nbs1 bringing the MRN complex to topoisomerase DSBs for 
repair (Ramírez-Lugo et al., 2011). 
 
1.6.4 CtIP and And-1 
The acidic nucleoplasmic DNA-binding protein 1 (And-1) has a well-established role at the replication 
fork to couple the CMG-helicase and DNA polymerase alpha ensuring fast replication. And-1 has been 
shown to have many other functions here at the replication fork including its role in the replication 
pausing complex, recruitment of polymerase alpha to chromatin, activation of Chk1 during replication 
stress and more recently a function in fork protection preventing excessive spans of ssDNA which are 
converted to DSBs (Abe et al., 2018; Errico and Costanzo, 2010; Hao et al., 2015; Yoshizawa-Sugata 
and Masai, 2009; Zhu et al., 2007). Depletion of And-1 has been reported incompatible with 
replication, causing cells to accumulate in G2 phase due to activation of DNA damage checkpoint 
control. Within the fork protection aspect of And-1 it was shown that loss of And-1 allows Mre11 to 
resect DNA to produce long ssDNA stretches. Removal of the And-1 WD40 domain had the same effect 
as knockdown of And-1 indicating this region to be important for the function (Abe et al., 2018). 
Since And-1 and Mre11 are connected in the fork protection pathway is it not surprising that 
interactions with CtIP have been reported. Identification through a co-immunoprecipitation 
interaction study has shown that CtIP and And-1 can interact through its C-terminal and a region 
spanning from residues 850-1050 of And-1. GFP-tagged And-1 immunofluorescence of U2OS cells 
showed co-localisation to γH2AX sites of DSB prior to CtIP. And-1 knockdown showed a dramatic 
inhibition of CtIP localisation and reduced subsequent Rad51 foci formation. Measuring HR efficiency 
on siRNA knockdown of endogenous And-1, and addition of siRNA resistant And-1 that lacked the CtIP 
interaction patch, failed to restore HR with hypersensitivity to DNA damaging agents. Addition of 
siRNA resistant wild type And-1 did however recapitulate resection. The results published by Chen et 
al. showed an important role for the newly discovered And-1 CtIP interaction in the HR pathway, with 
cells sensitized to DNA damage and replication stress. An increased proportion of chromosome 
abrogations were also reported suggesting the interaction plays a role in maintaining genome integrity 





1.6.5 The endonuclease activity of CtIP 
Studies on Sae2 showed that it possesses endonuclease activity independent of Mre11 (Lengsfeld et 
al., 2007). However, a recognisable nuclease active site is absent from the amino acid sequence with 
other groups unable to show nuclease activity (Cannavo et al., 2018). Unlike the MRX nuclease (yeast 
homologue to MRN) which requires manganese, Sae2 can operate with either manganese or 
magnesium to digest DNA. This activity is strongly activated by adjacent DNA hairpin structures which 
have been shown to be cleaved cooperatively between Sae2 and MRX (Lengsfeld et al., 2007). In 
contrast, although many other functions are comparable between Sae2 and other homologues, in 
Ctp1 no intrinsic nuclease activity has been seen (Andres et al., 2015).  
There has long been debate within the CtIP field regarding an intrinsic enzymatic nuclease activity. No 
known nuclease fold can be detected from the human amino acid sequence or through structural 
predictions. In 2007 Sartori et al. assessed the nuclease activity of HEK293 expressed CtIP with no 
activity present (Sartori et al., 2007). However, the T. Paull group, through various experiments using 
insect cell expressed CtIP showed nuclease activity. A region between residues 165 and 347 was shown 
to be important with asparagine 289 and histidine 290 necessary, with claimed homology to Mre11 
H129N. The previously mentioned “minimum DNA interaction region”, which was later shown to also 
bind to PCNA, was also required for the nuclease activity (Makharashvili et al., 2014). A further group 
also expressing CtIP from insect cells reported evidence of CtIP’s nuclease activity, however both 
groups confirmed that the action is outside of canonical HR (Makharashvili et al., 2014; Wang et al., 
2014). In contrast, expression of CtIP in human cells has not been reported to have nuclease activity 
(Anand et al., 2016; Liao et al., 2016). Although CtIP nuclease activity cannot be ruled out it remains 
to be solidified. One possibility is that the different purification methods yield different post 
translational modifications or co-purify different binding partners from the host expression system. 
These events could enforce an unknown enzymatic conformation within CtIP. 
1.6.6 Oligomerisation and DNA binding of CtIP 
Although sequence homology is more limited at the N-terminal domain, oligomerisation of CtIP does 
exist throughout various orthologues of CtIP. From analytical ultracentrifugation experiments Sae2 
has been reported to form several multimeric complexes with a dimeric form dominating. DNA binding 
of Sae2 has also been seen through electrophoretic mobility shift assays forming a stable complex. 
Consequently, removal of the N-terminal region resulted in monomeric protein which lacked nuclease 
activity both with and without MRX and failed to bind DNA. More recently two domains were 
identified at the N-terminus that are required for oligomerisation and confirmed the functional 
importance (H. S. Kim et al., 2008). Original discoveries of CtIP identified the N-terminal to be the 
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region for dimerization through a coiled-coil domain, this dimerisation was reported to stabilise the 
interaction with RB (Dubin et al., 2004; Stokes et al., 2007). More recently Ctp1 and CtIP have been 
shown to form a dimer of dimers orientation to generate a tetrameric species. Crystal structures for 
the start of the domain were published showing a head to head orientation of two parallel coiled-
coils. Removal of the N-terminal region in both cases when measuring HR showed the domain to be 
critical for DSB repair (Andres et al., 2015; Davies et al., 2015). DNA binding activities of the C-terminal 
domain were also reported. For Ctp1 the tetramerisation made bridging of two DNA strands possible 
through the DNA binding at the opposing C-termini, weak DNA binding was also reported for the N-
termini of Ctp1. For human CtIP DNA binding was only reported for the C-terminus of the protein 
binding to dsDNA (Andres et al., 2015; Davies et al., 2015).  
Within the oligomerisation of CtIP, the extent to which the dimerisation extends remains unclear. 
Early reports indicated a secondary coiled-coil at the C-terminus of CtIP however with low probability 
(Dubin et al., 2004; Fusco et al., 1998). Interestingly for the interaction of CtIP and LMO4 the dimeric 
region of CtIP is required, showing that even ~500 amino acids away from the N-terminal coiled-coil 





1.6.7 Seckel and Jawad syndromes 
Complete deficiency of CtIP in humans has not been seen. Inactivation of CtIP through deletion studies 
or removal of the T847 CDK site in mice leads to early embryonic lethality. This is due to inability to 
overcome the G1 to S phase checkpoint (Chinnadurai, 2006), with haploid insufficiency leading to 
tumorigenesis and cancer progression in mice (Chen et al., 2005; Polato et al., 2014).  
However, two related disorders - Seckel and Jawad syndromes - have been shown to be caused by a 
frameshift or splicing mutation respectively in CtIP. Despite the recessive inheritance of the disorders, 
these mutations carry a dominant negative manifestation at the cellular level. Although normal 
expression levels of CtIP protein are seen, only low levels of truncated CtIP mRNA are present, while 
the ratio of mutant to wild type protein determines the strength of the disorder phenotype. 
Expression above the threshold to impede DNA DSB end resection and subsequent ATR signalling 
causes significant clinical symptoms with an early onset, such as mental retardation, dwarfism, 
microcephaly, skeletal abnormalities, and chromosome instability (Qvist et al., 2011). Further 
characterisation of patient-derived cell lines has shown hypersensitivity to DNA damage and a lower 
threshold for apoptosis. These phenotypes have been attributed to a truncated CtIP produced by the 
mutations. Notably in cases of Seckel syndrome only the last 152 amino acids are removed highlighting 
the importance of the C-terminal domain in CtIP function (Qvist et al., 2011).  
The magnitude of the phenotypes from such a small discrepancy in a subset of CtIP protein highlights 
the importance of its known and unknown functions both In DNA repair and in a larger cellular context. 
Studies to determine the structural and biochemical characteristics of CtIP will gain valuable insight 





1.7 Aims and objectives  
CtIP has been demonstrated to be a multivalent adaptor protein and an apical point of signal 
transduction within cellular processes. So far this includes an involvement in transcription, translation, 
checkpoint activation and now a firm role in DNA DSB repair, with intimate links between the various 
functions of CtIP. Considering the multiple functions of CtIP and its interacting partners it is expected 
the structure of CtIP plays a crucial role.  
The main aim of this project is to further our understanding of CtIP’s function in maintaining genomic 
stability. To this end, the objectives of the work summarised in this thesis are to purify and characterise 
the full-length CtIP protein and the individual N- and C-terminal domains using biochemical and 
biophysical methods. For the full-length CtIP protein the goal is to generate sufficient amounts of 
protein for biophysical analysis of the reported oligomeric state and DNA binding abilities, alongside 
structural studies using Cryo EM. The C-terminal domain objective is to confirm the DNA and zinc 
binding capacity along with interactions with And1, while probing the region adjacent for its 
oligomeric state. The objective of N-terminal domain work is to determine the crystal structure of the 









Chapter 2, Methods  
2.1 Molecular Cloning for recombinant protein production 
2.1.1 Sequence analysis 
Protein sequences of the C-terminus of CtIP human and its eukaryotic orthologues were extracted 
from the NCBI protein database. The sequences were aligned by ClustalW multiple sequence 
alignment algorithm (Larkin et al., 2007), and displayed using Jalview (Clamp et al., 2004; Waterhouse 
et al., 2009). A prediction of coiled–coil structure within CtIP was generated using COILS (Lupas et al., 
1991), MARCOILS (Delorenzi and Speed, 2002) and Paircoil2 (McDonnell et al., 2006).  
2.1.2 Cloning  
For amplification of the N-terminal domain (NTD) constructs PCR was performed on either CtIP image 
clone 4830693 (Source Bioscience) or a synthesised gene fragment (G-block IDT) generated using the 
same sequence. CtIP residues 1-897 (CtIPFL) for pACEBac1 or pACEMam1 constructs were amplified 
from cDNA (mRNA variant X3) which was kindly donated to the lab by Tanya Paull. Constructs spanning 
CtIP residues 694-775 (dCTD) and 694-897 (CTDex) were selected through coiled-coil prediction 
software and amplified from cDNA (mRNA variant X3) with all primers in Appendix 2. PCR strategy 
used consisted of initial denaturation at 98°C for 3 minutes, followed by 25-35 cycles of: denaturation 
at 98°C for 30 seconds, annealing at the appropriate temperature for 30 seconds, followed by 
extension at 72°C for 30 seconds per 1 kb (minimum 30 seconds) using Phusion® polymerase (Thermo 
Scientific).  
PCR products were cleaned by a PCR purification kit (Thermo Scientific) using manufacturer’s 
instructions and digested with appropriate restriction endonuclease (Appendix 2) at 37°C for 1 to 2 
hours. Digested DNA was purified using a DNA Clean and concentrator (Zymogen D4003) kit prior to 
ligation. Alongside this, the vector (pMAT11 – Bacterial expression with N-terminal His-Maltose 
Binding Protein (MBP tag), pACEBac1 – Baculovirus expression, pACEMam1 – HEK293F expression) 
was digested with the same enzymes, dephosphorylated with Antarctic phosphatase (NEB) for 45 
minutes followed by 2 minutes 80°C heat kill, and either gel-extracted using Thermo Scientific gel 
extraction kit (Cat No. K0691) or purified using a DNA Clean and concentrator (Zymogen D4003) kit to 
give purified cut vector. DNA concentrations were analysed using a Nanodrop™ spectrophotometer 
at 260 nm. Quick Ligation™ kit (NEB) was used to ligate the cut PCR product into the cut vector at a 
3:1 mass ratio with 50 ng of vector used. Ligated plasmid was transformed immediately.  
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Heat-shock bacterial transformation was performed on Dh5α (NEB) or Dh10β (NEB) bacterial cell lines. 
1 to 2 µL of the Quick Ligation reaction was added to 25 or 50 µL of cells and incubated for 30 minutes 
on ice. Cells were heat shocked at 42°C for 45 seconds followed by 5 minutes of recovery at 4°C. 300-
900 µL of SOC medium was added and cells were transferred to a 10 mL culture tube for incubation 
with orbital shaking at 37°C for 1 to 2 hours. 300 µL of the cell culture was plated onto LB agar plates 
containing the appropriate antibiotics (pMAT11 – Ampicillin, pACEBac & pACEMam – Gentamicin) and 
incubated at 37°C overnight.  
Colonies were isolated and grown in liquid media for plasmid extraction. Restriction digest was 
performed using the original insertion primers to confirm incorporation of the insert. For CtIPFL XhoI 
and SalI were used to confirm insertion. Positive clones were sequence-confirmed using the 
appropriate plasmid-specific primers along with internal primers where required (Appendix 2) by the 
Department of Biochemistry DNA Sequencing Facility, University of Cambridge.  
For addition of an N-terminal Twin Strep tag (appendix figure 7.7) the sequence-confirmed CtIPFL 
construct was digested with the SalI restriction endonuclease. The amplified Twin-Strep sequence 
from a synthesised gene fragment was also digested with SalI, and ligation was performed with a 3:1 
insert to vector mass ratio. Positive clones were identified by digestion with BstBI (NEB) (appendix 
7.7). Positive clones were then sequenced to confirm the Twin Strep tag was in the correct frame 
orientation with CtIPFL.  
2.1.3 Mutagenesis 
The Cluster mutations and L27E were introduced by the QuickChange® site directed mutagenesis 
(Strategene) method using manufactures guidelines and primers detailed in Appendix 2. Zinc binding 
mutations C89A/C92A were introduced to a synthesised gene fragment and sub cloned into the 
pMAT11 expression vector.  
CtIP residues 769-897 (CtIP-CTD) point mutations and combination mutations were generated by 
overlap extension PCR (figure 2.1.3). Two initial PCR reactions were performed using template, 
mutation primer pairs at an annealing temperature of 55°C (figure 2.1.3a – part 1). These two PCR 
products were purified by gel electrophoresis. For the second stage, 5 PCR cycles were performed with 
these two extracted DNA products with a 55°C annealing temperature. Only end primers were then 
added and a further 28 cycles of PCR performed at a 64°C annealing temperature (figure 2.1.3a part 
2). For combination mutations sections of CtIP-CTD were amplified using the same technique (figure 
2.1.3b part 1). Second round PCR was used to anneal together and amplify the DNA to generate first 
round combination mutant PCR products (figure 2.1.3b part 2). For mutations in close proximity, 
alternate primers were used to gain multiple mutations from a single primer. Addition of non-mutated 
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CtIP-CTD DNA or different combinations of mutated DNA template then allowed generation of a 
multitude of mutation products through successive rounds of PCR (figure 2.1.3b – part 3).  
These were then sub-cloned into the pMAT11 expression vector to generate His-MBP fusion proteins 
for purification. Other PCR constraints followed manufacturer’s protocol. All constructs were 









Figure 2.1.3: Overlap extension PCR method. Arrows indicate primers; perpendicular lines 
indicate mutations within primer. Fragments were gel purified after PCR. A) Process for single 
mutants. B) Process for combination mutants, with black lines indicating amplified wild type 
DNA. Multiple rounds of the same protocol were performed consecutively, each contained two 
DNA fragments at a time until the full length was restored to form the multiple mutations 




2.2 Recombinant protein production in E. coli 
All buffers were filtered and degassed using a 0.22 µm membrane (Triple Red FPE214500). 
E. coli Rosetta™ 2 (DE3) cells were transformed using the heat-shock protocol mentioned previously. 
Antibiotic resistance was used as selection marker for the sequence confirmed construct and addition 
of chloramphenicol for the T-rare Rosetta™ 2 plasmid. Transformed cells were grown on LB-agar plates 
until a lawn of colonies was present (16-24 hours) before starting a pre-culture of 10-40 mL in 2XYT 
grown at 37°C 200 RPM with the same antibiotics. The pre-cultures were then inoculated into between 
2 to 8 litres of 2XYT pre- warmed to 37°C with the same antibiotic selection. Cells were grown at 37°C 
200PRM with the optical density at 600 nm (OD600) being measured regularly. For growth of cells with 
zinc-supplemented media when OD600 reached 0.4, zinc acetate was added to a final concentration of 
250 µM. When cells reached between an OD600 of between 0.8 and 1.0, IPTG (Generon) was added to 
a final concentration of 0.5 mM to induce protein production, at this point the temperature was 
reduced to 20°C for overnight expression. The cells were grown for 16 h before they were harvested 
by centrifugation at 4,000 RCF (relative centrifugal force) for 10 minutes at 20°C. Cell pellets were 
suspended in 24 mL of standard buffer (20 mM Tris pH 8, 300 mM NaCl) with SigmaFAST™ EDTA-Free 
protease inhibitors per 2 litres of culture before flash-freezing in liquid nitrogen. 
2.2.1 E. coli cell lysis 
The resuspended cell pellets were thawed and either lysed by sonication or using a high-pressure 
homogenizer (Avestin Inc EmulsiFlex C5). For sonication, cells were lysed within their individual 50 mL 
tubes on ice for a net time of 3.0 minutes, with a 5 second pulse every 10 second sonication interval 
(Sonics Vibra-ell™.) When using a high-pressure homogeniser (EmulsiFlex), cells were passed through 
a total of 3-4 times, maintaining lysis pressure between 5,000 and 10,000 PSI (pound per inch2). 
Multiple tubes were combined prior to and re-distributed on exit from the EmulsiFlex. 
2.2.2 Protein purification of N-terminal His-MBP tagged CtIP NTD  
All protein purification stages were carried out at 4°C unless stated otherwise.  
A resuspended pellet from 2 litres of E. coli Rosetta™ 2 (DE3) cell expression of a NTD construct were 
thawed and lysed by sonication, followed by clarification by 45,000 RCF for 1 hour at 10°C and 
subsequent 5.0 µM filtration (Minisart 17594-K). Filtered supernatant was then bound to a 2ml Ni-
NTA column (Qiagen 30230) by gravity flow dropwise, washed with 20 mL of wash buffer (standard 
buffer with 10 mM imidazole) before elution with 9 mL of the same buffer with 200 mM imidazole. 
Ni-NTA elution fractions containing CtIP-NTD were bound to a 5 mL Amylose (NEB) column by gravity 
flow dropwise and washed with 10 mL of standard buffer. For removal of the His-MBP tag the resin 
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was re-suspended in 10 mL of standard buffer inside the chromatography column with TEV protease 
and 0.5 mM TCEP added. The slurry was rolled at 4°C overnight. Amylose resin was incubated without 
rolling for 5 minutes prior to collection of the flow through. Five 5 mL washes were performed with 
the standard buffer. The flow through and first wash fractions were pooled, and 10 mM imidazole 
added for a 1 mL Ni-NTA column recapture of contaminants. Ni-NTA flow through was collected and 
concentrated to 1 mL using a 10,000 MWCO concentrator (VivaSpin VS2002). For final polishing a 
Superdex 200 16/60 Size Exclusion Chromatography (SEC) column was equilibrated into standard 
buffer, protein applied, and fractions collected. Fractions corresponding to the CtIP-NTD construct 
were selected by SDS-PAGE, pooled and concentrated using a fresh 10,000Da MWCO concentrator 
until the protein concentration was above 10 mg/ mL. Concentrated protein was centrifuged at 4°C, 
14,000 RCF for 15 minutes before the concentration was measured by absorbance at 280 nm. For 
constructs inclusive of residues 28-145, protein concentration was determined through comparison 
to an amino acid analysis standard curve. Protein was aliquoted, and flash frozen in 10/20 µL shots 
and stored at -80ᵒC for long term storage. 
2.2.3 Purification of N-terminal His-MBP, C-terminal Strep tagged NTD and dCTD 
constructs 
For each purification 2 litres of cells were thawed and lysed by high-pressure homogenisation 
(EmulsiFlex) to disrupt the cell membrane. Lysate was clarified by centrifugation at 45,000 RCF for 1 
hour at 10°C, followed by filtration through a 5.0 µm membrane (Minisart 17594-K). For initial capture 
filtered supernatant was bound to a 2 mL Ni-NTA column by gravity flow dropwise, washed with 20 
mL of wash buffer (standard buffer with 10 mM imidazole) before elution with 9 mL of standard buffer 
with 200 mM imidazole. Protein was dialysed overnight into the standard buffer + 2 mM DTT (Sigma) 
with addition of TEV were necessary to remove the His-MBP tag. For MBP-fused protein addition of 
TEV was omitted. To separate the cleaved protein from the His-MBP tag a 2 mL Strep-Tactin™ 
Superflow® (Strep-Tactin) column was prepared and equilibrated into the standard buffer. The 
dialysed and cleaved protein was then added to the Step-Tactin resin (IBA 2-1206-025) column and 
incubated for 5-10 minutes without flow. Using a flow restrictor, the gravity flow of the column was 
restricted to 0.1-0.2 mL/min to allow the protein to bind. The column was then washed with 20 mL of 
standard buffer before elution with 9 mL of standard buffer with 25 mM d-desthiobiotin (Sigma). This 
elution fraction was bound to a 1 mL His-Trap™ column (GE Healthcare) equilibrated into standard 
buffer. The column was washed with 6% buffer B (standard buffer + 200 mM imidazole) for 5 CV to 
remove weakly bound impurities before elution of NTD-Strep with 10% buffer B. The contaminants 
were then eluted with 100% buffer B.  
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For a final polishing step, a Superdex 75 16/60 SEC column was equilibrated into standard buffer. 
Multiple 2 mL sequential applications were performed dependent on His-Trap™ elution volume with 
SEC flow reduced to 0.4 mL/min. Fractions containing NTD-Strep or dCTD were identified by SDS-PAGE, 
pooled and concentrated using a 10,000 Da MWCO concentrator (Vivaspin Vs2002) until protein 
concentration was above 10 mg/mL or volume was below 150 µL. Before aliquoting protein was 
centrifuged at 4°C, 14,000 RCF for 15 minutes and final protein concentration measured by 
absorbance at 280 nm using a Nanodrop™ spectrophotometer. Protein was flash-frozen in 10-20 µL 
aliquots and stored at -80ᵒC for long-term storage. 
2.2.4 Preparation of selenomethionine-labelled NTD31-145-strep and NTD31-145DM-Strep 
The Molecular Dimensions minimal media base (MD12-501 / MD12-502) was used for production of 
selenomethionine-labelled protein. Initially 4 litres of Rosetta2™ DE3 cells expressing NTD31-145-Strep 
or NTD31-145DM-Strep were grown in 2XYT media to OD600 0.6 using the standard procedure. Cells were 
harvested at 4,000 RCF for 10 minutes before suspending in 10 mL of autoclaved PBS, combined 
together and a further centrifugation at 4,000 RCF for 10 minutes. The cell pellet volume was adjusted 
to 45 mL with autoclaved PBS and distributed between the four 1 litre flasks of minimal media. Cells 
were grown for 40 minutes in minimal media at 25°C before addition of 50 mg of powdered 
selenomethionine (Arcos 259960025) per 1 L of minimal media. After a further 90 minutes protein 
production was initiated using 0.5 mM IPTG and temperature reduced to 20°C for 16 hours for protein 
production. Cells were subsequently harvested at 4,000 RCF for 10 minutes, prior to suspension in 
standard buffer supplemented with 3 mM TCEP and protease inhibitor tablets. 
Protein was purified from 4 litres of cells using the standard procedure (2.2.3) with the following 
alterations. Initial capture was with a 5 mL Amylose column (NEB) pre-equilibrated into standard 
buffer + 3 mM TCEP, with 0.5 mM TCEP included throughout this procedure. Dialysis with TEV cleavage 
was performed using the standard protocol followed by Strep-Tactin capture with no reducing agent 
on elution. His-Trap™ chromatography was performed as standard with elution fractions applied in 
two sequential Superdex 75 16/60 SEC column runs at flow rate 0.4 mL/min pre-equilibrated into 
standard buffer either with or without 2mM DTT (sigma)  
2.2.5 Purification of CTDex, MBP-CTD, CtIP-CTD and its mutants 
For each purification, a resuspended pellet from 2 litres of cells was thawed and lysed by either 
sonication or high-pressure homogenisation (EmulsiFlex) before clarification at 45,000 RCF for 1 hour 
at 10°C, then filtered through a 5.0 µm membrane (Minisart 17594-K). For initial capture, a 5 mL 
Amylose (NEB) column was prepared and pre-equilibrated with the same resuspension buffer. Filtered 
supernatant was bound to the column by gravity flow dropwise, washed with 20 mL of standard buffer 
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before elution with standard buffer + 10 mM maltose. Protein was dialysed overnight into the 
standard buffer with addition of TEV were necessary to remove the His-MBP tag. TEV protease was 
pre-activated with 10 mM DTT (Sigma) for 30 minutes at 25°C before mixing with the eluted protein.  
To remove the cleaved His-MBP tag from the protein preparation, the dialysed sample was first diluted 
to 100 mM NaCl with 20 mM Tris pH 8.  Diluted sample was subsequently loaded onto a 5 mL Hi-Trap™ 
Heparin column (GE Healthcare) that had been pre-equilibrated with buffer A (20 mM Tris pH 8, 100 
mM NaCl). The column was then washed with 10 mL of buffer A, before the flow was reversed and a 
further 10 mL of buffer A was washed over the column. Contaminants were removed with a step to 
17.5% v/v buffer B (20 mM Tris pH 8, 1000 mM NaCl) for 15 mL before reducing the buffer B% to 0 
over a further 10 ml. A gradient of buffer B from 0-60% was then used to elute the CTD protein and 
mutants. 100% v/v buffer B was used to wash the column of other bound proteins. For CTDex, a step 
gradient of 40% v/v buffer B was used to elute and concentrate the protein. 
Elution fractions corresponding to CtIP-CTD were pooled and concentrated using a 10,000 MWCO PES 
concentrator (Vivaspin® vs2002) until the pooled volume was below 1 mL. Where indicated within the 
results a 200 µl amylose column was then prepared using a 1 mL gravity flow column (Expedeon 
AMCO25), pre-equilibrated into the standard buffer before allowing the concentrated CTD to pass 
through by gravity flow. The flow, along with a 200 µL wash fraction from the final amylose column 
(or the 1 mL concentrated fraction when this stage was omitted) was then spun at 14,000 RCF for 10 
minutes 4°C before injection onto a pre-equilibrated Superdex 75 16/60 SEC column. The eluted 
fractions were collected. Fractions corresponding to CtIP-CTD were pooled and concentrated, with 
final concentration measured by absorbance at 280 nm. Protein was flash frozen in 10-20 µL aliquots 
and stored at -80ᵒC for long-term storage. 
2.2.6 Expression and purification of And11-826 and And1316-826 
Rosetta™ 2 (DE3) cells were transformed with an And11-826 or And1316-826 construct using the standard 
procedure prior to growth in liquid media. Four litres of 2XYT media were used for each construct, 
grown until OD600 reached 0.8, and induced with 0.5 mM IPTG (Generon). Cells were incubated at 20°C 
before harvesting 16 hours post induction. Cells were resuspended using 20 mM HEPES pH 7.2, 500 
mM NaCl, 10 mM imidazole and SigmaFAST™ EDTA-Free protease inhibitors before flash freezing in 
liquid nitrogen. 
For each construct four litres of cells were lysed by high-pressure homogenisation (EmulsiFlex) (4 
passes) before clarification at 45,000 RCF for 1 h at 10°C and filtration through a 5.0 µm membrane. A 
2 mL Ni-NTA column was prepared using His-select® Ni-NTA affinity gel (Sigma Cat no. H0537) at 25°C 
56 
 
and equilibrated with the resuspension buffer. Protein was bound dropwise before washing with 12 
CV of resuspension buffer and elution in 1 CV fractions with 20 mM HEPES pH 7.2, 500 mM NaCl, 200 
mM imidazole. Fractions containing And1 were identified by SDS-PAGE and pooled for further 
purification by ion exchange chromatography using a 5 mL HiTrap™ Q column (GE healthcare). NaCl 
concentration was diluted to 160 mM for binding to the column, which had been pre-equilibrated in 
buffer A (20 mM HEPES pH 7.2, 100 mM NaCl). A linear gradient of buffer A to buffer B (20 mM HEPES 
pH 7.2, 1 M NaCl) was used to elute the protein. Fractions containing And1 were analysed by SDS-
PAGE, pooled, and concentrated using a 10,000 Da MWCO PES concentrator (Vivaspin® VS2002). 
Purified And11-826 was flash frozen in liquid nitrogen for future pull-down experiments. Purified 
And1316-826 was further polished by SEC using a Superdex 200 16/60 column. Resultant fractions 
corresponding to And1316-826 were identified by SDS-PAGE, pooled and flash frozen in liquid nitrogen. 
2.2.7 E. coli purification of CtIPFL 
A resuspended pellet from 2 litres of E. coli Rosetta™ 2 (DE3) cell expression of CtIPFL was thawed and 
sonicated using the standard procedure; cell debris were removed by centrifugation at 45,000 RCF for 
1 hour at 10°C. Supernatant was filtered through a 5.0 µm membrane before loading onto a 2 mL Ni-
NTA resin (Qiagen) bed dropwise by gravity flow. The column was washed with five 5 mL washes with 
standard buffer supplemented with 10 mM Imidazole, then eluted with five 3 mL washes of standard 






2.3 Bacmid generation for baculovirus insect cell expression 
2.3.1 Transformation and selection 
Dh10Bac cells (Gibco) were used for recombination of the pACEBac vector into the bacmid within the 
Dh10Bac cells for viral amplification. Cells were transformed using the standard protocol with 1 ng of 
an individual pACEBac1 protein expression construct (CtIP, Mre11, Rad50 and Nbs1) with 20 µL of 
DH10Bac cells. Following transformation cells recovered at 37°C for 5 hours with orbital shaking. Cells 
were then plated out onto LB-agar with selection (table 2.3.1). Plates were incubated for 48 h at 37°C 
until blue and white colonies could be distinguished. Individual white colonies were picked and plated 
on fresh LB-agar plates with the same selection for a further 24-48 hours at 37°C. Confirmed white 
colonies were then cultured for alkaline lysis. 
Ingredients  Stock solution/ mg 
per mL 
Solvent Final concentration/ 
μg per mL 
Volume for 
100ml of agar/ 
μL 
Kanamycin 34  Milli-Q water 50  150 
Gentamycin 7 Milli-Q water 7  100 
Tetracycline 5 Ethanol 10  200 
X-Gal 20  DMSO 200  1000 
IPTG 238.3 Milli-Q water 40  67 
Table 2.3.1: Selection of blue white colonies using Dh10Bac cells and pACEBac1. 
2.3.2 Alkaline lysis Ethanol precipitation 
Cells were grown in the presence of the same antibiotics as in the LB-Agar (table 2.3.1) in 5 mL of 2xYT 
for 24-36 hours at 37°C with orbital shaking. 0.3 mL of the cells were removed for a glycerol stock and 
mixed with 0.3 mL of 50% v/v glycerol and kept at -80°C. The remaining cells were harvested at 5,000 
RCF for 10 minutes before resuspension in 0.3 mL of buffer P1 (table 2.3.2), 0.3 mL of buffer P2 was 
added and the tube inverted 4-6 times to achieve lysis; this was followed by addition of 0.3 mL of 
buffer P3 and inversion 4-6 times for neutralisation. The mixture was then incubated on ice for 10 
minutes before 10 minutes centrifugation at 14,000 RCF.  
Buffer Composition 
P1 50 mM Tris-HCL pH 8.0 
10 mM EDTA 
100 µg/mL RNase A 
P2  200 mM NaOH 
1% w/v SDS 
P3 3.0 M potassium acetate pH 5.5 




2.3.3 Ethanol precipitation 
Supernatant from alkaline lysis or DNA from large volume PCR reactions were precipitated by 
dropwise addition to 0.8 mL of isopropanol (Sigma) and incubation on ice for 10 minutes. DNA was 
pelleted by centrifugation at 14,000 RCF for 15 minutes, washed with 0.5 mL of cold 70% v/v ethanol 
(Sigma) and re-pelleted at 14,000 RCF for a further 10 minutes before the supernatant was removed. 
The pellet was air-dried for 20 minutes at room temperature. It was then dissolved in TE buffer. 
2.3.4 Bacmid PCR confirmation and Colony PCR 
For colony PCR the starting material was either purified bacmid (1.5 µL) or a single colony from a 
transformation plate. For a single colony the cells were mixed into 10 µL of LB-broth which contained 
25% v/v glycerol. 1 µL of this was then used for the 13 µL PCR reaction using the M13 primers. Cycle 
conditions were 98°C for 5 minutes followed by 35 cycles of 98°C for 30 seconds, 55°C for 30 seconds, 
72°C for 30 seconds per 1 kb of DNA with final extension for 10 minutes at 72°C. Products were 





2.4 Recombinant protein production in Sf9 insect cells  
Sf9 insect cells were grown in Lonza insect express medium (Cat NO. BE12-730Q) at 27°C with constant 
120 RPM orbital shaking, 25 mm throw, (no humidity or CO2 control) continually with passage number 
recorded. Stock cells were maintained in flat-bottomed flasks (Table 2.4). Protein expression was 
performed in 1 litre of cells per 2 litre baffled-bottom flask. Cell density was maintained between 
0.5x106 and 5x106 cells per mL with cell viability monitored. The passage number of the cells was 
recorded, and the cells were split on Mondays, Wednesdays and Fridays until the passage number was 
above 25 or the cell viability reduced to below 80%. Frozen cell stocks were maintained to allow 
constant availability of cells for expression.  
Flask size Culture volume/ mL  
125 mL – Corning 431143, Triforest 355117B 20-50 
250 mL – Corning 431144 50-100 
2L Baffled – Corning 432156, triforest 355131B 1000 
2L Non-baffled – Corning 431255, triforest 
355133B 
Insect cells 200-800 
HEK293F cells 300-400ml 
Table 2.4: Flask details for HEK293F and insect cell expression.  
All protein purification stages were carried out at 4°C unless stated otherwise, with buffers filtered 
and degassed using a 0.22 µm membrane (Triple Red FPE214500). 
2.4.1 Expression and purification of the MRN complex 
Plasmids for baculovirus expression in insect cells of Flag-tagged Mre11, His6-HA tagged Rad50 and 
Nbs1 were donated by Tanya Paull (Lee and Paull, 2006). All purification stages were carried out at 
4°C with the MRN buffer containing 50 mM phosphate buffer pH 7.0, 100 mM KCl, 10% v/v glycerol 
filtered and degassed using a 0.22 µm membrane (triple red FPE214500). 
One litre of Sf9 cells were transfected at a cell density of 2x106 cells per mL with a Multiplicity of 
infection (MOI) ratio of 2.0 Mre11, 6.0 Rad50 and 4.0 Nbs1 bacmids. Cells were harvested by 
centrifugation at 500 RCF for 10 minutes at 3 days post infection, washed in PBS and the cell pellet 
flash frozen in liquid nitrogen. The cell pellet was thawed and resuspended in 70 mL of MRN buffer 
with additional 0.5% v/v Tween 20 and protease inhibitor tablets (SigmaFAST™ EDTA free). Cells were 
lysed by high-pressure homogenisation (EmulsiFlex) (4 passes) and lysate clarified at 75,000 RCF for 
1.5 hours, 10°C using polypropylene centrifuge tubes (Nalgene CAT NO: SQ-3119-0050). Clarified 
lysate was filtered sequentially through a 5.0 µm membrane syringe filter (Minstart cat no 514-4129) 
and a 0.45 µm membrane vacuum filter (Milipore cat no. SCHVU01RE) to remove any large particles 
and to de-gas the sample. A 20 mL 16/10 Fast flow Hi-Prep™ heparin column (GE Healthcare) was pre-
equilibrated with MRN lysis buffer. Filtered lysate was bound to the heparin column by sample pump 
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at 2.0 mL/min prior to washing with MRN buffer for 40 mL in forward flow, and 40 mL in reverse. 
Protein was eluted in reverse flow with 50% MRN buffer B (MRN buffer with final concentration 1 M 
KCl) in a 1 CV peak. For the next step of Flag-affinity purification, a 1 mL M2 anti-Flag affinity column 
(Sigma Cat no. A2220) was prepared in MRN buffer. The combined heparin elution salt concentration 
was diluted to 100-200 mM and washed twice over the anti-Flag column with gravity flow dropwise. 
The column was washed four times with 10 mL of MRN buffer. Protein was eluted by overnight 
incubation with 2 mL of MRN buffer containing 1 mg/mL Flag peptide at 4°C with constant rolling. A 
second elution fraction was obtained by washing further with 2 and then 1 mL of elution buffer. The 
eluted samples were combined and bound to a 5 mL Hi-Trap™ S column (GE Healthcare) equilibrated 
into MRN buffer for removal of Flag peptide, and the protein was eluted with MRN buffer containing 
500 mM KCl. Elution fractions from Hi-Trap™ S were combined and buffer exchanged into MRN buffer 
using a PD10 column (GE Healthcare). Protein was concentrated to 200 µL using a 30,000 MWCO 
concentrator (Vivaspin) with concentration determined by Cary UV absorbance at from 220-360 nm 
using a theoretical extinction coefficient of 159,980 M-1. A concentration of 0.15 mg/mL in 200 μL of 
sample volume was normally achieved per 1 L of insect cell culture. 
2.4.2 Expression and purification of And1 
Sf9 cells at 2.0x106 cells per mL were transfected with 3 mL of recombinant baculovirus per litre of 
cells. Baculovirus was generated by Dr Mairi Kilkenny. Cells were harvested 3 days post transfection 
by centrifugation at 500 RCF for 10 minutes, followed by washing with 1X PBS and a further 500 RCF 
centrifugation. Cells were frozen in liquid nitrogen and stored at -80°C for storage. 
One litre of Sf9 cells were thawed and suspended in 100 mL of And1 lysis buffer (25 mM HEPES pH 
7.2, 500 mM KCl, 5% v/v glycerol, SigmaFAST™ EDTA-Free protease inhibitors, Benzonase® before lysis 
by high-pressure homogenisation (EmulsiFlex) (4 passe). Cell lysate was clarified by centrifugation at 
45,000 RCF for 1 h at 10°C followed by vacuum filtration through a 0.45 µm membrane (Millipore cat 
no. SCHVU01RE). Clarified lysate was bound to a pre-equilibrated 3 mL Ni-NTA column (Sigma H0537) 
and washed with And1 wash buffer (25 mM HEPES pH 7.2, 500 mM KCl, 5% v/v glycerol, 25 mM 
imidazole). Elution was performed in 1 CV fractions using And1 elution buffer (25mM HEPES pH 7.2, 
500 mM KCl, 5% v/v glycerol, 200 mM imidazole). Fractions containing And1 were confirmed by SDS-
PAGE and subsequently pooled, then supplemented with 1 mM EDTA and incubated overnight at 4°C. 
Protein salt concentration was diluted to 200 mM KCl and applied to a 5 mL Hi-Trap heparin™ column 
(GE Healthcare) and eluted with a linear gradient from 100 mM to 1M KCl. Fractions containing And1 
were confirmed by SDS-PAGE, pooled and concentrated to 1 mL using a 30,000 MWCO concentrator 
(Vivaspin® VS2022). Concentrated protein was applied to a 16/60 Superdex 200 SEC column, pre-
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equilibrated into 25 mM HEPES pH 7.2, 140 mM KCl, 0.5 mM TCEP. Fractions containing And1 were 
detected by SDS-PAGE, pooled and concentrated to 1.2 mg/mL. Protein aliquots were frozen in liquid 
nitrogen before storage at -80°C. 
2.4.3 Baculovirus expression of CtIPFL and L27E CtIPFL 
CtIPFL P2 virus was filtered and frozen in 1 mL aliquots for amplification of P3 virus for protein 
expression. Fresh P3 virus was added at a MOI of 2.0 into 50 mL to 2 L of Sf9 cells at 2.0X106 cells per 
mL with constant 120 RPM shaking, 25 mm throw at 27°C with a viability of ≥95% that was monitored 
daily. Cell harvesting occurred at day 2 by centrifugation at 500 RCF for 10 minutes, with supernatant 
removed and cell pellet washed with PBS prior to freezing. 
A cell pellet from 0.5 to 2.0 litres of Sf9 cells that had expressed CtIPFL was thawed and suspended in 
35-140 mL final volume of lysis buffer (20 mM Tris pH 8, 100 mM NaCl, 0.5 mM TCEP pH 8, 10% v/v 
glycerol, 0.5% v/v Tween 20, SigmaFAST™ EDTA-Free protease inhibitors, 2.5 units of Benzonase® 
(Sigma)). Cells were lysed by high-pressure homogenisation (EmulsiFlex) (4 passes) and lysate clarified 
at 75,000 RCF for 1.5 hours, 10°C using polypropylene centrifuge tubes (Nalgene CAT NO: SQ-3119-
0050). Clarified lysate was filtered sequentially through a 5.0 µm membrane syringe filter (Minstart 
cat no 514-4129) and a 0.45 µm membrane vacuum filter (Milipore cat no. SCHVU01RE) to remove 
any large particles and to de-gas the sample. Filtered lysate was bound to a 1 mL M2 anti-Flag affinity 
column (Sigma Cat no. A2220) by gravity flow dropwise and washed in Sf9-CtIP buffer (20 mM Tris pH 
8, 100 mM NaCl, 0.5 mM TCEP pH 8 and 10% v/v glycerol). Protein was eluted by overnight incubation 
with 2 mL of Sf9-CtIP buffer containing 1 mg/mL Flag peptide at 4°C with constant rolling. A second 
elution fraction was obtained by washing further with 2 and then 1 mL of elution buffer. Fractions 
containing CtIP were confirmed by SDS-PAGE, pooled and concentrated to 0.5 mL using a 30,000 
MWCO concentrator (Vivaspin® VS2022). Concentrated protein was applied to a Superdex 200 10/300 
SEC column, pre-equilibrated into Sf9-CtIP buffer. Fractions containing CtIPFL were detected by SDS-
PAGE. Protein was concentrated to 400 µL using a 30,000 MWCO concentrator (Vivaspin® VS2022) 
with concentration determined to be 0.7 mg/mL or 6.75 µM by Cary UV absorbance at from 220-360 
nm using a theoretical extinction coefficient of 41715 M-1. Protein aliquots were frozen in liquid 





2.5 Recombinant protein production of CtIPFL from HEK293F cells 
Human Embryonic Kidney 293 freestyle (HEK293F) cells (Invitrogen) were grown in Freestyle™ media 
(Invitrogen) in a Kuhner incubator at 37°C, 8% CO2, 100% Humidity, 125 RPM shaking, and 25 mm 
throw, continually with passage number recorded. Flat bottomed flasks detailed in table 2.4 were 
used. Cells were split Mondays and Fridays to 0.2x106 cells per mL in 25 mL to maintain cells in the 
growth phase until the passage number reached above p15 or cells began to form clumps. At this point 
a fresh batch of cells would be started from a frozen cell stock. 
2.5.1 DNA purification for HEK expression 
For high quantities of DNA for transfection a QIAGEN® Mega prep (endotoxin free – Cat No. 12381) 
was used, yielding around 1 to 3 mg of plasmid DNA from 1 Litre of cells. The sequence confirmed 
pACEMam1 CtIPFL DH10β glycerol stock was inoculated into 50 mL of 2xYT with gentamicin. The cells 
were grown at 37°C for 8 hours before inoculation into 1 Litre of LB media with gentamicin. The 1 litre 
culture was grown at 30°C 180 RPM overnight before harvesting by centrifugation at 4000 RCF for 10 
minutes. The manufacture’s protocol was then followed for the remainder of the purification with a 
few alterations. Firstly, on binding to the column (step 13) the remainder of the filtered DNA was kept 
on ice. In step 16 the eluted DNA was chilled prior to precipitation, with the centrifugation (step 17) 
increased to 30 minutes to ensure the DNA was precipitated. 
2.5.2 HEK293F protein expression 
For protein expression, cells were split until the required volume was achieved at 0.5x106 cells per mL 
on the day prior to transfection. The following day cells were counted using a nebular chamber, and 
the total number of cells was calculated. To transfect the cells, Freestyle™ media (Invitrogen) 
corresponding to 1/10th of the total culture volume was used; 1.2 µg of pACEMam Twin-Strep CtIPFL 
DNA along with 2.4 µg PEI were added per 1 million cells. The mixture was vortexed for 10 seconds 
and incubated at room temperature within the hood for 15 minutes before addition to the cells that 
were to be transfected. Three to four hours post transfection a final concentration of 4 mM filtered 
valproic acid was added to the transfected cells. The length of expression was experimentally 
determined by removal of 1 mL of cells daily with total and soluble protein analysed by Western Blot.  
Valproic acid-treated cells were harvested four days post transfection at 500 RCF for 10 minutes, 
washed in 1X PBS, and harvested at 500 RCF for 10 minutes with supernatant removed. Cell pellets 
were flash frozen in liquid nitrogen prior to storage at -80°C. 
All protein purification stages were carried out at 4°C unless stated otherwise, with buffers filtered 
and degassed using a 0.22 µm membrane (Triple Red FPE214500). 
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2.5.3 CtIPFL HEK293F Protein purification  
A cell pellet from 0.4-1.2 L of HEK293F cells that had expressed CtIPFL was thawed on ice for 1 hour 
prior to resuspension in 20 to 40 mL final volume of lysis buffer (50 mM Tris pH 8, 100 mM NaCl, 0.5 
mM TCEP pH 8, 10% v/v glycerol, 0.5% v/v Tween 20, SigmaFAST™ EDTA-Free protease inhibitors, 2.5 
units of Benzonase® (Sigma)). Lysis by sonication, pulsing with 5 seconds on, 10 seconds off for 3 
minutes with 60% amplitude was performed at 0.5°C using an ice water bath. To pellet cell debris the 
lysate was equally distributed into two polypropylene centrifuge tubes (Nalgene™ CAT NO: SQ-3119-
0050) and centrifuged at 70,000 RCF for one and a half hours at 10ᵒC (to limit the temperature increase 
the rotor was precooled to 5ᵒC at 50,000 RCF). Following centrifugation, the supernatant was filtered 
sequentially through a 5.0 µm membrane syringe filter (Minisart cat no 514-4129) and a 0.45 µm 
membrane vacuum filter (Milipore cat no. SCHVU01RE) to remove any large particles and to de-gas 
the sample. Filtered lysate was loaded at 0.1 mL/min via 50 mL Superloop onto a pre-equilibrated with 
lysis buffer 1 mL StrepTrap™ HP (GE healthcare) column controlled by an AKTA purifier at 10°C. The 
column was further washed with lysis buffer until UV reached the baseline level, followed by reversing 
the flow and washing with HEK293F-CtIP buffer (50 mM Tris pH 8, 200 mM NaCl, 0.5 mM TCEP) for 10 
CV. Protein was eluted in a sharp peak using standard buffer with additional 25 mM d-desthiobiotin 
(Sigma), with pH adjusted to 8. Fractions containing CtIPFL were identified by SDS-PAGE before further 
purification, preparation of Cryo EM grids, or flash freezing for experimental analysis. Protein 
concentration was determined by UV absorbance at 280 nm using concentrator flow through as a 
blank due to buffer background absorbance. 
Buffer exchange was achieved by two methods: SEC and NAP-5 (GE Healthcare) desalt columns. For 
SEC either GE Superose 6 3.2/300 increase or GE Superdex 200 10/300 column was used, and 50 or 
200 µL fractions were collected. For NAP-5 buffer exchange the manufactures protocol was used, 
collecting 200 µL fractions on elution. Both methods buffer exchanged CtIPFL into HEK293F-CtIP buffer 
for analysis by SDS-PAGE and protein concentration estimation by absorbance at 220-360 nm. 
2.6 SDS-Page Protein Analysis  
10 µL of protein solution was mixed with 5 µL of loading buffer (27 µL of 10X BOLT® reducing agent 
(Invitrogen) with 63 µL of 4X NuPage® LDS buffer (Invitrogen)). Following heat treatment at 100°C for 
1-minute 10 µL of the resulting sample was loaded onto a 12% Bis-Tris gel or 4-12% gradient gel 
(Invitrogen), together with either See-Blue® or See-Blue® Plus 2 pre-stained protein marker in the first 
lane (Invitrogen). 
To prepare 12% Bis-Tris gels, 1 mm BOLT® gel cassettes (Invitrogen) were filled with 12% separating 
gel (diluted from 30% v/v acrylamide solution), 0.36 M Bis-Tris pH 6.8, 0.11% TEMED (v/v) and 0.035% 
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ammonium persulphate (w/v), overlaid with isopropanol and allowed to set. After 1 hour, isopropanol 
was poured off and allowed to evaporate before addition of 4% stacking gel (diluted from 40% 
acrylamide), 0.36 M Bis-Tris pH 6.8, 0.35% TEMED (v/v) and 0.1% ammonium persulphate (APS) (w/v) 
with either a 12 or 15 lane comb inserted. Finished gels were stored at 4°C with 1X MOPS running 
buffer. 
Polyacrylamide gels were run in BOLT® 1X MOPS running buffer (Invitrogen) at 200 V for 33 minutes. 
Before staining, gels were washed in 50 mL of distilled water with heating for 30 seconds. This was 
followed by staining with SimplyBlue™ SafeStain (Invitrogen): 50 mL of stain was added to the gel and 
microwaved for 40 seconds on high before gentle rocking for approximately 5 minutes. This was 
repeated 2-3 times until bands were visible. De-staining was performed with distilled water.  
For western blot analysis the Bolt mini blot module was used using manufactures guidelines and 
nitrocellulose membranes (0.45 µm pore size). Antibodies were used according to manufactures 
protocol, see appendix 1 supplementary figure 7.6 for antibodies used. 
2.7 Nuclease assay 
The nuclease assay was performed as described by Sartori et al. 2007. The PhiX174 circular single-
stranded virion DNA substrate (5,386 nucleotides, New England Biolabs) was mixed with 40 ng of 
purified Mre11-Rad50-Nbs1 together with 200 ng BSA.  For HEK293F CtIPFL, either 200 or 350 ng of 
CtIP was used per reaction. Reaction buffer contained 30 mM potassium-MOPS, pH 7.2, 1 mM 
dithiothreitol, 1 mM ATP, 25 mM KCl and 5 mM of either MgCl2 or MnCl2. After incubation at 37 °C for 
3 h, nuclease reactions were terminated by adding 0.1 volume of stop solution (3% SDS w/v, 50 mM 
EDTA) and samples were run in a 0.8% w/v agarose gel (1× TAE) for 90 min at 100 mA, 4°C. DNA species 
were stained with SYBR Gold Nucleic Acid Gel Stain (Molecular Probes) for 20 min and visualized using 
the UV trans-illuminator (UVP). 
2.8 Thermal melt analysis 
SYPRO® Orange binds non-specifically to hydrophobic surfaces, with water strongly quenching its 
fluorescence (Huynh and Partch, 2015). When a protein unfolds, any hydrophobic surfaces that are 
now exposed bind the dye, resulting in an increase in fluorescence by excluding water. This technique 
can be used with increasing temperature to denature the protein and a measurement of the resultant 
fluorescence plotted to calculate the melt peak.  
For thermal melt analysis Melt curves were generated using the Bio-Rad CFX Connect real time PCR 
machine with temperature increased by 1.0°C every 30 seconds and fluorescence recorded. Two 
concentrations of CtIPFL were used: 8 µM and 5 µM, and dilutions were made with the standard buffer. 
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Final dilution of SYPRO® Orange was 1:2000. The NTD protein concentration was optimised to 12.5 
µM for the buffer screen (Appendix figure 7.1), with 12.5 µL of protein mixed with 12.5 µL of buffer to 
be assessed with final concentration 1:2000 SYPRO® Orange. For thermal melt analysis of the NTD 
cluster mutations concentrations of 16, 32 and 64 µM of protein were used in 25 µL with final 
concentration 1:2000 SYPRO® Orange.  
2.9 Spectrophotometric analysis of zinc content 
To assess the concentration of zinc in a protein sample, a 30 µM 4-(2-pyridylazo)-resorcinol (PAR) and 
a zinc acetate standard curve were generated. For the standard curve, known concentrations of zinc 
acetate were diluted from a 1 M zinc acetate stock (Sigma) using filtered MiliQ water. Sequential 10x 
dilutions were made from 1 M to 1 mM zinc acetate, with this used to make a 50 µM stock. The 50 
µM stock used to generate a series of zinc standards from 5-50 µM in 5 µM steps. For the PAR, a 140 
mM stock was prepared in DMSO with 3 µL diluted in 14 mL of protein buffer for 30 µM working stock. 
For the baseline reading, 3 µL of DMSO was added to 14 mL of protein buffer. 10 µL of the 5-50 µM 
zinc acetate solutions were incubated with 80 µL of 30 µM PAR for 5 minutes before the UV spectra 
were measured over a range of 300-600 nm (Varian Cary 50 spectrophotometer). The absorbance of 
each peak at 492 nm and 414 nm was recorded. Plotting of A492/(A492+A414) against zinc acetate 
molar concentration was generated as a standard curve. (Pfister et al., 2000). 
The purified proteins (in 20 mM Tris pH 8, 300 mM NaCl buffer) were diluted to 0.5 to 1 mg/mL 
depending on the expected yield of zinc, with accurate protein concentration determined by UV 
absorbance at 280 nm. 5 µL of protein was removed for SDS page before protein samples were 
digested in a total volume of 80 µL with 50 µg of protease K (Sigma) at RT overnight with gentle 
agitation (or 60°C for 1 hour) followed by centrifugation at 14,000 RCF for 10 minutes at 4°C. The 
supernatants were collected for zinc analysis. A further 5 µL of supernatant was removed for a post-
digestion SDS-PAGE sample.  
For each sample, 10 µL of supernatant was mixed with 80 µL of 30 µM PAR solution and incubated at 
room temperature for 5 minutes. A spectrum was taken and the value of A492/(A492+A414) was 
calculated compared with the standard curve. The determined zinc molar concentration and known 
protein molar concentration together gave a ratio of protein to zinc. Graphs were generated in 




2.10 SEC-SAXS  
Size Exclusion Chromatography Small Angle X-Ray Scattering (SEC-SAXS) is a powerful technique that 
can be used to obtain structural information about ordered and disordered regions of biological 
samples to a low resolution (Feigin and Svergun, 1989). It can provide information about the shape 
and size of proteins as well as structural changes that can occur from mutation and addition of protein 
tags. The high-throughput of samples under physiological conditions can provide structural 
characterisation to compliment other techniques (Rambo and Tainer, 2013). X-rays are scattered by 
electrons that are part of an individual macromolecule. When a sample is homogeneous this collection 
of scattered electrons defines the molecular form factor A(q). The molecular form factor determines 
the amplitude of the scattered X-rays at a scattering vector, q, by an object with fixed orientation and 
electron density, p(r): 
𝐴(𝑞) = ∫ 𝑝(𝑟)  𝑥 𝑒𝑖𝑞𝑟 𝑑𝑉  
The scattering integral is evaluated at a distance r throughout the particle volume V, therefore an 
observed scattering intensity I(q) depends directly on the paired distance between all electrons in the 
particle. This gives rise to the electron paired-distance distribution function P(r) (Rambo and Tainer, 
2013). From this P(r) distribution the maximal distance between two electrons within the molecule 
(DMAX) can be calculated. 
SEC-SAXS experiments were performed at Diamond Light Source on beamline B21 under the 
supervision of Dr Robert Rambo and Dr Nathan Cowieson. Default settings were used for the B21 
beamline set up. Camera length is fixed at 4.014 meters with an energy of 12.4 Kev and flux of x1012 
photons per second. 
Protein samples were taken to DLS on dry ice. After thawing, tubes were centrifuged briefly, combined 
and diluted with standard buffer were necessary before centrifugation at 14,000 RCF for 10 minutes. 
For all proteins the standard 20 mM Tris pH 8 300 mM NaCl buffer was used. A minimum of 50 µl of 
each sample was dispensed into a Greiner V-bottom 96 well plate (651201) sealed with an X-pierce™ 
cross slit seal (Sigma Z722529) and stored within the HPLC system at 4°C prior to injection. SEC was 
performed by the Agilent 1200 HPLC system with a Superdex 200 increase 3.2/300 2.4 mL column (GE 
Healthcare) at a flow rate of 0.05 or 0.07 mL/min with automatic sample loading. 35 µL of sample was 
used in session 1, and 45 µL of sample was used in session 2 for each SEC run for SEC-SAXS 





2.10.1 SCÅTTER analysis of SAXS data and DAMIN/DAMIF model generation 
The X-ray scattering data were processed using the B21 automatic processing pipeline. SCÅTTER 
(version 3.0) was used to determine the radius of gyration (RG) and DMAX values based on Guinier 
analysis and the P(r) distribution function as outlined in the Bioisis.net tutorial. The first horizontal 
portion of the SEC trace was used for baseline subtraction. Models that fit the SAXS data were 
generated from the P(r) distribution and DMAX values using 23 rounds of DAMMIF followed by 
averaging by DAMAVA to generate a DAMFIT file for modelling, these three programs form part of the 
ATSAS (Petoukhov et al., 2012) package and also covered in the bioisis.net tutorial. SAXS figures were 
generated in PyMol and overlaid manually. 
 
  
Protein Concentration mg/ mL Flow rate / mL per min 
NTD30-145 15.70  0.05 
NTD31-145 20.14 0.05 
NTD30-145Strep 4.62 0.05 
NTD31-145Strep 12.47 0.05 
MBP30-145strep 12.50 0.05 
NTD31-145C1-Strep  12.47  0.05 
NTD31-145C2-Strep 13.13  0.05 
NTD31-145C3-Strep 10.63  0.05 
MBP 6.97 0.05 
Table 2.10-1 Protein concentrations for NTD SEC-SAXS. Session 1. 
 
Protein Concentration mg/ mL Flow rate / mL per min 
NTD31-145DM-strep 9.80  0.05 
NTD31-145Strep 9.93  0.05 
NTD18-145 4.42 0.05 
NTD31-88Strep 3.69 0.05 
NTD93-145Strep 5.86  0.05 
MBP 6.97  0.05 and 0.07 separately 
CTDex – B 2.86 0.07 
dCTD 3.86 0.07 




2.11 Mass spectrometry analysis 
Purified protein samples in solution and protein species separated by SDS-PAGE where indicated were 
analysed by MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionisation – Time of Flight Mass 
Spectrometry) by Dr Len Packman (Protein & Nucleic Acid Chemistry Facility (PNAC), University of 
Cambridge). Amino Acid Analysis (AAA) was performed on purified homogeneous proteins at full and 
half concentrations by Peter Sharratt (PNAC Facility, University of Cambridge). 
2.12 Semi-analytical analysis of CtIP-CTD 
MBP-fused CtIP-CTD protein was purified using the standard procedure in 2.2.5 until after the heparin 
chromatography stage with removal of the TEV cleavage. From here, protein containing MBP-CTD was 
concentrated to 1 mL using a 30,000 MWCO PES concentrator (Vivaspin® VS0221). SEC was performed 
at room temperature using a Superdex 200 10/300 SEC column (GE), pre-equilibrated with standard 
buffer.  For each experiment, a 100 µL of sample (90 µL of protein and 10 µL of standard buffer with 
10X additive) was applied to the column. Traces were overlaid using the Unicorn software. 
2.13 Cryo-EM   
Grids (Quantifoil R 1.2/1.3 Cu 300 mesh) were glow discharged using a Pelco Easiflow device using 
manufacturer’s instructions under the following settings: 25 mA, 0.39 mBar, 2 minutes, and carbon 
side up. Following glow discharge on a single side, 3 µL of freshly purified CtIPFL (Nap5 buffer 
exchanged protein into 50mM Tris pH 8.0, 300 mM NaCl, 0.5 mM TCEP at 0.9 mg/ml (monomer)) was 
applied and snap frozen in liquid ethane using a Vitrobot Mark IV (FEI) device using manufacturer’s 
instructions under the following settings: grids were blotted for 2.5 seconds at 4°C and 100% humidity, 
with a ‘blot force’ of -5 and no pause between sample application and blotting. The grids were 
visualised in the Titan Krios G2 microscope of the Cryo-EM facility at the department of NanoScience 
University of Cambridge. The microscope was prepared by Dr Dima Chirgadze with the Falcon 3 
detector on integration mode and controlled by Dr Jamie Blaza. 
For MBP-NTD18-145 the same grids, settings and procedures were used however with a 30 mA glow 
discharge. Protein was applied to the grid in buffer containing 150 mM NaCl, 20 mM Tris pH 8.0 at a 
protein concentration of 0.75 mg/mL (monomer). The grids were visualised in the Talos Arctica™ 
microscope of the Cryo-EM facility at the Department of Biochemistry, University of Cambridge. The 





2.14 Analytical Ultra Centrifugation (AUC)  
Under ultra-centrifugal conditions the sedimentation of a protein occurs and is governed by three 
factors: (1) the centrifugal force - this is set depending on the predicted molecular mass of the protein 
and determined by the speed of rotation; (2) the buoyancy force, which is proportional to the mass of 
the displaced solvent, as well as the speed of rotation; (3) the frictional force, which is governed by 
the frictional coefficient and the sedimentation velocity of the protein. The balance of these three 
factors at a constant ultra-centrifugal velocity allows determination of the sedimentation coefficient. 
This coefficient remains constant incorporating both the shape and molecular mass of the measured 
protein (Mächtle and Börger, 2006; Scott et al., 2005). In general proteins with an asymmetrical 
structure and smaller proteins sediment slower than those of higher mass and compact globular 
structure which are fast to sediment. 
A fresh CtIPFL purification was performed from HEK293F cells. Fractions containing the bulk of CtIPFL 
were pooled and dialysed against 2 litres of the standard gel filtration buffer overnight before 
centrifugation at 14,000 RCF, 4°C for 10 minutes. Protein concentration was measured using the 
Nanodrop™ spectrophotometer and was calculated to be 1.3 mg/mL; two dilutions were made at 50% 
and 25% concentration with the dialysis buffer. 
The experiment was performed using an analytical centrifuge (Beckman Optima XL-A/1) at 40,000 
RPM pre-equilibrated to 20°C. 400 µL of the dialysis buffer was dispensed into chamber 1 and an equal 
volume of protein sample dispensed into chamber 2 for analysis by sedimentation velocity analytical 
ultracentrifugation. Both interference and absorbance data were collected with assistance from Dr 
Katherine Stott. Protein partial specific volume, buffer density and buffer viscosity were calculated 
using the program Sednterp (Hayes, Laue, & Philo, 1995). Sedimentation distribution was analysed by 





2.15 DNA oligo design and annealing  
Substrates for DNA binding were designed using the online server NUPACK for generation of specific 
secondary structure and to ensure the double stranded DNA ends were stable at room temperature. 
Oligoes were ordered from IDT and are shown in table 2.15. DNA oligoes were annealed by heating to 
9°C for 3 minutes before cooling by 0.5°C every 30 seconds until reaching 4°C. Final concentration of 
all annealed substrates was 50 µM; the substrates were stored in black opaque tubes at -20°C. 























Table 2.15: Fluorescent oligoes.  
For the 200 bp substrate, primers [Flc] CCGAAGGTAACTGGCTTCAG and GCCTTATCCGGTAACTATCGTC 
were used to PCR amplify a dsDNA region spanning 200 bp from Puc19. Eight 50 µL, 40 cycle, PCR 
reactions were used per purification with an annealing temperature of 64°C and minimal Puc19 
template (<10 pg). DNA was purified by ethanol precipitation (section 2.2.3).  
2.16 Electrophoretic Mobility Shift Assay  
Buffer concentrations were constant for each Electrophoretic Mobility Shift Assay (EMSA). For EMSAs 
in Chapter 5 CtIP full-length the buffer contained 20 mM Tris pH 8, 300 mM NaCl, 0.5 mM TCEP and 
10% v/v glycerol. For EMSAs in Chapter 4 CtIP-CTD the buffer contained 20 mM Tris pH 8, 150 mM 
NaCl, either with or without 50 µM zinc acetate. Serial dilutions of CtIP-CTD, CtIPFL and L27E CtIPFL 
were generated maintaining buffer concentrations. 9 µL of protein was mixed with 1 µL of 
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fluorescently labelled DNA to give a final DNA concentration of either 1 µM or 100 nM within the 
EMSA. Protein:DNA mixture was incubated for a minimum of 20 minutes at 4°C. Separation of protein-
DNA complexes from free DNA was performed by electrophoresis using a 1x Tris Borate (TB) ultrapure 
agarose gel for 3 hours at 25V, 4°C.  DNA was visualised by UV trans-illumination or scanned using a 
Typhoon FLA 9000 imager (GE healthcare) at 473 nm.  
2.17 Fluorescence polarisation  
The theory of FP comes from observations that when small fluorescent molecules (tracers) are excited 
with plane-polarized light, the emitted light is largely depolarized because the molecules tumble 
rapidly in solution during their fluorescence lifetime (the time between excitation and emission). 
However, if bound by a larger molecule, the tracer’s effective molecular volume is increased. The 
tracer’s rotation is therefore slowed with more of the emitted light in the same plane as the excitation 
energy. The bound state therefore has a high intrinsic polarization value verses a low value for the 
free state. The measured polarization is a weighted average of the two values, thus providing a direct 
measure of the fraction of tracer bound to receptor. In this assay, the DNA was labelled with 
fluorescein and the anisotropy of this fluorescent species determined. As protein is added, it can bind 
the labelled species to produce a complex that tumbles more slowly and increases the anisotropy of 
the fluorophore. Analysis of the anisotropy change as a function of protein concentration produces a 
binding isotherm from which shows the formation of the protein-DNA complex (Lundblad et al., 2008; 
Rossi and Taylor, 2011). 
The CtIP-CTD protein buffer was exchanged into 20 mM Tris pH 8, 150 mM NaCl with or without zinc 
acetate as indicated, followed by a 2-hour incubation on ice and centrifugation at 14,000 RCF for 10 
minutes at 4°C. The CtIP-CTD concentration was quantified by 220-360 nm absorbance measured by 
a Cary-UV spectrophotometer using a theoretical extinction coefficient of 14690 M-1.  A serial dilution 
was used to generate the protein concentrations, retaining a consistent zinc concentration in the 
buffer. Protein samples were incubated with annealed 10 nM linear 5’ Fluorescein-dsDNA 60 bp 
substrate, in 20 mM Tris pH 8, 150 mM NaCl with or without zinc acetate. Protein-DNA mixtures were 
transferred to black 96-well half-area plates (Corning Cat No. 3686). Fluorescence anisotropy data 
were recorded at 25°C using a PHERAstar FS plate reader (BMG Labtech), with fluorescence 
polarisation optics module exciting at 485 nm and recording emissions at 520 nm. Data were plotted 




2.18 SEC-MALS analysis of CtIP-CTD 
The theory behind SEC Multi Angle (Laser) Light Scatter (SEC-MALS) is demonstrated by the Debye-
Zimm equation (Eq.2.18-1). The equation describes the relationship between the angular dependence 







+ 2𝐵𝐶 + 3𝐵𝐶2+ . .. 
In this equation R(θ) is the Rayleigh excess ratio, which describes the ratio of the intensity at angle θ 
(Iθ) to that of the incident light (I0) and can be measured by the light scattering detector. K is an 
experimental constant depending on the square of the solvent refractive index (n0), the square of the 
refractive index increment (dn/dC) and the inverse fourth power of the incident wavelength (λ). The 
refractive index detector can determine n0 and the concentration, C, of the protein while dn/dC has a 
constant value for all proteins, with M representing molecular mass of the protein. The non-ideality 
of the solution is accounted for by a power series about C, with B being the second virial coefficient. 
The low concentrations used for SEC-MALS and the dilution by SEC means the team 2BC becomes 
negligible. For large macromolecules with dimensions greater than λ/20 light can scatter from 
different parts of the molecule and cause destructive interference that reduces the intensity of scatted 
light. To correct for this the structure factor P(θ) is required. This allows for extrapolation to θ = zero, 
where there is no destructive interference of the scattered light. To use the equation for mass 
determination further information about P(θ) is required from theoretical analysis of large-particle 
scattering. Along with the relation of P(θ) to the angular dependence of the scattered light intensity 
and the mean-square radius of gyration of a protein S. Replacing P(θ) with this theoretical term a new 
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In SEC-MALS the differential refractive index detector measures the concentration of the sample with 
the MALS detector measuring simultaneously the light scattered at several angles. Using the equation 
above, a plot of KC/Rθ vs sin2 (θ/2) is used to calculate the molecular weight from the intercept at sin2 
(θ/2) = zero and the gradient of the slope giving the radius of gyration (Harding and Jumel, 1998; 
Wyatt, 1993).  
SEC-MALS was performed using the following setup. The ÄKTA purifier system with Superdex 200 
10/300 analytical filtration column (GE healthcare) was connected to the DAWN® HELEOS™ 8 multi-





technology) in this specific order. The system was washed overnight at 0.5 mL/min in standard buffer 
to reduce noise in the scattering signal to <40 µV. For normalisation, 50 µL of MBP or BSA at 2 mg/mL 
was injected into the system prior to the protein samples for calibration of the inter-detector delay. 
Data were analysed using the ASTRA®6 software (Wyatt technology). The protein samples were 
diluted to ~2 mg/mL where necessary, with 50 µL of protein applied to the system. Data were collected 
using the ASTRA®6 software (Wyatt technology) with assistance from Dr Joseph Maman.  
2.19 Pull-down experiments with CtIP and And1 
For pull-down experiments 50 µL of amylose resin (NEB) was pre-equilibrated with pulldown buffer 
(25 mM HEPES pH 7.2, 100 mM KCl, 0.5 mM TCEP, 0.1% v/v igepal CA630) supplemented with 2 mg/mL 
BSA. Bait proteins (MBP-NTD and MBP-CTD) were incubated with the amylose resin for 1 h at 4°C with 
constant rolling. Amylose beads were pelleted by centrifugation at 1,000 RCF for 2 minutes at 4°C and 
washed twice with 500 µL of pulldown buffer. Prey proteins (And1FL, And1316-1129, And1826-1129, And11-
316, And11-826, and And1316-826) were buffer-exchanged using protein desalting spin columns (Cat no. 
89862 Thermo fisher) into pulldown buffer supplemented with 2 mg/mL BSA. Following buffer 
exchange, prey proteins were incubated with the amylose beads, either with or without bait, for 1 h 
at 4°C with constant rolling. Amylose beads were pelleted by centrifugation at 1,000 RCF for 2 minutes 
at 4°C and washed twice with 500 µL of pull-down buffer A. MBP-bound protein was eluted from the 
beads with 30 µL of pulldown buffer supplemented with 20 mM maltose; the fractions were analysed 
by SDS-PAGE. 
Where necessary, TEV digestion was performed using 3 µL of 2 mg/mL TEV added to 15 µL of bead 





2.20 Crystallisation and X-ray data collection 
Initial crystallisation trials were performed using commercial 96 well crystallisation screen reagent kits 
(table 2.20). CtIP protein was thawed on ice prior to dilution and addition of glycerol where indicated. 
Where nucleation was an issue, protein was not centrifuged prior to dispensing. 
For Strep-tagged constructs, optimal crystallisation conditions were at a final concentration of 7.5 
mg/mL protein with 5% v/v glycerol added after protein thawing. Drop size and ratio was optimised 
for wild type strep tagged proteins to 400 nL of protein with 200 nL of reservoir. NTD31-145DM-Strep 
gave crystals at a drop size and ratio of 200 nL protein + 200 nL of reservoir. 
X-ray diffraction data were collected the MX beamlines IO3, IO4, IO4-1 and I24 at Diamond Light 
Source (DLS). During DLS maintenance the European Synchrotron Radiation Facility (ESRF) in Grenoble 
was used on the ID30B Micro focus beamline. Images were viewed on ADXV either on a Linux machine 
or a NoMachine connection to DLS on windows. 
Crystallisation screen Company Overview 
The Classics Suite I Qiagen A spectrum of the most popular chemicals in protein 
crystallography 
JCSG+ ™ Qiagen JCSG = Joint Centre for Structural Genomics 
Members of the JCSG identified “conditions most 
essential for promoting crystal formation for the most 
diverse set of proteins.” 
pHClear I Qiagen Easy analysis of the effect of precipitant concentration 
with respect to pH pHClear II Qiagen 
PACT Suite Qiagen A screen looking at the effect of different Poly ethylene 
glycols with pH 
MPD Suite Qiagen A combination of MPD with various salts, pH conditions 




Derived from extensive data mining, uses a 3D grid 
covering a range of pH PEGs and salt additives with all 
conditions acting as a Cryogenic protective.  
Wizard™ Classic 1 & 2 Molecular 
Dimensions 
Random sparse matrix screen designed to increase the 
probability of producing crystals during initial screening 
of biological macromolecules.  
Table 2.20 List of commercial crystallography screens used.  
 
2.20.1 Crystallisation techniques 
Conditions for optimisation were generated in accordance to the manufactures original condition. 
Each buffer condition was made as a “high” and “low” pH to enable generation of any pH in-between 
by dilution (table 2.20.1-1). 500 mL of each buffer was made at 0.5 M, pH corrected, filtered and 
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degassed all on the same pH meter sequentially and stored at 4°C. 50 mL of each condition was stored 
at 19°C ready for plate generation until used. 
Buffer pH Supplier 
MES pH 5.5 Low Melford Cat no. E24103 
MES pH 6.7 High Melford 
HEPES pH 6.8 Low Melford Cat No. H7530 
HEPES pH 8.2 High Melford 
TRIS pH 7.0 Low Sigma     Cat no. T6791 
TRIS pH 9.0 High Sigma 
CHES pH 8.6 Low Sigma     Cat no. 2885 
CHES pH 10.0 High Sigma 
Table 2.20.1-1: Crystallisation stock buffers. 
 
Stock solutions of precipitants (table 2.20.1-2) were made in Milli Q water, filtered and degassed prior 
to storage at 4°C. In accordance to manufactures conditions they were not pH corrected. 50 mL of 




mass/ g mol-1  
Concentration Supplier 
Ammonium sulphate 500  132.14 3M Sigma Cat No. 31119 
Sodium thiocyanate 50  81.07 2M Sigma Cat No. 467871 
Sodium tartrate 500  194.05 2M Sigma Cat No. 228729 
Sucrose 250  342.29 0.1M Fisher Cat No. S/8600/60 
Maltose 250 360.31 0.1M Sigma cat No. 63418 
Glycerol 250   50% Sigma G5516-1L 
Ethanol 50   35% Sigma 02854-1L 
MPD 50   35% Sigma 112100 
Methanol 50  35% Sigma 603-001-00-X 
Isopropanol 50   35% Sigma 33539 
SEC-butanol 50   20% Sigma B-1888 
Table 2.20.1-2: Crystallisation stock precipitants. 
 
2.20.1.1  Manual screening 
For manual screening 24 well XRL crystallisation plates were used (molecular dimensions). 1 mL of 
each 24 crystallisation conditions were made by manual pipetting with 0.5 mL dispensed into each 
well. Where hanging drop crystallisation method was used, protein drops were dispensed onto 
siliconized coverslips (Hampton research) with wells sealed with Dow Corning® vacuum grease. Sitting 
drop crystallisation used a Micro-bridge® (Hampton Research) in each well for a single protein drop. 
Plates were sealed with Duck Crystal clear tape. 
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2.20.1.2  Dragonfly® optimisation screens 
Optimisation screens were designed using the Dragonfly® (TTP labtech) software package. Software 
was used to calculate dispense volumes for manual hand pipetted screens or CSV files for use with the 
Dragonfly® Robotics. The instrument was prepared with 19°C pre-equilibrated buffers and 96-well 
plates dispensed. Syringes and reservoirs were washed with Milli Q water before and after each use. 
Plates were mixed using the MXone® mixer (TTP Labtech) for 2 minutes prior to sealing with Duck 
Crystal Clear tape. MXone mixer was cleaned with Milli Q water before and after every use. Plates 
were incubated for a minimum of 20 minutes to equilibrate to room temperature before drop 
dispensing.  
2.20.1.3  Seed Bead seed stock generation 
For generation of a seed stock the Seed-bead™ (Hampton research) was used. Suitable crystals were 
selected and 5 µL of reservoir solution added to the drop, mixed, and aspirated into the seed bead 
tube on ice. 10 µL of reservoir solution was then washed around the crystal containing well and 
aspirated into the seed bead tube, this is repeated 8 times. Crystals were fragmented by a 30 second 
vortex mixing pulse with 1-minute interval on ice for a total of 2 minutes. 
2.20.1.4   Seed Bead Seed stock from a single crystal 
Crystal was thawed directly into an equilibrated crystallisation condition, identical to the original 
condition, for aspiration and seed generation by seed bead. The crystal loop was removed from liquid 
nitrogen and placed directly into a clear 400 nL equilibrated crystal drop, 5 µL of reservoir solution 
was added and aspirated into a seed bead tube. A further 50 µL of reservoir solution was aspirated, 
10 µL at a time into the well and then into the seed bead tube. Seeds were generated by vortex mixing 
using a 20 seconds pulse with 1-minute interval on ice for a total of 2 minutes. For Mosquito® seeding 
10 nL of undiluted seeds were mixed with 190 nL of reservoir solution prior to addition to protein 
drops. 
2.20.1.5  Manual streak seeding 
For manual seeding the seed stock was used undiluted. A seeding whisker (Hampton research) was 
used to drag through three consecutive identical protein crystal drops to give a dilution of seeds. For 
hanging drop crystallisation three drops were dispensed onto the same coverslip, for sitting drop 




2.20.1.6  Mosquito® micro seeding 
The identical condition from which the seeds were made from was produced to enable serial dilutions 
from the concentration seed stock of 1:10, 1:100, and 1:1000. The Mosquito® Robottics (TTP labtech) 
multi-aspirate mode was used to mix 5% seed with 95% reservoir condition, for example, 10 nL of 
seeds with 190 nL of reservoir solution prior to dispensing into the drop. Optimum seed concentration 
is determined experimentally with fresh dilutions generated from the stock on each preparation.  
2.20.2 Crystallisation of NTD31-145DM-Strep 
The Morpheus® (Molecular Dimensions) crystal screen was performed with purified NTD31-145DM-
Strep protein in buffer containing 20 mM Tris pH 8.0, 300 mM NaCl, 5% v/v glycerol at 7.5 mg/mL. The 
protein was mixed with crystallisation buffer and micro seeds at a 1:19:1 ratio in 0.4µL in a 96 well 
MRC 2 drop crystallisation plate using the Mosquito® robot. Final crystallisation condition for structure 
determination was G6 (MDSR-47-2-30), containing 30% w/v EDO_P8K (40% v/v ethylene glycol; 20 % 
w/v PEG 8000), 0.1M MB2 pH 7.5 (sodium HEPES; MOPS (acid)), 10% MCA (0.2 M Sodium formate; 0.2 
M ammonium acetate; 0.2 M sodium citrate tribasic dihydrate; 0.2 M sodium potassium tartrate 
tetrahydrate; 0.2 M sodium oxamate).  
2.20.3 Visualisation of protein models. 
Determined protein crystal structures and SAXS models were visualised using PyMol. The “align” tool 
was used to align the NTD31-145DM-Strep structure with PDB entry 4D2H to generate a model of CtIP 
residues 18-136. This model was further overlaid with the NTD18-145 model to fit the SEC-SAXS data 
manually. Further SEC-SAXS models described in the main text were overlaid manually. The model to 







Chapter 3, CtIP N-terminal domain  
3.1 Introduction 
The N-terminal domain (NTD) of CtIP possesses conserved structural elements that have been shown 
to be important for CtIP activity (Davies et al., 2015). Functional studies of CtIP have illustrated its 
critical role in homologous recombination (HR) mediated DSB repair, with deletion studies of the N-
terminal region showing CtIP-null like results highlighting its importance. U2OS cells expressing CtIP 
with an N-terminal 200 amino acid deletion showed sensitivity to Ionising radiation and camptothecin 
in EGFP-based HR repair assays, with complete loss of self-association between CtIP alleles (Wang et 
al., 2012). In IR treatment experiments, HeLa cell lines possessing an N-terminal deletion of 17-160 
exhibited loss of Chk1 phosphorylation, reduction in RPA DNA recruitment and reduced DSB repair 
efficiency through HR (Yuan and Chen, 2009). In immunoprecipitation studies an N-terminal domain 
of CtIP comprising residues 1-160 was sufficient to interact with the MRN (mre11-Rad50-Nbs1) 
complex, with deletion of residues 22-45 removing the interaction with Nbs1 (Yuan and Chen, 2009). 
In contrast, mutation of the central tetramerization Lysine on CtIP, resulting in dimeric CtIP, had no 
effect on MRN interaction (Davies et al., 2015). 
Experimentally derived models of the tertiary CtIP structure are limited to short protein interaction 
sites (figure 1.6-3 introduction) and the putative coiled-coil region at the N-terminus (Fusco et al., 
1998). The latter region covers residues 45-160, and early studies using analytical ultracentrifugation 
(AUC) demonstrated that it could self-associate in vitro (Dubin et al., 2004). This domain could be 
further divided into two sub domains: CtIP residues 45-92 and CtIP residues 93-160. Both were seen 
to form homodimers with some coiled-coil characteristics (Dubin et al., 2004). More recently, residues 
18-52 of CtIP were observed to form a tetrameric species, which was dependent on a lysine at position 
27 (Davies et al., 2015). Tetramer formation was also found to be essential for correct functioning of 
CtIP in vivo (Davies et al., 2015). 
To date, these 34 residues compose the largest functionally relevant domain of CtIP that has been 
structurally characterised. While the architecture of the coiled-coil domain (residues 52-160) is 
unknown, structural and biophysical analysis of this region should clarify whether CtIP is largely 
elongated or compact. To further explore the N-terminal region of CtIP, domains contained therein 





3.2.1 Expression, purification and crystallisation trials of the NTD 
Tetramerisation of the NTD has been shown by crystallography to have a dimer of dimers orientation 
(Davies et al., 2015). However, residues 18-52 comprise the largest determined structure of CtIP to 
date. To further our understanding of the domain architecture a structure of residues 18-145 (NTD18-
145) was desired including the tetramerisation and dimerisation domains. Initial crystallisation of NTD18-
145 gave no tractable conditions. Crystallisation experiments were therefore focused specifically on the 
coiled-coil domain to enable an ensemble of the two structures to be generated. 
As leucine 27 is the central residue in tetramerisation (Davies et al., 2015), the first construct spanned 
from CtIP residue 28 to 145 (NTD28-145), including the zinc binding site at C89 and C92 (CXXC), (figure 
2.2.1). The C-terminal boundary of this domain at 145 was previously determined by colleagues (Sun, 
2013). The DNA was cloned from the CtIP image clone (4830693) into pMAT11 to generate an N-
terminal His6 MBP tagged fusion protein. 
 
 
3.2.1.1 Recombinant protein expression and purification 
Protein expression was performed in Rosetta™ 2 (DE3) using sequential Ni-NTA, Amylose 
chromatography, on-column TEV cleavage and a final Ni-NTA recapture. Final polishing was through 
Superdex 75 16/60 SEC. As NTD28-145 contains no tryptophan residues, and only three phenylalanine 
residues, the absorbance at 280 nm was minimal with fractions analysed by SDS-PAGE to identify 
NTD28-145 (figure 3.2.1.1). Fractions corresponding to NTD28-145 were pooled for further analysis. 
Purifications of NTD28-145 contained a co-migrating higher molecular weight band, MALDI-TOF mass-
spectrometry (PNAC facility, Department of Biochemistry, University of Cambridge) confirmed this to 
contain NTD28-145 and therefore a SDS-PAGE gel artefact. Multiple purifications of NTD28-145 were used 
to calculate the protein concentration and for crystallisation. 
Figure 3.2.1: Schematic drawing of NTD28-145. CtIP residues 28-145 are highlighted in blue, with 
the alpha helical tetramerisation domain (α) and zinc binding domains shown (CXXC). 
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3.2.1.2 Protein concentration determination of the coiled coil domain 
For systematic screening of crystal conditions an accurate protein concentration was required. The 
Bradford assay was used, however the linear range of NTD28-145 was below 0.35 mg/mL. Desired 
concentrations for crystallography were between 5-15 mg/mL, dilution and extrapolation from the 
linear range for the Bradford assay would introduce a wide error range in concentration predictions 
and affect reproducibility. Thus, Amino Acid Analysis (AAA) was used to determine protein 
concentration.  
3.2.1.2.1 Amino acid analysis and generation of a standard curve  
Each individual amino acid contributes to the protein concentration in AAA giving a more accurate 
result. This process was carried out by Mr Peter Sharratt in the Department of Biochemistry PNAC 
facility (University of Cambridge). To overcome the need to analyse every sample, a standard curve 
was generated correlating the AAA result to the weak NTD28-145 UV absorbance measured at 280 nm. 
Purifications of NTD28-145 were analysed by AAA obtaining 10 AAA results from 5 independent 
purifications. Measurements were also taken for the weak 280nm absorbance with a linear 
relationship between the two measurements up to 15 mg/ml as recorded by AAA. After 16 mg/mL the 
correlation between the readings deteriorate, however the linear region is sufficient to calculate 
protein concentrations for crystallography. Measurements were taken at 230 nm for the peptide 
backbone absorbance however there were no correlations. The standard curve equation Y =6.814x 
+0.2354 (where X is absorbance at 280 nm at a 1:1 ratio and Y is mg/mL) was used for calculation of 
protein concentration for all NTD constructs without a tryptophan residue.  
Figure 3.2.1.1: Purification of NTD28-145. A) Chromatogram of the Superdex S75 16/60 SEC with 
fractions analysed by SDS-PAGE in B. B) final Ni-NTA recapture flow-through (Load) which was 
concentrated for SEC. Blue lines indicate fractions analysed by SDS-PAGE from A, with the red 






3.2.2 Crystallisation of the N-terminal coiled coil domain 
The purified NTD28-145 was dispensed into commercially available crystallisation conditions: Morpheus 
®, Wizard™ 1&2, JCSG+™ pHClear 1 and pHClear 2 using the Mosquito® crystallisation robot for vapour 
diffusion at 7.5 mg/mL. Only small nuclei were seen that could be either salt or protein crystals. 
Optimisation of these conditions by reducing the salt concentration increased nucleation, while 
addition of zinc ions failed to show any crystals. Manual pipetted screens were dispensed using the 
hanging-drop method, although nuclei were present there were no signs of crystal growth. After 20 
crystallisation trials there were no defined crystals to optimise.  
 
  
Figure 3.2.1.2.1: Amino Acid Analysis standard curve of NTD28-145. Protein absorbance at 280 nm 
at a 1 absorbance unit to 1 mg/mL ratio was plotted against absolute protein concentration 
measured by Amino Acid Analysis. A line of best bit was calculated using data within the linear 
range. R2 for the linear relationship is 0.9927. 
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3.2.2.1 Thermal shift analysis of NTD28-145 
The analysis of a protein thermal melt by binding to SYPRO® orange can be used to determine the 
optimum buffer for protein stability (Huynh and Partch, 2015). The higher the melt temperature 
required the more stable the protein is for a given buffered condition. Melt curves for NTD28-145 were 
generated using a buffer screen generated by the Hyvönen group (Appendix figure 7.1). From the 96 
conditions many gave no point of inflection with reductions in stability, the top 4 hits are shown in 
figure 3.2.2.1. The standard buffer gave the greatest melt peak of 47°C, showing the protein buffer 
was optimal for stability. Construct optimisation was performed next to encourage crystallisation.   
  
Figure 3.2.2.1: NTD28-145 thermal melt peak and melt curve. From the binding of SYPRO orange to 
unfolded protein the fluorescence increases and is measured in relative fluorescence units. 
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3.2.2.2 Construct optimisation and protein purification.  
For construct optimisation the N-terminal start residue was targeted, changing the position by one 
amino acid per construct generating 10 start positions from residue 29 to residue 38. These were 
cloned into pMAT11 to generate His6-MBP tagged constructs (figure 3.2.2.2-1). 
 
The new constructs were expressed in Rosetta™ 2 (DE3) and purified using the Ni-NTA purification 
system, with soluble protein expressed for all constructs. Figure 3.2.2.2-2 is an example of an original 
(a/b) and optimised (c/d/e) NTD31-145 purification, with identical optimised purifications for the other 
protein variants. For both purifications the soluble protein was bound to Ni-NTA resin, washed and 
eluted. Protein was subsequently dialysed overnight with 2 mM DTT and addition of TEV removing the 
His6MBP tag from the NTD proteins. Unfortunately, the reaction did not go to completion generating 
three stable products (figure 3.2.2.2-2B/C). The sizes these products correspond to the molecular mass 
of NTD31-145 (14.2 kDa), the His6-MBP tag (44.7 kDa) and the un-cleaved fusion protein (58.9 kDa.) TEV 
protease (27 kDa) was also detectable by SDS-PAGE. Desalting chromatography removed the DTT from 
the protein buffer to enable recapture by Ni-NTA. Figure 3.2.2.2-2C shows sequential flow-through 
through Ni-NTA, Amylose and Ni-NTA recapture columns, with removal of contaminants at each stage 
by binding to the column allowing the NTD to flow through. In the optimised purification a third Ni-
NTA stage removed further contamination. The Ni-NTA#2/3 flow through protein was subsequently 
concentrated and applied to a Superdex 75 16/60 SEC. SDS-PAGE analysis showed the optimisations 
removed the vast amount of contamination (figure 3.2.2.2-2 A/B and D/E) at the cost of NTD31-145 yield 
from the addition of the Ni-NTA stage prior to Amylose re-capture. A protein concentration 
dependency was also apparent for the SDS-PAGE ‘dimer’ band. The very weak 280 nm absorbance 
made tracking the protein by SEC difficult (figure 3.2.2.2-2D) with an intense band by SDS-PAGE giving 
Figure 3.2.2.2-1: Schematic 
drawing of N-terminal 
truncations. CtIP constructs are 
highlighted in blue, with the 
alpha helical tetramerisation 
domain (α) and zinc binding 




only a 10 mAu absorbance reading on the AKTA purifier at 4°C. Protein concentration was however 
determined using the NTD28-145 AAA calibration curve for all purifications. 
       
Figure 3.2.2.2-2: Purification of NTD31-145 by Ni-NTA and amylose chromatography. A) Original 
NTD31-145 final stage purification Superdex 75 16/60 SEC chromatogram. B) SDS-PAGE analysis 
from SEC fraction, only one fraction was pooled for analysis. The dotted line separates original 
from the optimised purification. C) Protein was purified by Ni-NTA (N) with elution factions (N#1-
E) dialysed overnight with TEV protease to remove the tags. Protein was further purified using an 
addition Ni-NTA column (N#2) with the flow-through (FT) passed over an amylose (A) column. 
This amylose flow-through (A-FT) was further passed over a 3rd Ni-NTA column with flow-through 
(N#3-FT) concentrated for SEC in D. D) Chromatogram of the Superdex 75 16/60 SEC. Blue lines 
indicate fractions analysed by SDS-PAGE in E. E) SDS-PAGE analysis shows a large reduction in 
contaminations at the cost of the protein yield. Fractions indicated in red were pooled and 




3.2.2.3 Initial screening of N-terminal truncations  
Constructs NTD29-145, NTD30-145, NTD31-145, NTD32-145, NTD33-145, and NTD38-145 were purified identically 
and dispensed using the Mosquito® crystallisation robot at 7.5 mg/mL into the commercially available 
Morpheus®, Wizard™ 1&2 and pHClear I screens. NTD31-145 was the only construct to show signs of 
crystallisation in Wizard™ 1&2; one condition (D6) containing 15% v/v ethanol and 100 mM Tris pH 
7.0 gave a shower of small needle crystals (figure 3.2.2.3.) The same Wizard 1&2 screen was repeated 
with two concentrations of NTD31-145 with the high concentration giving the same needle crystals. 
Lower concentrations of NTD31-145 however failed to crystallise (figure 3.2.2.3 C/D.)  
 
3.2.2.4 Optimisation of NTD31-145 Needle crystals 
Hand pipetted screens failed to reproduce crystallisation. A 96-condition screen was made using the 
Dragonfly® discovery robot varying ethanol concentration and Tris pH. Using the Mosquito® robot 
protein was dispensed with larger crystals at pH 7.2 and lower ethanol concentrations (figure 3.2.2.4-
1).  
 
Figure 3.2.2.3: Wizard 
1&2 condition D6, 
NTD31-145 Needle crystal. 
X1.0 is the same 7.5 
mg/mL concentration as 
the previous screen, and 
X0.5 is half protein 
concentration. Both 
images C/D were taken 
at the same time. 
Figure 3.2.2.4-1: 
Effect of Ethanol and 





with varying ethanol 
concentration on the 
X axis from 10-21% 
and the Tris pH on 
the Y-axis from pH 
6.8 to 8.8. 
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Crystals were growing mainly in one direction with a high density. To further optimise the crystals the 
protein to crystallisation condition drop ratio was varied from 1:1, 2:3 and 1:2. Ethanol concentrations 
(10-17%) and Tris pH (7.0-7.3) were further varied. However, batch to batch protein variations meant 
only one drop at a ratio of 1:2 contained a needle crystal (figure 3.2.2.4-2A). Protein concentration 
was assessed using the 1:2 ratio. Panels A and B of figure 3.2.2.4-2 show the same condition and 
protein concentration between the two screens with vast differences in nucleation and crystal growth. 
Reducing the protein concentration gave a reduction in crystal size with vast amounts of nuclei seen. 
Surprisingly, the small changes in pH and ethanol which from this screen gave drastic changes in 
number and appearance of crystals (figure 3.2.2.4-2 B/C/D).  
 
Reproducibility of the needle crystals was poor. Crystals were also fragile which impeded crystal 
mounting for x-ray diffraction. Two crystals were mounted onto cryo loops by Dr Paul Brear (University 
of Cambridge X-Ray Facility) and exposed to synchrotron radiation at ESRF with no diffraction. 
In an attempt to change crystal form four other alcohols were used: isopropanol, methanol, MPD and 
1-butanol. From this optimisation only, small nuclei were seen in a single drop with large crystals 
absent from the control 11% v/v ethanol, tris pH 7.2 condition. To try to recapitulate the large needle 
crystals, a commercial MPD screen, and further optimisation screens were performed with different 
protein concentrations, fresh alcohols, and fresh purifications with the crystals seen in figure 3.2.2.4-
2D unable to be reproduced. After a total of 9 NTD31-145 purifications and 27 crystallisation trials a new 
approach was necessary. 
Figure 3.2.2.4-2: NTD31-145 ethanol condition optimisation. The ethanol concentration was varied 
from 8-15% with Tris pH varied from 7.2-7.4. Small changes in concentration changed the 
appearance of the needle crystal with a drastic plate to plate variation. 
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3.2.3 Crystallisation optimisation of the N-terminal coiled-coil domain  
Many of the complications from the first rounds of crystallisation were due to uncertainty in protein 
concentration and intrinsic affinity of the NTD to Ni-NTA resin, with a large amount of NTD protein 
retained on Ni-NTA recapture. These were combined with the small window for crystal formation and 
volatility of alcohol conditions. To address these issues, the construct design and purification strategy 
was altered to include a C-terminal Strep affinity tag to allow recapture of the NTD protein following 
cleavage to increase purity. With the short sequence and tryptophan residue, the Strep II Tag along 
with Strep-Tactin resin was perfect for this application as the tryptophan also gave an absorbance at 
280 nm. 
3.2.3.1 Construct design 
For addition of the C-terminal tag constructs from NTD28-145 through to NTD38-145 (figure 3.2.3.1) were 
cloned into pMAT11 with the WSHPQFEK (Strep tag) protein sequence added in frame at the c-
terminus of the protein by primer extension. This generated a His6-MBP-NTD-Strep fusion protein. All 
constructs were cloned using the same method and were sequence-verified. 
 
  
Figure 3.2.3.1: Schematic drawing of C-terminal Strep tagged NTD constructs. CtIP constructs 
are highlighted in blue, with the alpha helical tetramerisation domain (α) and zinc binding 




3.2.3.2 Recombinant protein expression and purification 
Protein expression was performed in Rosetta™ 2 (DE3) cells with all protein variants expressed and 
purified using the same techniques. Protein was soluble following lysis and centrifugation, and was 
subsequently purified using Ni-NTA affinity chromatography utilizing a 10 mM imidazole wash to 
remove weakly-bound impurities prior to final elution. Protein was dialysed overnight with addition 
of TEV to cleave the MBP tag producing a mixture of cleaved and un-cleaved products. The strep tag 
affinity to Strep-Tactin resin captured the NTD with flow rate reduced to 0.1-0.2 mL/minute. After 
washing with standard buffer, the protein was eluted from the Strep-Tactin resin and bound to a Hi-
trap Ni-NTA column using the intrinsic affinity of the NTD. Figure 3.2.3.2A/B shows this small affinity 
with a step to 6% buffer B removing some contaminants and 10% buffer B removing the NTD protein. 
The His6MBP retains bound to the column due to its high affinity, allowing removal of 99% of the 
contaminants. The combined fractions containing the NTD-Strep protein were applied to Superdex 75 
16/60 SEC with a sharp symmetrical peak (figure 3.2.3.2C). Compared with non-strep tagged NTD 
constructs, the addition of the c-terminal Strep tag enabled higher purity without excessive use of Ni-
NTA chromatography (figure 3.2.3.2D) and allowed the purification to be followed by 280 nm 
absorbance. Further to this, the strep tag enabled reliable protein concentration determination due 
to the presence of a tryptophan residue in the tag sequence with concentrations between 10-15 
mg/mL achieved prior to aliquoting and freezing. The higher molecular weight “dimer” band was 











Figure 3.2.3.2: Purification of C-terminal Strep tagged NTD construct NTD31-145Strep, using Ni-
NTA and Strep-Tactin chromatography. A) SDS-PAGE analysis of stages after initial capture. 
Protein was initially purified through Ni-NTA with elution fraction (N-E) subject to TEV cleavage 
(TEV) to remove the MBP tag. Protein was bound to a Strep-Tactin column with flow-through (S-
FT), wash (S-W) and elution (S-E) fractions shown. Elution 1&2 were pooled for subsequent His-
trap Ni-NTA. Blue lines indicate the fractions analysed from B, with fractions highlighted in red 
pooled for SEC in C. B) Chromatogram for the His-Trap Ni-NTA, intrinsic NTD31-145Strep affinity to 
the column allowed purification eluting with 10% imidazole. C) Blue trace – SEC Superdex 75 
16/60 of fractions indicated in red from A/B for NTD31-145Strep. Red trace – comparable SEC 
analysis of NTD31-145. Both traces are independent runs on the same column, absorbance values 
are comparable. D) SDS-PAGE of the fraction loaded onto the SEC column (load) prior to analysis 
of SEC elution fractions. Fractions containing NTD31-145Strep (red highlight) were pooled for 




3.2.3.3 Initial screening of N-terminal truncations 
The NTD-strep constructs starting from residues 30, 31, 32, 33, 35 and 38 were dispensed into the 
Morpheus®, Wizard™ 1&2, pHClear and JCSG+™ crystal screens. Only NTD31-145Strep and NTD32-
145Strep in Wizard™ 1&2 gave crystals. Figure 3.2.3.3 shows these hits and any differences between 
the two constructs. Needles along with a further pyramid crystal form were present, appearing in 
ammonium sulphate, sodium tartrate and ammonium phosphate conditions. For crystal condition G5 
the single amino acid difference changed the crystal form from needles to pyramids (figure 3.2.3.3). 
There were no large differences between ammonium sulphate and sodium tartrate conditions. With 
the addition of the Strep-tag UV absorbance now could be used to indicate NTD-Strep crystals. The 
UV detection shows immediately that the crystal in G9 did not contain NTD-Strep. Although the 
pHClear screen gave 0 hits, the 
crystals formed over a large range 
of pH from pH 6.0 MES to pH 9.5 
CHES. The initial Wizard™ 1&2 
screen was repeated confirming 
the presence of medium sized 
crystals with well-defined edges. 
The larger pyramid crystals were 
mounted on crystal loops for X-
ray diffraction without addition 
of cryo-protectant. Large ice rings 
were apparent however 
diffraction maxima were present 
at 36 Å. Now that crystals were 
appearing reproducibly, and had 
the potential to diffract, 
necessary optimisation was 
carried out.  
    Figure 3.2.3.3: Wizard™ 
1&2 screening of strep 
tagged NTD constructs. 
Where no differences 
were seen the best crystal 
image was selected. 
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3.2.4 Optimisation of NTD31-145Strep 
The first optimisations were carried out using a 2D grid screen of ammonium sulphate vs buffer pH 
prepared using the Dragonfly® crystallisation robotics. See chapter 2 for stock solutions and 
preparation. Figure 3.2.4-1 shows the first optimisation grid screen and the appearance of crystals 
within the screen, three crystal forms were present: pyramids, needles and rods each with their own 
distribution over the plate. Pyramids could be seen in the presence of rods, along with pyramids and 
rods appearing adjacent in similar conditions showing the sensitivity of crystal form formation.  
  
 
Data collection without cryo-protection gave large ice rings with minimal diffraction. Addition of a 20% 
v/v glycerol, 80% v/v reservoir mixture directly to the drop prior to crystal mounting and freezing has 
been seen to provide cryo protection. Without a low percentage of cryo-protectant within the 
crystallisation condition this can cause the crystal to crack which is detrimental to diffraction (Holzer, 
2017). To generate divergence between the crystal forms, enable cryo-protection and increase crystal 
size for the second optimisation: drop size was increased while maintaining ratio, the range of 
Figure 3.2.4-1: Optimisation 1 of NTD31-145Strep crystals. Top panel shows the Dragonfly® 
optimisation screen with a range of ammonium sulphate concentrations over the X axis for 12 
wells. Colours indicate crystal form shown in legend with blank squares having 0 crystals. 




ammonium sulphate concentrations reduced, and 2% v/v glycerol added to half of the plate to enable 
cryo-protection. 
The larger 600 nL reservoir mixture (figure 3.2.4-2) in some cases doubled crystal size with a reduction 
in mixed crystal form drops. The addition of 2% v/v glycerol increased the requirement for ammonium 
sulphate (figure 3.2.4.2-2 – A11/A12), however the collective changes allowed assessment by X-ray 
diffraction. The crystals highlighted by the measurements in figure 3.2.4-2 were mounted on cryo 
loops. For this procedure 2 µl of a solution containing 20% v/v glycerol 80% v/v reservoir solution was 
added to each crystal drop and the crystal mounted with no signs of reduced stability. Crystals were 
tested for diffraction at the Diamond Light Source synchrotron on IO4. Only one crystal (A11) gave 




Figure 3.2.4-2: Optimisation 2 of NTD31-145Strep crystals. Top panel shows the optimisation 
screen with a range of ammonium sulphate concentrations over the X axis for 6 wells repeated 
on the Left-Hand Side and Right-Hand Side. Colours indicate crystal form shown in legend with 
blank squares having 0 crystals. Numbers correspond to the bottom panel crystal images. 
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From optimisation 2 the diffracting crystal was grown in the presence of pH 6 MES and 1500 mM 
ammonium sulphate. Further optimisation rounds were carried out on this condition to narrow down 
the crystallisation window for the two crystal forms. Both robotic and manual crystallisation trials 
were performed with optimal crystals from robotic screening. The two final conditions were 1550 mM 
ammonium sulphate, MES pH 5.8 for pyramids, and 1500 mM ammonium sulphate, MES pH 5.9 for 
plates, both with 2% v/v glycerol within the reservoir solution and 5% within the protein solution 
(figure 3.2.4-3). Crystals from the two conditions were mounted onto cryo loops and exposed to 
synchrotron radiation at Diamond Light Source with the outermost Bragg spots at 16.5 Å.  
  
3.2.4.1 Silver Bullets additive screen 
X-ray diffraction had so far been optimised by screening around the original crystallisation condition 
improving by more than 2-fold on the “plate” and “pyramid” crystals harvested. Additive screens are 
a portfolio of small molecules known for their ability to improve crystal formation, packing, and 
change crystal form (Culurgioni et al., 2010). The Silver Bullets additive screen contains a mixture of 
between 1 and 20 similar compounds in a single condition allowing testing of a cocktail of additives in 
a single crystal drop. Similarities between the 96 cocktails narrow down the compounds which help 
crystal formation with general trends between conditions. 
To test the effects of the additives on both the “plate” and “pyramid” crystals, their buffer conditions 
were mixed and dispensed manually into four 96 well plates. Using the Mosquito® multi-aspirate 
technique 400 nL of protein was dispensed with 25 nL of additive + 175 nL of reservoir for each for the 
two crystal forms. Control plates were also dispensed with all plates sealed, stored at 19°C and imaged 
daily.  
Comparison between the control and the silver bullet plates showed many additives had little effect 
on crystals. Some additives swapped the crystal form from “pyramid” to “plate” with others 
encouraging crystal formation where crystals were absent in the control. In one condition the additive 
Figure 3.2.4-3: Optimal pyramid (A) and 
plate (B) shaped crystal forming 
conditions for NTD31-145Strep. Crystals 
were grown at 19°C in the presence of 
2% v/v glycerol within the reservoir and 
5% v/v glycerol added to the protein 
solution prior to plate dispensing.   
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changed crystal form from pyramids to plates with one further cylinder crystal form present (figure 
3.2.4.1A). Crystals were mounted onto cryo loops covering a wide selection of conditions with cryo-
protection for X-ray data collection at Diamond Light Source I24. Additives did not improve any of the 
pyramid crystals that were screened. The “plate” crystals did improve with additives known for 
dehydrating the crystal with a new diffraction pattern seen with a repeating 4:2 pattern of Bragg 
maxima (figure 3.2.4.1C). Further improvements were seen for the new “cylinder” crystal form with a 
greater distribution and amount of diffraction maxima over a single image and over a data collection 
(figure 3.2.4.1B). For this cylinder crystal (figure 3.2.4.1A) data were collected and auto processed to 
11.5 Å, the presence of Zinc was also detected by X-ray fluorescence scan with a peak at 1.2823 Å and 






3.2.4.2 I24 Dehydration HC1 & in-situ data collection 
Further optimisation was necessary to improve crystal diffraction with the additive screen conditions 
alluding to dehydration improving the “plate” crystals. In-situ dehydration of crystals using the HC1 
dehumidifier and direct X-ray data collection allows analysis of crystal diffraction with precise changes 
Figure 3.2.4.1: NTD31-145Strep Crystals show 4:2 Bragg diffraction pattern. A) A new crystal form 
was seen with a cylindrical appearance alongside the previously seen ‘plate’ crystal form. B) 
Diffraction obtained from the ‘cylinder crystal in A. The edge of this image is 11.5 Å. C) Diffraction 
obtained from the ‘plate’ crystal in A, the edge of this image is 13 Å.  
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in relative humidity. The diameter of the crystal is measured as an indication of hydration to determine 
and control of the rate and amount of crystal dehydration. The effect of dehydrating the crystal by X-
ray diffraction can then be measured directly and experiment changed accordingly (Lobley et al., 
2016). Unfortunately attempts to dehydrate crystals and measure X-ray diffraction were impeded by 
the low 11% humidity within the beam hutch. This resulted in a drastic reduction in X-ray diffraction 
during the process of crystal mounting, transfer and wicking. To ensure the starting crystals could 
diffract, in-situ plate crystal diffraction was collected. In contrast, diffraction was present to the same 
extent as previously seen for crystals collected at cryo conditions for both “plates” and “pyramids”. 
Other methods to dehydrate a crystal such as transferring the crystal into a higher percentage 
precipitant and additives were also tested, however diffraction did not improve.  
3.2.4.3 Hampton additive screen 
Crystallisation solutions were further optimised to give cylinder crystals without the need for additives 
(figure 3.2.4.3A). As further screening of Silver Bullets additives gave no additional improvement a 
change of approach was taken. The Hampton additive screen is composed of 96 individual conditions 
with the additive included in the reservoir condition enabling easier optimisation (Hampton Research, 
2001). 
The starting point for the Hampton Additive screen was 1450 mM ammonium sulphate, 6.5% v/v 
glycerol, 100 mM MES pH 5.9 with 5% v/v glycerol in the protein solution. This condition was made at 
110% to allow 10% individual addition of each of the 96 additives. A second control plate was made 
with 10% water instead of additive. Both plates were dispensed and imaged using the standard 
protocol. From the additive screen maltose and sucrose gave more defined edges to “plate” crystals. 
These were further tested with no improvement over the previous 11.5 Å resolution. Few conditions 
gave rise to a swap in crystal form however the pyramid crystals still gave poor diffraction. One further 
crystal form appeared in the presence of sodium thiocyanate, this crystal grew from a small piece of 
dust into a 2D plate (figure 3.2.4.3B). The crystal was mounted onto a cryo loop, cryo-protected and 
exposed to X-rays at the Diamond Light Source synchrotron beamline IO3. The diffraction pattern 
showed similarities to the plate 4:2 Bragg diffraction, although with separated spots (figure 3.2.4.3C). 




3.2.4.4 Sodium thiocyanate crystal seeding methods 
Further optimisation rounds were performed with small rod-shaped crystals appearing in low 
concentrations of sodium thiocyanate (figure 3.2.4.4A). Variation of the crystal condition failed to 
increase the crystal size. Since small crystals did appear these were used as starting seed material to 
encourage crystal growth. A seed stock was generated from the crystals in figure 3.2.4.4A as described 
in chapter 2. 
Traditional streak seeding was used both with manual 24 well plates and Mosquito® dispensed 96 well 
plates with no crystalline material present after 31 days. Using the Mosquito® multi-aspirate seeding 
technique can be used with a dilution series of seeds from 10-, 100- and 1000-fold with 1:100 seed 
dilutions giving the best results. Rather than rod-like crystals within the solution, crystals were now 
forming on the surface of the plate with a wedge shape (figure 3.2.4.4B). Crystals were cryo-protected 
by quickly passing through a 20% v/v glycerol 80% v/v reservoir solution when mounted onto cryo 
loops prior to freezing. Data were collected at the Diamond Light Source synchrotron on beamline IO3 
with a resolution improvement to 7.86 Å. The same diffraction pattern as the previous sodium 
thiocyanate crystal with spots overlapping the Bragg 4:2 diffraction was also maintained.  
Figure 3.2.4.3: Hampton additive screening, 
sodium thiocyanate additive gives a 2D plate 
crystal. A) Control screen without addition of 
additive. B) Same condition as in A, however 
with sodium thiocyanate additive. C) Diffraction 
obtained from the crystal in B. Auto processing 
gave a resolution of 9.77 Å with the crosshair on 




3.2.4.5 Variation of temperature 
Temperature can be a significant variable in crystallisation due to its ability to change solubility, 
supersaturation and speed of crystal growth (Hampton Research, 2001). So far, all crystallisation trials 
were carried out at 19°C. Therefore 19°C, 11°C and 4°C were tested using identically dispensed plates. 
Optimisation screen 18 was used with sodium thiocyanate and a 1:100 seed stock (appendix figure 
7.3). The “cylinder” crystal form gave the best improvements, with visual changes from a cylinder to 
a hexagonal prism with sharp defined edges. This is apparent in figure 3.2.4.5 comparing from left to 
right as the temperature reduces, UV detection confirmed that these new hexagonal prism crystals 
contained NTD31-145Strep.  
Figure 3.2.4.4: Mosquito® 
seeding for sodium 
thiocyanate crystals from 
Hampton additive 
screen. A) Crystals used 
for the seed stock. B) 








Hexagonal prism crystals were mounted onto cryo loops and cryo-protected by quickly transferring 
into a 20% v/v glycerol 80% v/v reservoir solution prior to flash freezing. Crystals were analysed by X-
ray diffraction at the Diamond Light Source Synchrotron on beamline IO3. Figure 3.2.4.5E shows the 
diffraction obtained from the crystal circled in blue with AutoProc processing giving an outer shell 
resolution of 8.45 Å. Further X-ray diffraction maxima were seen at 4.63 Å in a subset of the images 
however there were no signs of diffraction in-between. A zinc fluorescence scan gave a peak at 1.2816 
Å showing the presence of zinc within the crystal with further resolution optimisation necessary. 
3.2.4.6 Purification of Selenomet NTD31-145DM-Strep 
Generation of phases from the zinc ions present within the crystals was limited by the diffraction 
resolution. Expression of protein containing heavier atoms such as selenium is one method to 
Figure 3.2.4.5: Temperature variation improving cylinder crystal to a hexagonal prism. For the 
three identical plates A) 19°C, B) 11°C, C) 4°C. Crystal circled was mounted for X-ray diffraction in 
E. D) UV detection of the 4°C crystal shows they contain protein. E) X-ray diffraction pattern of the 
hexagonal prism circled in blue, outer edge of diffraction in this image is 8.0 Å. 
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generate phases. Generally, selenomethionine (SeMet) incorporation leads to a lesser diffracting 
crystal. Nevertheless, a change to the protein and its surroundings has the potential to improve 
diffraction. NTD31-145Strep contains three methionine residues and so a SeMet labelled preparation 
was performed. The purification deviated from the non-labelled purification to allow addition of 3 mM 
TCEP with an amylose initial capture. Figure 3.2.4.6 shows the final polishing step of the purification 
with fractions containing NTD31-145Strep pooled. For final SEC both with and without 2 mM DTT was 




To encourage crystal formation non-labelled micro seeds were used in half of the crystallisation trials, 
with Wizard 1&2, Morpheus, JCSG and optimisation 1/18 (appendix 7.2/7.3) screens dispensed for 
both with and without DTT supplemented protein. Crystal plates were incubated at 4°C to give the 
best chance of crystals with identical screens at 19°C. Over all the different crystallisation conditions 
there were zero signs of crystal formation with absence of all previous crystal forms. 
Figure 3.2.4.6: SEC purification of SeMet NTD31-145Strep. Protein was purified using the standard 
procedure with adaptions detailed in the main text. A) SEC chromatogram of SeMet NTD31-
145Strep using the Superdex 75 16/60 SEC column. Fractions were analysed by SDS-PAGE in B. B) 
Protein eluted from the initial amylose column (pre-TEV) was further processed using the 
standard procedure with Streptactin elution (S-E) and protein applied to the SEC column (Load) 
shown. Fractions from SEC are shown with fractions in red pooled and concentrated to 10 
mg/mL for crystallisation trials. 
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3.2.5 Surface entropy minimisation of NTD31-145Strep 
Further methods of optimisation were required to increase the diffraction. It is well known that 
protein crystallisation is dependent on formation of an ordered lattice. This is countered by the 
entropic cost of ordering and the loss of side change conformational freedom involved in crystal 
contacts. Clusters of highly entropic amino acids such as lysine, glutamine and glutamic acid can 
therefore be detrimental to this crystallisation process. A strategy to improve and encourage protein 
crystallisation is to therefore reduce patches of the surface entropy by mutational surface engineering. 
This should then lower the energy barrier for crystal formation (Derewenda and Vekilov, 2006). 
Examples from the literature show surface entropy minimisation providing an improvement in 
diffraction and crystal formation (Cooper et al., 2007; Derewenda and Vekilov, 2006; Parthasarathy et 
al., 2008; Rzechorzek et al., 2014). 
3.2.5.1 Construct design 
To determine key clusters of residues for surface entropy minimisation the online UCLA SERp server 
was used in October 2017 (Goldschmidt et al., 2007). Here three patches were chosen for surface 
entropy minimisation named cluster 1 (C1), 2 (C2) and 3 (C3) each in a different location on the protein 
(figure 3.2.5.1). Mutations were mapped onto the known structures of Rad50 and Cortexillin with side 




3.2.5.2 Recombinant protein expression and purification 
Protein expression was performed in Rosetta™ 2 (DE3) with two litres of culture used per protein per 
purification. The same purification strategy as wild type protein was performed with initial Ni-NTA 
followed by overnight cleavage and secondary strep capture. NTD31-145C2-Strep purification is shown 
in figure 3.2.5.2. SEC showed overlapping traces for the three clusters eluting at the same elution 
volume (figure 3.2.5.2E) indicating no gross change in shape from the mutations.  
Figure 3.2.5.1: Schematic drawing of NTD31-145Strep cluster mutations. NTD31-145Strep is shown in 
blue, with tetramerisation domain (α) and zinc binding domain shown (CXXC). NTD31-145C2-Strep 
(C2 = K46A, Q47A, E48A). NTD31-145C1-Strep (C1 = K107A, K108A, Q109A). NTD31-145C3-Strep (C3 = 









3.2.5.3 Initial crystal screening 
Crystal screens were dispensed for each NTD31-145Strep cluster mutated protein, including Wizard™ 
1&2, Morpheus® and JCSG+™ both with and without micro seeds. Zero crystals were seen without 
micro-seeds however micro seeding gave UV absorbing crystals in five conditions. A total of 32 crystals 
Figure 3.2.5.2: Purification of NTD31-145Strep Cluster mutants. A) Initial purification of NTD31-145C2-
Strep through to elution from the Streptactin column. B) His-trap chromatogram. C) SDS-PAGE 
analysis of His-trap column with blue lines corresponding to fractions in B). Fractions highlighted in 
red were pooled for SEC in D/E. D) Superdex 75 16/60 SEC. Fractions for Cluster 1 and Cluster 2 
were analysed by SDS-PAGE in E with traces overlaid for the three clusters. E) SDS-PAGE analysis of 
fractions of cluster 1 & 2 along with the protein loaded onto the column for cluster 2 (N#2-E (C2)). 




were mounted and cryo-protected for data collection at Diamond Light Source, however there were 
no signs of protein diffraction. Many crystals had salt diffraction patterns, therefore UV absorbance 
was likely from protein deposited on the salt crystal surface. Thermal melt analysis was performed of 
the cluster mutated proteins showing a reduction in the melt peak compared to wild type protein. 
This indicated reduced stability and is likely the reason why the mutations failed to help with 




Figure 3.2.5.3: Thermal melt peak and melt 
curve. From the binding of SYPRO orange to 
unfolded protein the fluorescence increases 
and is measured in relative fluorescence 
units. Three repeats for each protein gave 
the same melt temperatures of 36°C (C2) 
41.5°C (C1) and 46.0°C (Wild type) 
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3.2.6 Crystallisation of NTD31-145DM-strep 
The NTD31-145 is predicted to contain two coiled-coil regions separated by a zinc-binding motif based 
on amino acid sequence analysis. Previous studies of a double cysteine-to-alanine mutation targeting 
the putative zinc ligands C89 and C92 showed no change to the dimerization state of the CtIP-NTD 
(Davies et al., 2015). As incomplete or diverse incorporation of zinc by recombinant CtIP-NTD was a 
possible source of sample heterogeneity hampering crystallisation, a double mutant NTD31-145DM-
Strep construct replacing C89 and C92 with alanine was generated (figure 3.2.6).  
 
 
3.2.6.1 NTD31-145DM-Strep protein purification. 
Protein expression was performed in Rosetta™ 2 (DE3) cells transformed with NTD31-145DM-Strep. Two 
litres of cells were used for each purification using the same protocol as for the wild type construct. 
NTD31-145DM-Strep eluted from the His-Trap Ni-NTA column in the same concentration of imidazole 
although with a wider peak (figure 3.2.6.1). In the Superdex 75 16/60 SEC, NTD31-145DM-Strep eluted 
in the same elution volume as the wild type protein (figure 3.2.6.1D), confirming previous results that 
the protein can still form a dimer without the incorporation of zinc. Eluted fractions from SEC 
containing NTD31-145DM-Strep, as shown by SDS-PAGE, were pooled and concentrated to 200 µL. The 
Strep tag enabled a protein concentration of 9.8 mg/mL to be determined by absorbance at 280 nm. 
Protein was snap frozen with liquid nitrogen in 20 µL aliquots. No higher molecular weight dimer band 
was seen after SEC, with minimal appearance on the Hi-Trap Ni-NTA gel. 
  
Figure 3.2.6: Schematic drawing of NTD31-145DM-Strep. NTD31-145DM-Strep is shown in blue, with 
tetramerisation domain (α) and zinc binding domain mutated to alanine’s (AXXA). DM stands for 




Figure 3.2.6.1: Protein purification of NTD31-145DM-Strep. A) SDS-PAGE analysis of initial capture 
with Ni-NTA combined elution (N-E) pooled for subsequent TEV cleavage and Strep-Tactin 
capture. Strep combined elution (S-E) was loaded into the Hi-Trap Ni-NTA column in B. B) 
Chromatogram for the His-Trap Ni-NTA, intrinsic NTD31-145DM-Strep affinity to the column 
allowed purification eluting with 10% v/v buffer B (1M NaCl) with fractions analysed by SDS-PAGE 
in C. C) Fractions highlighted in red were pooled for SEC in D. D) Superdex 200 16/60 SEC of 
pooled Ni-NTA elution from C with SDS-PAGE analysis in E. E) fractions highlighted in red were 
pooled and concentrated to 10 mg/mL prior to freezing for future experimentation.  
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3.2.6.2 Crystal screening of NTD31-145DM-Strep 
The Morpheus® (appendix 7.8) and Wizard™ 1&2 crystallisation screens were dispensed using a 1:1 
and 2:1 protein to reservoir drop ratio at a protein concentration of 7.5 mg/mL. Crystallisation plates 
were stored at 19°C and imaged daily. In contrast to the wild type protein, there were no hits for the 
Wizard 1&2 screen. For the Morpheus® screen, only condition F6 (appendix 7.8) yielded a crystal, 
which continued to grow for 8 days (figure 3.2.6.2-1). At this point it was mounted onto a cryo loop 
without further cryo-protectant from the 400 nL 1:1 ratio drop. The crystal was very fragile and broke 




The two mounted parts of the crystal were screened at beamline IO4 of Diamond Light Source. The 
NTD31-145DM-Strep crystal showed strong diffraction to almost 3A resolution (figure 3.2.6.2-2a/b), 
confirming that this crystal form was suitable for single-crystal X-ray diffraction analysis.  
  
Figure 3.2.6.2-1: Growth NTD31-145DM-Strep crystal F6 Morpheus®. See Appendix 7.8 for crystal 
conditions. The blue dashed line indicates where crystal broke. Fast UV was performed to detect 








3.2.6.3 NTD31-145DM-Strep Matrix Micro Seeding 
Upon repeat of the Morpheus® crystallisation condition, no new crystals were obtained. To promote 
crystal formation a seed stock was made from the crystal that had been exposed to synchrotron 
radiation (methods 2.19.1.4). The technique of Matrix Micro Seeding was used to directly seed into 
the Morpheus® crystallisation screen using the multi-aspirate seeding technique (D’Arcy et al., 2007). 
Two crystallisation trials were performed both with and without seed stock, a constant 1:1 protein to 
crystallisation condition drop ratio and a 400 nL drop volume. 
For the crystallisation trial without seeds, crystals were seen in wells D7, E11 and F11 (figure 3.2.6.3-
1). The crystals from D7 and F11 broke into two parts giving two attempts at data collection for each 
crystal. The change of additive from monosaccharides in F11 to ethylene glycols made crystal E11 less 
fragile and therefore did not break (see appendix 7.8 for conditions).  
 
Figure 3.2.6.2-2: X-ray Diffraction of NTD31-145DM-Strep compared to NTD31-145-Strep. A) 
Diffraction pattern of NTD31-145DM-Strep crystals formed in well F6 of Morpheus screen, the 
outer edge of the diffraction in this image is 3.5 Å. Auto processing gave a space group of P31 
with A 86.81, B 86.81, C 42.89, α 90.00, β 90.00, γ 120.00 unit cell dimension. B) Diffraction 
pattern of NTD31-145Strep hexagonal crystal formed in optimisation 18 at 4°C, outer edge of 






From matrix micro seeding 65 out of 96 conditions yielded crystalline material; half of these gave 
crystals of sufficient size to be tested for X-ray diffraction (figure 3.2.6.3-2). Like the wild type protein, 
NTD31-145DM-Strep tended to crystallise under basic pH conditions. 32 Crystals were of sufficient size 
to be harvested after 4 days. Morpheus® conditions already contain additives to provide cryo-
protection so no further cryo-protection was added on crystal mounting. Most of these crystals were 
attached to the plate surface and were very delicate, making crystal mounting difficult, especially in 
conditions containing alcohols.  
Upon X-ray diffraction screening of the non-seeded crystals, the cryo loops contained excessive ice, 
using grid screening over the cryoloop surface, diffraction could be seen through the ice indicating the 
presence of protein crystal diffraction the same as previous data collections. 
Figure 3.2.6.3-1: Growth of NTD31-145DM-Strep crystals formed in Morpheus repeat #3. Crystals 
formed in condition D7, E11 and F11 (see Appendix 7.8 for crystal conditions). The blue dashed 
line indicates where crystals were broken to enable two data collections. Crystals were initially 
seen at +12 hours. The crystal from condition D7 was harvested after 7 days (d), whereas the 




Figure 3.2.6.3-2: Crystals formed in Morpheus® screen with Matrix Micro Seeding. The crystal 
plate was stored at 19°C and imaged daily by RockMaker. See appendix 7.8 for crystal conditions. 
Crystal diameter along the longest axis was measured to classify, ≤40 µm were classed as “tiny 
Crystals”, ≤60 µm were classed as “small crystals”. Crystals that were ≥80 µm are depicted, with 
blue circles indicating a selection of mounted or important crystals.  
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3.2.6.4 SeMet NTD31-145DM-Strep protein purification 
As the zinc binding site had been mutated, zinc was no long present in the crystal and could not be 
used to obtain phase information using its anomalous scattering signal. Therefore, a SeMet-labelled 
protein preparation was performed.  
Protein expression was performed using Rosetta™ 2 (DE3) bacterial cells transformed with NTD31-
145DM-Strep. Four litres of cells were grown in minimal media supplemented with SeMet as detailed 
in methods 2.1.4. The standard purification protocol was adapted to use a 5 mL amylose column for 
initial capture enabling addition of reducing agent. TEV overnight cleavage and strep capture were 
performed as previously described. SeMet NTD31-145DM-Strep eluted from the 1 mL His-Trap Ni-NTA 
column in the same concentration of imidazole with a similar profile to the non-labelled protein. 
Fractions corresponding to NTD31-145DM-Strep were analysed by SDS-PAGE (figure 3.2.6.4C) and 
pooled for final polishing by Superdex 75 16/60 SEC (figure 3.2.6.4D/E). Eluted NTD31-145DM-Strep was 














Figure 3.2.6.4: Protein purification of SeMet NTD31-145DM-Strep. A) SDS-PAGE analysis of initial 
capture with Ni-NTA elution fractions pooled for subsequent TEV cleavage and Strep Tactin 
capture in B. B) Combined strep elution’s (S-E) were applied to the Hi-Trap Ni-NTA column in C, 
with fractions indicated in B corresponding to C. C) Chromatogram for the Hi-Trap Ni-NTA, 
intrinsic SeMet NTD31-145DM-Strep affinity to the column allowed purification eluting with 10% 
buffer B with fractions analysed by SDS-PAGE in B. Fractions highlighted in red were pooled for 
SEC in D. D) Superdex 200 16/60 SEC of pooled Ni-NTA elution from C with SDS-PAGE analysis in 




3.2.6.4.1 SeMet NTD31-145DM-Strep Matrix micro seeding  
SeMet NTD31-145DM-Strep was dispensed into two Morpheus screens, with and without micro seeds, 
at a constant concentration of 7.5 mg/mL with 5% v/v glycerol. For both screens the drop ratio was 
the same as previous crystallisation trials with plates were stored at 19°C and imaged every 12 h for 
10 days. In the control non-seeded plate only two amorphous spherulite crystals were present. 
Whereas in the seeded screen, addition of protein crystal nuclei resulted in 86 out of 96 conditions 
containing crystals. General crystallisation trends were seen similar to wild type protein; figure 
3.2.6.4.1 shows examples of crystals formed.  
  
 
A total of 32 SeMet NTD31-145DM-Strep crystals were screened for X-ray diffraction at beamline IO3 of 
Diamond Light Source. Many of the crystal loops contained excessive ice with grid screening over the 
cryo-loop obtaining diffraction to around 9.0 Å (E2 and H2 figure 3.2.6.4.1). Two crystals (C2 and G6 
figure 3.2.6.4.1) diffracted to ≤5.0 Å however they suffered greatly from radiation damage with 
insufficient diffraction for generation of phase information.  
Figure 3.2.6.4.1: SeMet NTD31-145DM-Strep crystals. Circle represents a 200 µm diameter and 
indicates crystals mounted for X-ray diffraction. 
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3.2.7 Molecular Replacement  
Crystals from the Morpheus seeded plate (section 3.2.6.3) were sent to the ESRF for X-ray data 
collection. X-ray diffraction data were collected at beam wavelength 0.976251 Å and 100K at 69.28% 
transmission as 990 contiguous frames with 0.02 second exposure and 0.1° oscillation on a 
Pilatus3_6M detector at beamline ID30B of the ESRF Grenoble, France. The diffraction images were 
indexed and intensities extracted and scaled in XDS (Kabsch, 2010) and further scaled and analysed 
using Aimless (Evans and Murshudov, 2013) with help from Prof. Luca Pellegrini . All crystals were 
screened, and 6 crystals provided complete datasets to 3.0 Å resolution or better. All data sets were 
in the same trigonal P31 space group with unit cell dimensions: a=b=86.6A c=42.6A, ==90, =120. 
Two copies of the NTD31-145DM sequence forming one dimer were seen in the asymmetric unit. A 







Figure 3.2.7-1: Example crystal and diffraction pattern for NTD31-145DM-Strep. A) Crystal of 
NTD31-145DM-Strep grown in the condition G6 Morpheus (molecular dimensions). Crystals 
indicated were mounted and exposed to X-rays. B) Crystal of NTD31-145DM-Strep immobilised in 
the cryo-loop. C) Representative X-ray diffraction pattern of NTD31-145DM-Strep, the resolution of 
the outer edge of this image is 2.58 Å. 
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The structure of NTD31-145DM was determined by Molecular Replacement (MR) using Phaser (McCoy 
et al., 2007) as implemented within the CCP4 suite of crystallographic software (Collaborative 
Computational Project, 1994). Two helical coiled-coil models spanning amino acids 56-83 and 99-144 
of human CtIP, corresponding to the regions of CtIP NTD strongly predicted to form coiled-coil 
structures, were generated in CBuilder2.0 (Wood and Woolfson, 2018) and used as search templates. 
Phaser successfully placed both models in the asymmetric unit, with no model clashes and clear 
indication of extra electron density for the missing parts of the crystallographic model. An initial poly-
alanine model was refined in Phenix (Adams et al., 2010), adding side chains and extending the model 
to boundaries of the interpretable density maps. Refinement in Phenix was interspersed with manual 
rebuilding in Coot (Emsley and Cowtan, 2004), to improve fitting to the electron density map and the 
stereochemistry of the model. The refined crystallographic model of the human CtIP NTD comprise 
amino acids 31 to 136 for both chains, with Rwork/Rfree = 0.2229/0.262, no Ramachandran outliers and 
a Clashscore of 2.45 (Davis et al., 2007) (see Table 3.2.7-2). Figure 3.2.7-3 shows an overlay of the 2Fo-











Unit cell:    86.60Å   86.60Å   42.60Å   90.00°   90.00°  120.00° 
Space group: P31 
                                           Overall InnerShell  OuterShell 
Low resolution limit (Å)                   43.30     43.30      2.95 
High resolution limit (Å)                   2.80      8.86      2.80 
Rmerge                                       0.065     0.033     0.718 
Rmeas                                        0.081     0.041     0.886 
Rpim                                        0.047     0.024     0.513 
Total number of observations               24003       700      3599 
Total number unique                         8686       273      1283 
Mean((I)/sd(I))                              9.5      25.1       1.5 
Mn(I) half-set correlation CC(1/2)         0.997     0.998     0.575 
Completeness                                98.7      98.0      99.2 
Multiplicity                                 2.8       2.6       2.8 
Mean(Chi^2)                                 0.98      1.11      0.91 
Average mosaicity:   0.15 
𝑅𝑚𝑒𝑟𝑔𝑒 =




























              Resolution range  37.5  - 2.802 (2.902  - 2.802) 
            Unique reflections                      8676 (878) 
Reflections used in refinement                      8655 (877) 
   Reflections used for R-free                        387 (38) 
                      R-factor                 0.2229 (0.3215) 
                        R-free                 0.2620 (0.3143) 
  Number of non-hydrogen atoms                            1831 
                macromolecules                            1809 
                       solvent                              22 
              Protein residues                             214 
                    RMS(bonds)                           0.001 
                   RMS(angles)                            0.23 
      Ramachandran favored (%)                          100.00 
      Ramachandran allowed (%)                            0.00 
     Ramachandran outliers (%)                            0.00 
          Rotamer outliers (%)                            1.00 
                    Clashscore                            2.45 
              Average B-factor                           99.69 
                macromolecules                           99.97 
                       solvent                           77.10 
Table 3.2.7-2: X-ray data collection and crystallographic refinement of CtIP NTD31-145DM. Rmerge 
equation is shown where Ihkl is the average of the symmetry related observations of a unique 
reflection. Rmeas is the redundancy-independent merging R-value where n is the number of 
observations. Rpim is the precision-indicating merging R-value. Rmerge in the top intensity bin (low-
resolution bin) is an indicator of overall data quality. Mean ((I)/sd (I)) describes the ratio of 
signal/noise. CC1/2 is the correlation coefficient between two data sets generated by randomly 
splitting the data into two halves and is a measure of internal consistent of the collected data. 
Completeness is the number of crystallographic reflections measured, expressed as a percentage 
of the total number. Multiplicity is the average number of times that each spot of the diffraction 
pattern is measured.  R-factor = Σ (|Fobs  - Fcalc|)  / Σ|Fobs|, where Fobs and Fcalc are the observed 
and calculated structure factors. R-free = R-factor calculated using a randomly selected 5% subset 
of the diffraction data, omitted throughout the refinement. Root-mean-square (RMS) is the 





The crystal structure revealed that the NTD region spanning residues 31-136 forms a highly elongated 
dimer of parallel uninterrupted alpha helices (figure 3.2.7-4). Within this helical structure, two coiled-
coil regions (amino acids 31-85 and 110-136) form on either side of the zinc binding site; the residues 
surrounding the cysteine pairs, which act putatively as zinc ligands, forms instead two alpha helices 
that run alongside each other in the dimer. Formation of the first coiled coil agrees with a prevalence 
of hydrophobic residues at the ‘a’ and ‘d‘ positions of the heptad repeat (figure 3.2.7-5), which 
disappears as the sequence progresses in the central parallel alpha helix region (figure 3.2.7-5A / figure 
3.2.7-6A/C). Here (green figure 3.2.7-6A), the most prominent connection between the two alpha 
helices is a pair of phenylalanine residues (amino acid 106); their side chains form a π-stack that likely 
helps to form the start of the C-terminal coiled coil region (figure 3.2.7-6A). 
Inspection of the structure shows that the position of the putative zinc-binding cysteines 89 and 92 
falls within the central region of parallel alpha helices. Surprisingly, the alanine residues point towards 
the solvent and away from the inside of the coil, not as would be expected for shared coordination of 
a zinc ion. The reason for this unexpected conformation is currently unknown. It is possible that in the 
wild-type sequence the cysteines are part of local random-coil motif that lets them coordinate the 
zinc, and that in the mutant protein the presence of alpha-promoting alanine residues has caused 
formation of a continuous helical region (figure 3.2.7-6B/D). Further experiments will be necessary to 
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86 AGLADRAAVTEEHMRKKQQEFENI 109 
110 RQQNLKLITELMNERNTLQEENKKLSEQ 137 
Figure 3.2.7-5: Heptad repeat A, D representation of the two coiled coils (31-85 and 110-136) 
with sequence. Residues shown as a stick representation in the models are highlighted in cyan in 
the sequence. 
Figure 3.2.7-4: The structure of NTD31-145DM. The secondary structure is colour coded with blue 
representing the coiled-coils (amino acids 31-85 and 110-136) separated by a parallel alpha helix 






Figure 3.2.7-6: Residues 86-109 form a set of parallel alpha helices with C89A&C92A mutation 
residues solvent exposed. A) A, D heptad repeat sequence from the first coiled-coil is continued 
however residues are no longer in the correct positions for coiled-coil formation shown in C. 
Arginine 91 is pointing towards the solvent. B) Location of the C89A/C92A mutations with alanine 
residues shown as a space-fill representation. C) Visualisation of the change from coiled-coil (blue) 
to parallel alpha helices (green). D) End on view of the C89A/C92A mutations showing their 




3.2.8  SEC-SAXS of the NTD 
SEC-SAXS is a powerful technique that can be used to obtain structural information about ordered and 
disordered regions of biological samples to a low resolution (Feigin and Svergun, 1989). Here SEC-SAXS 
is used for determination of the orientation of the alpha helices and gain insights to supplement the 
crystal structure. 
3.2.8.1 Analysis of strep tag addition on protein folding. 
Tagged and untagged NTD31-145 were analysed by SEC-SAXS to assess the effect of the Strep tag 
addition on the protein structure. The scattering-based Kratky-plot for the two samples gave similarly 
shaped curves with both indicating an elongated protein (figure 3.2.8.1A.) Performing a Guinier 
analysis of the SAXS data showed a slight increase as expected for increasing the length of the protein 
(figure 3.2.8.1B). Further data analysis using the Pair-distribution function gave DMAX. This value 
increased by 10 Å, however, the data still gave a P(r) distribution with a steady decay (figure 3.2.8.1C). 







Figure 3.2.8.1: SEC-SAXS analysis of NTD31-145 vs NTD31-145Strep. A) Dimensionless Kratky plot for 
non-tagged NTD31-145, and NTD31-145Strep. B) Guinier fitting for non-tagged NTD31-145, and NTD31-




3.2.8.1.1 The NTD exists as a parallel coiled-coil  
Svergun and Koch’s article in 2003 depicts a comparison between pair-distribution functions for 5 
different shaped particles showing that shape information can easily be obtained from the scattering 
data (Svergun and Koch, 2003). From the pair distribution function or P(r) distribution a protein 
envelope can be modelled as this shows all distances between the scattered electrons. Distinctive 
differences can therefore be seen between rod, globular, and dumbbell shaped proteins from P(r) 
distribution (figure 3.2.8.1.1) and enable a model to be generated. Addition of bulky protein tags to a 
single N- or C-terminus of a coiled-coil can determine the orientation of the coil from the change in 
shape. For a parallel coiled-coil a Y shaped envelope is expected, whereas an anti-parallel coiled coil 
form a dumbbell shape with a distinctive double peak distribution (Kim et al., 2017). In 2004 four 
models were proposed for the architecture of the N-terminal dimerisation domain: a straight rod of 
17nm, two shorter coils with a flexible region, a 4 helix bundle, and a ‘rad50 like’ zinc hook (Dubin et 
al., 2004). To confirm the parallel nature of the domain, in accordance to the crystal structure, SEC-








Figure 3.2.8.1.1: Comparison of P(r) 
distribution for 5 different shapes. A 
sphere in red, doughnut in blue, 
dumbbell in pink, disk in yellow and a rod 
in green, all with an identical DMAX of 10 
nm are shown. The graph on the LHS 
shows the P(r) distribution for the 5 
shapes. This shows how shape 
information can be obtained from 
scattering data, adapted from Svergun 
and Koch 2003. 
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3.2.8.1.1.1 Purification of MBP tagged NTD30-145Strep 
The MBP tag was already used in purification of NTD constructs, therefore, for an MBP fusion the TEV 
protease stage was omitted. The soluble protein was purified using sequential Ni-NTA and Strep-Tactin 
affinity chromatography prior to Superdex 200 16/60 SEC (figure 3.2.8.1.1.1). Fractions containing 
MBP-NTD30-145Strep were pooled and concentrated for SAXS analysis. MBP was purified as a bi-product 
from purification of cleaved NTD31-145Strep, for this the MBP was bound in excess to a 2 mL amylose 
column and purified by a Superdex 75 16/60 SEC column. 
 
3.2.8.1.1.2 SAXS Data analysis using SCÅTTER 
SEC-SAXS experiments were performed on B21 at Diamond Light Source individually on NTD30-145Strep, 
MBP-NTD30-145Strep and MBP to generate small angle scattering data for analysis. Comparisons 
between the scattering based dimensionless Kratky-plot can give first information about the proteins. 
MBP has a bell-shaped curve with an inflection at 1.0 which is typical of a globular protein. In contrast 
NTD30-145Strep has an increasing slope with a shifted and much higher inflection point indicative of a 
coiled-coil (Putnam et al., 2007) (figure 3.2.8.1.1.2-1). The addition of MBP onto the NTD results in an 
elongated trace with a similar inflection peak still showing a globular nature to the protein. Guinier 
fitting was performed to calculate RG with a larger value for MBP NTD31-145Strep as expected (figure 
3.2.8.1.1.2-2). The scattering data were further processed to obtain the P(r) distributions, both MBP 
and NTD31-145Strep gave P(r) distributions that are indicative of their globular and coiled-coil nature 
respectively (figure 3.2.8.1.1.2-1B). The single peak for MBP-NTD31-145Strep shows that this does not 
Figure 3.2.8.1.1.1: Purification of MBP-NTD30-145Strep by Ni-NTA and Strep-Tactin. A) MBP-NTD30-
145Strep was captured by Ni-NTA chromatography, 200 mM imidazole elution fraction (N-E) was 
bound to a Strep-Tactin column to remove impurities with the Strep elution (S-E) used for gel 
filtration. Blue lines indicate fractions analysed by SDS-PAGE from gel filtration in B, with the red 
box indicating pooled fractions for concentration and freezing. B) Chromatogram of the Superdex 









SEC-SAXS analysis of 
NTD30-145Strep fused to 
MBP. A) The Kratky 
plot, B) the P(r) 
distribution. Both 
indicate that the NTD is 
a long molecule and 
show the globular 
nature of MBP. From 
the traces we can see 
that the combined 
MBP-NTD has an 
elongated globular 
appearance indicating 
a parallel coiled-coil. 
Figure 3.2.8.1.1.2-2: SEC-SAXS Guinier 
fitting analysis of NTD30-145Strep, MBP-
NTD30-145Strep and MBP. Colours 
correspond to figure 3.2.8.1.1.2-1. 
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3.2.8.1.1.3 SAXS model comparisons 
Models to fit the SAXS data were generated through SCÅTTER using the ATSAS package program 
DAMMIF and DAMAVA. The resultant DAMFIT files from averaging were visualised using PyMol and 
aligned manually. To assess the quality of the data the model to fit the SAXS data for MBP were aligned 
with its known structure (3hpi) with no obvious discrepancies (figure 3.2.8.1.1.3A).  
The MBP tag on the N-terminus of the NTD30-145Strep construct will allow the location of this end to 
be determined. Alignment of the two models for NTD30-145 along with MBP-NTD30-145 show that the 
MBP-NTD30-145Strep has a much larger envelope and a non-symmetrical appearance (figure 
3.2.8.1.1.3B). The protruding section within this model is sufficient to align the NTD30-145Strep model. 
Further alignment of the model to fit the MBP SAXS data was only possible within one end of the MBP-
NTD30-145 SAXS envelope. However, the large space within one side of the model was sufficient for two 
MBP envelopes to be placed (figure 3.2.8.1.1.3C). From this it can be concluded that the CtIP NTD 
forms a parallel dimer in solution. As DAMAVER is known to average out flexibility, individual models 









Figure 3.2.8.1.1.3: DAMFIT models to fit the SAXS data of MBP, NTD30-145Strep and MBP-NTD30-
145Strep. A) Left to right, PDB model 3hpi of MBP, model to fit SAXS data, overlay of the two 
models. B) Overlay of NTD30-145Strep with MBP-NTD30-145Strep, adequate room for the coil-coil to 
fit within the protrusion of the fusion protein is observed. C) Docking of two models to fit the 
MBP SAXS data within one side only of the MBP-NTD30-145Strep SAXS data model. From this it can 
be concluded that the NTD forms a parallel coiled coil.  
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3.2.8.1.2 Assessing the architecture of the coiled coil  
As shown by secondary structure prediction (Dubin et al., 2004) and the determined crystal structure, 
the CtIP coiled-coil domain can be sub divided into two regions separated at the zinc binding motif. 
Performing a Guinier analysis of initial slope of SEC-SAXS data allows calculation of RG. Reducing the 
length (L) of a straight coiled-coil by half should reduce RG by half. This assumes the cross-sectional 
radius of gyration (RC) remains constant determined by equation 3.2.8.1.2. 
𝑅𝑔
2 − 𝑅𝑐





To confirm the elongated coiled coil is the correct model the NTD was separated at the zinc binding 
site and two individual sub domains were cloned, expressed and purified for scattering analysis. 
Calculating Rg for the two sub domains verses NTD31-145Strep will help elucidate the quaternary 
structure of the coiled-coils. 
3.2.8.1.2.1 Construct design and protein purification 
Constructs spanning from CtIP residues 31-88 (NTD31-88Strep) and 93-145 (NTD93-145Strep) were cloned 
into pMAT11 with an additional C-terminal Strep-tag. Positive clones were confirmed by DNA 
sequencing by the Department of Biochemistry’s DNA Sequencing Facility prior to protein expression 
using the Rosetta™ 2 (DE3) cell line. 
Two litres of cells expressing NTD93-145Strep and four litres of cells expressing NTD31-88Strep were used 
for each purification using the standard C-terminal strep tagged purification strategy. For SDS-PAGE 
analysis 4-12% polyacrylamide gels were used to enable visualisation. Fractions containing NTD 
protein were pooled and concentrated to 3.69 mg/mL for NTD31-88Strep and 5.86 mg/mL for NTD93-













Figure 3.2.8.1.2.1: Final stage purification of NTD31-88Strep and NTD93-145Strep. Proteins were 
purified using the standard N-&C-terminal tagged purification procedure. A) SEC chromatogram 
for NTD31-88Strep, fractions were analysed by SDS-PAGE in B. B) Protein applied to the SEC column 
(load) precedes elution fractions. First peak contains a protein of 14 kDa with the main peak 
containing NTD31-88Strep. Fractions in red were pooled for concentration and experimental 
analysis. C) SEC chromatogram for NTD93-145Strep analysed by SDS-PAGE in D. D) Protein applied 
to the SEC column (load) precedes elution fractions. Fractions in red were pooled for 
concentration and experimental analysis. 
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3.2.8.1.2.2 SAXS data analysis using SCÅTTER 
SEC-SAXS experiments were performed on B21 at Diamond Light Source individually on NTD31-88Strep, 
NTD93-145Strep, NTD31-145DM-Strep and NTD31-145Strep to generate small angle scattering data for 
analysis. Comparisons between the scatter-bases Kratky-plots can give a first indication of any change 
in length and the coiled nature of the sub domains proteins. Both sub domains maintained an 
inflection point greater than 1 indicative of coiled-coil protein. The sub domains however do have a 
lower inflection point than NTD31-145 indicating a shorter coiled-coil protein (figure 3.2.8.1.2.2-1). 
Comparison between the wild type and double mutant proteins show minimal differences with 







Guinier fitting of the scattering data to obtain RG and further P(r) distribution and DMAX values for the 
four proteins was performed. With equation 3.2.8.1.2 comparisons between these values can provide 
an insight into the domain architecture. The NTD31-88 (RG 30.0) and NTD93-145 (RG 28.7) RG values are not 
the same as the NTD31-145 (RG 48.5 or 48.1 for the DM) (figure 3.2.8.1.2.2-2A/B). This provides further 
evidence that the domain forms an elongated coiled-coil, as reduction in the length of the protein has 
reduced RG.  
Figure 3.2.8.1.2.2-1: Assessing the architecture of the NTD SEC-SAXS Dimensionless Kratky plot. 
The graph shows the Kratky plot for the two halves of the NTD, NTD31-88Strep and NTD93-145Strep 
verses NTD31-145Strep with and without the zinc-binding site (NTD31-145DM-Strep). The reduction in 
peak height compared to NTD31-145Strep for the two shorter constructs indicates a reduced length 
of these proteins. The difference between the DM and wild type protein is minimal, however the 




Comparison between these data and those presented in figure 3.2.8.1.2.2-2C show that there is 
variability within the RG and DMAX between the two independent SEC-SAXS data collections. The same 
column type was used for both experiments, with a broadening of the SEC peak noted for the second 







Figure 3.2.8.1.2.2-2: SEC-SAXS analysis of NTD31-88Strep, NTD93-145Strep, NTD31-145Strep and NTD31-
145DM-Strep, Guinier fitting and P(r) distributions. A) Guinier fitting for NTD31-88Strep (LHS) and 
NTD93-145Strep (RHS) with RG displayed in Å. B) Guinier fitting for NTD31-145DM-Strep (LHS) and 
NTD31-145Strep (RHS) with RG displayed in Å. C) P(r) distribution with DMAX showed. Colours 
correspond in figure 3.2.8.1.2.2-1. 
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The P(r) distributions show that the proteins decay towards 0 which is typical for rod structures. 
However, the bumpiness of the decay highlights the data collection or processing is not perfect. 
Bumpiness within the P(r) destitution is also apparent in comparison between with and without the 
Strep tag indicating this may influence the distribution. Nevertheless, model generation for NTD31-
145DM-Strep shows that the crystal structure fits into the model to fit the SEC-SAXS data with extra 
space within the envelope for the Strep tag at the C-termini of the protein (figure 3.2.8.1.2.2-3). 
Determination of DMAX and RG from the NTD31-145 crystal structure using SCÅTTER gives a value of 164 







Figure 3.2.8.1.2.2-3: Overlay of NTD31-145DM-Strep crystal structure with the model to fit the 
SEC-SAXS data. Figure was made manually in PyMol with crystal structure fitting within the SAXS 
envelope. Crystal structure is coloured from Blue to red from N- to C-terminus.  
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3.2.9 Structural analysis of the tetrameric NTD.  
The NTD contains multiple structural elements of known functional importance. However, the global 
architecture of the tetrameric domain is unknown. Efforts to crystallise CtIP residues 18-145 were 
broadly unsuccessful with no tractable conditions found. Alternative structural characterisation 
methods were therefore sought.  
3.2.9.1 Cryo EM analysis of NTD18-145 
Cryo-EM avoids the need for protein crystals but is typically restricted to large protein domains and 
complexes (>100 kDa). The relatively small size of the domain impedes effective analysis by this 
technique. Therefore, an MBP fusion of CtIP NTD was expressed giving a tetrameric protein with 4 
large globular MBP molecules to aid particle picking (figure 3.2.9.1). As residues 1-18 are predicted 
flexible (Sun, 2013) to increase the likelihood of selecting tetrameric particles the construct spanned 




3.2.9.1.1 Recombinant protein expression and purification, MBP-NTD18-145 
The MBP-NTD18-145 construct was expressed in two litres of Rosetta™ 2 (DE3) bacteria. The soluble 
protein was purified using sequential affinity chromatography: Ni-NTA resin, amylose resin and a Hi-
Trap Ni-NTA resin column, to give a concentrated fraction of fusion protein. Final polishing was 
performed using a 16/60 Superdex 200 SEC column (figure 3.2.9.1.1). Fractions were analysed by SDS-
PAGE with protein concentration of each fraction determined by absorbance at 280 nm. The peak 
fraction (figure 3.2.9.1.1) from the Superdex 200 16/60 SEC contained the most protein at 3.1 mg/mL 
and was used for preparation of Cryo-EM grids. 
All grid manipulations were performed by Dr Neil Rzechorzek using grids from Batch No.190698, 
QuantiFoil R 1.2/1.3 Cu300 and 3 µL of fresh protein per grid. 
 
Figure 3.2.9.1: Schematic drawing of NTD18-145. NTD18-145 is indicated in blue with the TEV 
cleavable MBP tag. The tetramerisation domain (α) alongside the boundaries for its structure (18-
52, PDB 4D2H) and the zinc binding domain (CXXC) are also shown. 
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3.2.9.1.2 Cryo-EM data collection  
Grids containing MBP-NTD18-145 were analysed using the Talos Arctica™ microscope controlled by Dr 
Neil Rzechorzek at the Department of Biochemistry Cryo-EM facility. An ice gradient was present 
across each grid analysed, however ice thickness limited square selection (figure 3.2.9.1.2-1). Squares 















image of grid indicating 
3 squares imaged. 
Figure 3.2.9.1.1: Purification of MBP-NTD18-145. A) The soluble protein was applied to a Ni-NTA 
resin, amylose resin and a His-Trap Ni-NTA column without TEV cleavage. The elution from the 
His-Trap Ni-NTA column was polished by Superdex 200 16/60 SEC B) Chromatogram showing SEC 
of MBP-NTD18-145: blue lines indicate fractions analysed by SDS-PAGE in A, with red fractions 





MBP was assumed to be the small black spots on the image (figure 3.2.9.1.2-2). Over the 4 grids 
imaged the 12 holes that were sampled gave very similar results: ice thickness made it difficult to 
select intact squares, with very few in close proximity. The high particle density and the flexibility of 
the linker region between the NTD and MBP meant that tetrameric particles could not be picked. 
Construct, protein concentration, grid preparation and data collection optimisation will be necessary 
to allow particle picking leading to a future structure determination.  
Figure 3.2.9.1.2-2: MBP-NTD18-145, Representative Talos Arctica™ microscope image. Many black 
particles can be seen across the grid, but a large proportion of protein is aggregated at the 




3.2.9.2 Small angle x-ray scattering of NTD18-145 
Cryo-EM analysis of the NTD has yet to be successful. However, with crystal structures for CtIP residues 
18-52 (4D2H) and 31-136 now available, alongside SAXS analysis confirming the parallel nature, a 
combined model of CtIP residues 18-136 can be generated. To assess the accuracy of such a model 
SEC-SAXS was performed on the cleaved NTD18-145 construct. 
3.2.9.2.1 Protein purification of NTD18-145 
Initial purification of NTD18-145 was through the standard procedure for non-Strep tagged protein with 
sequential Ni-NTA capture, TEV cleavage and amylose re-capture of MBP. To improve the NTD18-145 
homogeneity the intrinsic affinity to the Ni-NTA resin was exploited to give a high purity sample for 
Superdex 200 16/60 SEC (figure 3.2.9.2.1). Fractions by SDS-PAGE that contained NTD18-145 were 







Figure 3.2.9.2.1: Purification of NTD18-145 using intrinsic Ni-
NTA affinity. Protein was purified using the standard N-
terminal tagged procedure A) Protein eluted from initial Ni-
NTA (N-E) was TEV cleaved (TEV) before passage through an 
amylose column and flow collected (A-FT). This protein was 
subject to buffer exchange (desalt) to remove imidazole and 
bound to a 1 mL Ni-NTA column. 
 
A cont.) This column was washed with standard buffer (W1-3) before 20 mM imidazole with 
standard buffer wash (W4-6) and a final 200 mM imidazole with standard buffer wash (W7-9). 
W4-6 was pooled for SEC in B. B) Superdex 200 16/60 SEC with fractions analysed by SDS-PAGE in 
C. C) analysis of SEC fractions with NTD18-145 indicated. Fractions in red were pooled and 
concentrated for analysis.  
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3.2.9.2.2 Model generation of CtIP residues 18-145 
Analysis of the SEC-SAXS data for NTD18-145 gave a value for RG almost double that of NTD31-145 as 
expected indicating an elongated structure was retained (figure 3.2.9.2.2-1). The data were further 
processed to give a large DMAX value further supporting an elongated structure. The data however has 
imperfections shown in the P(r) distribution from a linear decay for a coiled-coil. Generation of an ab 
initio model using DAMMIF therefore gave some discrepancies from a straight coiled-coil with a better 
sample at higher concentration required (figure 3.2.9.2.2-1).  
Combination of the two structures allows visualisation of the 18-136 CtIP structure from the 
overlapping 16 amino acids between the two structures (figure 3.2.9.2.2-2). The coils from NTD31-145 
extend into the tetramerisation domain; this further supports the accuracy of the NTD31-145DM-Strep 
crystal structure as elongation of these coils past residues 31 would form the tetramerisation domain 
as expected (figure 3.2.9.2.2-2). Generation of SAXS data from the combined structures using SCÅTTER 
gives a DMAX value of 341 Å, which is within 10% of the SAXS data value (figure 3.2.9.2.2-1), and an RG 
value of 83.0 Å, which is within 2% of the SAXS value (figure 3.2.9.2.2-1), indicating the model and 
SAXS initial processing is likely to be correct. 
 
Figure 3.2.9.2.2-1: SEC-SAXS analysis of NTD18-145. Going clockwise, first panel is the 
dimensionless Kratky plot followed by Guinier fitting with RG displayed. The final panel is the 
P(r) distribution with the DMAX value displayed.  
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Despite the imperfections in the P(r) distribution, a model was obtained to fit the SEC-SAXS data for 
NTD18-145. The combined crystal structure fits within this envelope with both displaying an elongated 





Figure 3.2.9.2.2-2: Alignment of the CtIP 18-52 (4D2H) and CtIP 31-145 crystal structures 
overlaid with SAXS envelope for CtIP NTD18-145. Top structure shows a zoomed image of the 
alignment between the 16 overlapping residues between the two structures made in PyMol. 
Next three images are rotations of the aligned CtIP crystal structures with side end view 
shown. Last panel shows overlaid model to fit NTD18-145 SAXS data with the CtIP 18-145 crystal 
structures with side end view made in PyMol. 
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3.2.10 Conclusions and future work. 
The collective structural studies of the N-terminal region of human CtIP have confirmed the formation 
of a well-structured dimer which aligns to the previous tetrameric structure (PDB 4D2H). X-ray 
crystallography and SEC-SAXS have been used to investigate this structure with converging results 
showing the formation of a parallel dimeric coiled-coil adjacent to the tetramerisation motif.  
Formation of crystals for the N-terminal region was optimised through construct design, changes to 
the purification procedure and crystallisation buffer conditions. A magnitude of different techniques 
including, seeding, additive screens, changes in temperature, and optimisation of crystallisation 
conditions improved the resolution from 36 Å to 8.0 Å with many changes in crystal form. This 
resolution however was insufficient for structure determination by molecular replacement. 
Expression as SeMet-labelled protein failed to produce protein crystals. Further techniques including 
Surface Entropy Minimisation (SEM) gave salt crystals which limited further gains in diffraction 
resolution.  
Through a long and challenging crystallographic study the structure of the predicted coiled-coil 
domain spanning CtIP residues 31-136 with two cysteine-to-alanine mutations has been determined. 
This shows extension of the alpha helices from the tetramerisation domain into a coiled-coil. The 
heptad repeat for the coiled-coil formation discontinues at the zinc binding site with formation of 
parallel alpha helices. The only contact between these two alpha helices is that of two phenylalanine 
residues with their side chains forming a π-stack of which likely mediates the re-start of the coiled-coil 
within this structure. Analysis of the alanine mutations (C89A/C92A) show the R’ groups of the amino 
acids point towards the solvent rather than centre of the helix pair. The alanine mutations therefore 
likely encourage the alpha helical formation with a local change in conformation. However, SEC-SAXS 
shows minimal differences between the wild type and mutant protein with a model to fit the SEC-
SAXS data enclosing the crystal structure. This indicates any change in structure to be minimal around 
this region. A single point missense mutation in CtIP NTD of arginine at position 100 to tryptophan has 
been shown to be associated with primordial dwarfism (Shaheen et al., 2014). Visualisation of this 
amino acid in the structure shows that it is solvent exposed and not involved in formation of the coiled-
coil. This mutation therefore is less likely to disrupt the structure and is more likely involved with a 
protein-protein interaction. 
The complexity of the Morpheus screen and its 3-dimensional nature makes it difficult to pinpoint 
buffer components that encourage crystallisation. From the use of matrix micro seeding a vast 
increase in crystal numbers was seen, indicating that formation of nuclei is a large issue for the protein. 
So far wild type protein has yet to crystallise in the Morpheus screen. Matrix micro-seeding of NTD31-
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145DM-Strep micro-crystals into NTD31-145Strep protein crystallisation trials have also yet to be 
successful. 
SEC-SAXS enabled further biophysical characterisation of the NTD with an MBP fusion confirming the 
region forms a parallel coiled-coil in solution. The architecture of this domain was further explored 
through SEC-SAXS analysis of the two sub regions (CtIP residues 31-88 and 93-145) that are separated 
by the zinc-binding domain. These two studies provided evidence towards a long coiled-coil of 
residues 31-136 shown by crystallography and ruled out the formation of a Rad50 zinc hook structure 
for dimer formation.  
The previously determined NTD tetramerisation domain spanning from 18-52 (4D2H) (Davies et al., 
2015) has a 21 amino acid overlap with my NTD structure. Therefore, through alignment of the two 
models a structure of the N-terminal oligomerisation domain spanning residues 18-136 can be 
modelled. SEC-SAXS provided evidence to support this model with an envelope encompassing the 
modelled CtIP residue 18-136 structure. The alignment between the modelled structure and SEC-SAXS 
envelope provide further evidence that the dimer of dimers orientation forms a long-coiled coil rather 
than the C-termini of the coils in close proximity, leading to a model where there is potential for the 
two pairs of functionally significant C-terminal regions to be held at a distance from one another. 
Future work within this project area would be to confirm these predictions. Fluorescence Resonance 
Energy Transfer (FRET) could be used to determine the intramolecular distances between regions of 
the 18-145 protein and in CtIPFL. The long term aim of this project would be to build on preliminary 







Chapter 4, CtIP C-terminal domain 
4.1 Introduction 
Sequence conservation locates two regions at the N- and C-termini of vertebrate CtIP that are 
especially important in CtIP function (Sartori et al., 2007). The C-terminal domain (CTD) comprises a 
stretch of ~100 amino acids located at the C-terminal region of the protein. Clear similarity to the CTD 
sequence is present in CtIP homologues of varying species from lower animals to plants and fungi, 
highlighting its significance (Andres et al., 2015; Clerici et al., 2005; Limbo et al., 2007; Sartori et al., 
2007; Uanschou et al., 2007). 
The functional importance of the CtIP-CTD is demonstrated by genetic conditions such as Seckel 
syndrome, caused by a splice mutation resulting in a C-terminal 152 amino acid truncation of the CtIP 
protein, (Qvist et al., 2011).  In vitro studies using cells expressing a CtIP C-terminal 108 amino acid 
truncation resulted in a reduction in Chk1 phosphorylation and RPA recruitment with camptothecin-
induced DSBs (Sartori et al., 2007). In the same study laser micro-irradiation showed a decrease in 
RPA-ssDNA formation associated with this truncated form of CtIP. CtIP interaction partners mapped 
to the CTD including MRN and And1 have been identified through co-immunoprecipitation 
experiments, using both HeLa nuclear extracts and whole-cell chromatin-free preparations 
respectively (Chen et al., 2017; Sartori et al., 2007). Yeast-2-Hybrid experiments have identified further 
CTD interaction partners such as the E3 ubiquitin ligase SIAH1. CtIP has also been shown to possess a 
second zinc-binding domain at the C-terminal end, binding zinc at a 1:1 ratio through two cysteine 
residues C813/ C816 (Sun, 2013). The function of both zinc binding events however has yet to be 
determined. 
Within the C-terminal region are many post-translational modification sites such as the highly 
conserved CDK phosphorylation site threonine 847 (T847) (figure 4.1). Studies in the yeast homologue 
of CtIP, Sae2, have identified serine 267 as a functional equivalent of T847, highlighting the importance 
of the conserved phosphorylation site (Huertas et al., 2008; Huertas and Jackson, 2009a). Mutational 
analysis of T847 to either alanine or glutamic acid showed enhanced radiation-induced chromosome 
rearrangements, suggesting the importance of CDK regulation of CtIP DNA-end resection and cell cycle 
control (Huertas and Jackson, 2009a). It is now established that CDK phosphorylation at T847 is 
essential for MRN’s endonuclease activity in humans (Anand et al., 2016). Conversely, the Sae2 serine 
267 is dispensable for MRX activity in yeast (Cannavo and Cejka, 2014). Additional sites within the 
human CTD, such as the ATM/ATR phosphorylation site threonine 859 (Peterson et al., 2013; Wang et 
al., 2013) and the lysine 896 sumoylation site (Soria-Bretones et al., 2017) have also been reported to 
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be important for end-resection. Collectively these studies illustrate the functional importance of the 
C-terminal domain. To improve our limited understanding of CtIP’s biochemical function, a detailed 





Figure 4.1: Conservation of the CtIP C-terminal region in eukaryotes. ClustalW (Larkin et al., 
2007) sequence alignment using default settings with conservation shown. Zinc-binding residues 




4.2.1 DNA binding of the CtIP-CTD 
For both human CtIP and the S. pombe homologue ctp1, DNA-binding has been localised to the C-
terminal domain (Andres et al., 2015; Davies et al., 2015). To more thoroughly characterise this 
interaction, DNA-binding experiments were performed with purified human CtIP-CTD.  The results of 
these experiments are described below. 
4.2.1.1 Initial purification of CtIP-CTD 
A CtIP-CTD construct spanning residues 769-897 was expressed and purified in accordance with the 
protocol developed by the former PhD student Meidai Sun (Sun, 2013). The protein was purified from 
Rosetta™ 2 (DE3) cells transformed with the pMAT11 CtIP-CTD construct as a His-MBP fusion protein.  
Using Ni-NTA and amylose chromatography with addition of reducing agent protein was purified and 
His-MBP tag was removed by TEV protease. Protein eluted in a single main peak on SEC with fractions 
containing CtIP-CTD pooled and concentrated for analysis (figure 4.2.1.1).   






Figure 4.2.1.1: Purification of CTD according to Sun, 2013. A) Chromatogram of the CTD elution 
profile of Superdex 75 16/60 SEC. Fractions indicated were analysed by SDS-PAGE in B. B) SDS-





4.2.1.2 Zinc dependency of CtIP-CTD DNA binding  
The interaction of CtIP-CTD with dsDNA has previously been demonstrated using a 200 bp substrate 
in an EMSA (Davies et al., 2015). Using the same method, binding of a 60 bp fluorescently-labelled 
dsDNA substrate was also confirmed (figure 4.2.1.2b). DNA binding was further assessed by 
fluorescence polarisation (FP).  
Using FP, formation of a CtIP-CTD – DNA complex was shown to be dependent on the addition of 50 
µM ZnAc2 (figure 4.2.1.2a). In contrast, zinc was not necessary for DNA binding by the same protein 
sample in an EMSA (figure 4.2.1.2b). 
  
  
Figure 4.2.1.2: Zinc dependency 
of FP DNA binding versus EMSA 
DNA binding. DNA binding with 
linear dsDNA fdx60. A) Graphical 
representation of eight 
independent FP experiments 
with protein buffer containing 50 
µM ZnAc2 – blue circles. Five 
independent FP experiments 
without ZnAc2 – red squares B) 
EMSA with decreasing amounts 
of CtIP-CTD from 10-0.62 µM 
with 1 µM 60 bp dsDNA. 
Different protein concentrations 
were made by serial dilution in 
both experiments. A moving 




4.2.1.3 DNA binding by CTDDM 
Metal binding of CtIP-CTD was explored by Meidai Sun in her thesis. Two residues, C813 and C816, 
were determined by alanine mutagenesis to be responsible for zinc binding (Sun, 2013). Therefore, if 
DNA binding is dependent on these residues for zinc incorporation, mutation to alanine (figure 4.2.1.3-
1) should inhibit DNA binding. 
 
 
Figure 4.2.1.3-1: Schematic drawing of CtIP-CTD and CTDDM. CtIP residues 769-897 are shown in 
blue, with zinc binding site (CXXC) and T847 CDK site. For CTDDM the zinc-binding site is mutated to 
alanine (AXXA). 
Using the same purification procedure, a CTD C813A/C816A (CTDDM) protein was purified to 
homogeneity (figure 4.2.1.3-2); and incorporation of the two mutations was confirmed by mass-





Figure 4.2.1.3-2: Purification of CtIP-CTDDM according to Sun, 2013. A) Chromatogram of the 
CTD elution profile of Superdex 75 16/60 SEC. Fractions indicated were analysed by SDS-PAGE in 
B. Elution peak is at 64 mL B) SDS-PAGE analysis of SEC elution fractions. Fractions in red were 





DNA-binding experiments by EMSA were performed in triplicate with no differences observed 
between the mutated and non-mutated protein (figure 4.2.1.3-3). Preliminary FP studies using CTDDM 
have also shown similar DNA binding compared to CtIP-CTD; zinc dependency was also still apparent 
for CTDDM DNA binding by FP (figure 4.2.1.3-4). These results indicate that the two residues identified 
for zinc binding in CTDDM are not responsible for the zinc dependency for DNA binding by FP and 





Figure 4.2.1.3-3: CTDDM binds DNA by 
EMSA. EMSA with decreasing amounts 
of protein from 10-0.62 µM with 1 µM 6 
0bp dsDNA, resulting in the formation of 
slow migrating species which represent 
protein-DNA complexes. Different 
protein concentrations were made by 
serial dilution with identical 
concentrations for CTD (left hand side) 
and CTDDM (right hand side). 
Figure 4.2.1.3-4: Zinc dependency of FP DNA binding for CTDDM. DNA binding with linear dsDNA 
fdx60. Graphical representation of two CTDDM binding curves with buffer containing 50 µM ZnAc2 
(green squares) or without zinc (green diamonds). Blue traces represent CtIP-CTD binding curves 
with (circles) and without (diamonds) 50 µM ZnAc2. 
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4.2.1.4 Purification optimisation to enhance zinc incorporation 
The original purification for CtIP-CTD included a nickel affinity chromatography step, and it was shown 
that this resulted in nickel incorporation into the recombinant CtIP-CTD (Sun, 2013). In the light of the 
observed zinc dependency of DNA binding by FP, the purification protocol was adapted to ensure zinc 
incorporation into the CtIP-CTD over other metals. This would allow quantitative analysis of zinc 
incorporation and its effect on DNA binding.  
The nickel-affinity purification step was therefore eliminated from the protocol. The CtIP-CTD was 
initially purified from clarified lysate by amylose affinity chromatography, utilising the MBP tag of the 
fusion protein prior to TEV cleavage. Three procedures were tested for removal of contaminants. Zinc-
charged NTA resin bound CtIP-CTD without removing contamination (figure 4.2.1.4-1). Optimisation 
of a heparin chromatography stage and a second amylose step after TEV cleavage enabled removal of 
most contaminants (figure 4.2.1.4-1). 
 
 
Further optimisations to the protocol included the addition of final concentration 250 µM zinc to the 
growth media to enhance incorporation. This decreased the proportion of higher molecular weight 
species on Superdex 75 16/60 SEC (figure 4.2.1.4-2, P1) and increased the yield of CtIP-CTD for the 
Figure 4.2.1.4-1: SDS-PAGE analysis of CtIP-CTD purification optimisations. Position of CtIP-CTD is 
indicated on the gel. From left to right: Protein applied to onto each purification column (load). “Z” 
stands for Zn-NTA, “A” for Amylose, “FT” for flow-through, “W” for wash and “E” for elution. Lanes 
3-6 show recapture using a Zn-NTA column with most of the protein in the elution fraction. Lanes 
7-10 show recapture using an amylose column with most of CtIP-CTD within the flow-through and 
wash fractions while MBP-CTD and MBP remain bound. Lanes 11-17 are fractions from a 5 mL 
HiTrap Heparin column elution from 10-40% v/v buffer B (1M NaCL) in 5% v/v buffer B steps. 
Overlapping peaks were present with most of the contaminants eluted between 15-20% v/v B; 




same starting volume of cells (figure 4.2.1.4-2, p3). An earlier eluting peak (figure 4.2.1.4-2, P2) 
persisted irrespective of purification procedure at a larger weight than CtIP-CTD. 
 
 
4.2.1.5 Purification of CtIP-CTD 
A new purification strategy evolved from the series of optimisations. The CtIP-CTD construct was 
expressed in two litres of Rosetta™ 2 (DE3) cells with or without zinc supplemented media. Following 
lysis and clarification, supernatant was purified by amylose chromatography with elution before 
overnight dialysis with TEV cleavage. The TEV protease was pre-incubated with DTT with no DTT added 
to the dialysis buffer. Hi-Trap heparin chromatography was used to remove contaminants using a 
17.5% v/v buffer B (1 M NaCl) step with a gradient elution. Where necessary fractions containing CtIP-
CTD were further purified by a final amylose chromatography stage either before or after 
concentration to 1 ml for application to the Superdex 75 16/60 SEC chromatography. Fractions 
containing CtIP-CTD were analysed throughout the process by SDS-PAGE (figure 4.2.1.4-3).   
Figure 4.2.1.4-2: SEC traces for CtIP-CTD prepared according to three different zinc addition 
protocols. Blue trace: no zinc in the buffer or the growth media. Red trace: zinc added on cell 




Figure 4.2.1.4-3: Purification of CtIP-CTD by amylose and heparin chromatography. CtIP-CTD was 
expressed using zinc supplemented media A) SDS-PAGE analysis of CtIP-CTD purification by 
Amylose affinity chromatography (A), with flow-through (FT), washes and 10 mM maltose elution 
fractions (Elut) shown. B) Elution fractions 1-3 were pooled for TEV cleavage (TEV), followed by 
salt dilution (Pre-Hep) any application to a heparin column. Fractions indicated in red/ blue 
correspond to C. C) Hi-Trap heparin chromatography chromatogram, buffer B was 1 M NaCl with 
a 17.5% v/v step removing contaminants. Fractions in red were pooled for further processing. For 
this purification fractions pooled were concentrated to 1 mL for Superdex75 16-60 SEC in D. D) 
Chromatographic profile of CtIP-CTD elution, fractions indicated were analysed by SDS-PAGE in E. 
E) Fractions in red were pooled as CtIP-CTD and flash frozen in liquid nitrogen.  
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4.2.1.6 DNA binding of CtIP-CTD purified from zinc supplemented 2xYT media 
The DNA-binding ability of the CtIP-CTD expressed in zinc supplemented media was tested by FP and 
EMSA to determine if the modified purification method had removed the previously observed 
necessity for additional zinc in the FP experiments (figure 4.2.1.2). Preliminary FP results showed that 
the zinc dependency persisted, whereas DNA binding by EMSA consistently showed no difference 
(figure 4.2.1.6-1). The requirement for the presence of zinc in the buffer used in the FP experiments 
was not investigated further, and DNA binding by the CtIP-CTD was studied using the EMSA using the 
three different additions of zinc. Zinc binding by the CtIP-CTD was further investigated in section 4.2.2.  
 
Figure 4.2.1.6-1: Zinc dependency of FP DNA binding for CtIP-CTD expressed using zinc 
supplemented media verses EMSA DNA binding. DNA binding with linear dsDNA fdx60. A) 
Graphical representation of a single CtIP-CTD binding curve: Grey represents zinc media with or 
without additional 50 µM zinc. Purple represents the previous purification method with or 
without additional 50 µM zinc. B) EMSA with decreasing amounts of CtIP-CTD grown in the 
presence of zinc supplemented media from 12-1.5 µM, resulting in the formation of slow 
migrating species which represent protein-DNA complexes. EMSA was repeated three times with 
a representative gel shown. Different protein concentrations were made by serial dilution in both 




Optimisations to the purification strategy did not alter the ability of CtIP-CTD to bind DNA, as analysed 
by EMSA. Overall, both CtIP-CTD and CtIP-CTDDM were observed to display similar DNA binding 
characteristics that were broadly unchanged by the purification method chosen (figure 4.2.1.6-2).  
While replicates are yet to be performed, these will allow conclusive analysis of the small differences 
seen between CTDDM purification methods. 
 
 
4.2.1.7 Minimum DNA length required for CtIP-CTD interaction 
EMSA results were consistent for CtIP-CTD showing binding to a 60 bp dsDNA oligonucleotide. To 
deduce the minimum length of DNA necessary for the CtIP-CTD to DNA interaction further EMSAs 
were performed using the same procedure with progressively shorter dsDNA. Initial experiments 
showed DNA binding to 40 bp dsDNA with minimal signs of DNA binding for substrates of 20 bp dsDNA 
and below (figure 4.2.1.7). The length of substrates was reduced by 5 bp dsDNA iteratively, with similar 
amounts of binding shown from 40 bp to 25 bp dsDNA (figure 4.2.1.7). The DNA binding of CtIP to 20 
bp is greatly impaired with no binding at low concentrations and a large reduction at 5.0 µM. These 
results indicate the minimum length requirement of DNA for CtIP binding to be between 25 bp and 20 
bp. 
 
Figure 4.2.1.6-2: CtIP-CTDDM binds DNA irrespective of purification method as shown by EMSA. 
An EMSA with decreasing amounts of CTD from 10-1.5 µM, resulting in the formation of slow 
migrating species which represent protein-DNA complexes. LTR, CTDDM zinc on lysis, CTDDM zinc 
media, CTD zinc media each with 100 nM 60 bp fluorescent dsDNA or ssDNA as indicated. 





4.2.2 Zinc incorporation by the C-terminal domain 
Reminiscent of the NTD, the CTD of CtIP has been shown to contain a zinc-binding domain.  Previously, 
two cysteine residues (amino acids 813 and 816) were shown to be necessary for zinc chelation (Sun, 
2013).  However, results described above are at odds with this observation, as the CTDDM appeared to 
be still able to bind DNA by FP in the presence of 50 µM zinc.  To address these discrepancies, the zinc 
content of the CtIP-CTD was analysed using spectrophotometry analysis. The chosen spectroscopic 
assay involves the use of the metal chelator 4-(2-pyridylazo)-resorcinol (PAR), which undergoes a 
wavelength shift in peak absorbance upon binding to zinc.  This allows quantification of zinc content 
in the sample by comparison to standards of known zinc concentrations.  
The binding of PAR is not specific for zinc, but extends to nickel, copper, cobalt and other divalent 
metals. This method has therefore been established for many years to determine trace levels of 
different metalloproteins within a sample (Ahrland and Herman, 1975; Hunt et al., 1985; Jezorek and 
Freiser, 1979; Säbel et al., 2009). The spectrophotometric profile of PAR bound to copper and cobalt 
is different to that in the presence of nickel and zinc, allowing discrimination between these two sets 
of metals;  in contrast, the spectra of PAR-bound nickel and zinc are indistinguishable from each other 
for an unknown concentration of metal within a sample (Säbel et al., 2009).  Therefore, to determine 
Figure 4.2.1.7: Determination 
of minimum DNA length for 
CtIP-CTD: DNA interaction. 
Top panel: triangle represents 
decreasing concentrations of 
CtIP-CTD from 5.0 µM down to 
0.31 µM. LTR EMSAs with 60, 
40, 20 and 10 bp fluorescently-
labelled dsDNA at 100 nM. 
Bottom panel – triangle 
represents decreasing CtIP 
concentrations from 5.0 µM to 
0.62 µM. LTR, 40, 35, 30, 25 
and 20 bp fluorescently 
labelled dsDNA at 100 nM. 
Addition of CtIP-CTD results in 
the formation of a slower 
migrating species which 
represents protein-DNA 
complexes. Protein was 
prepared by serial dilution, 
with both experiments 
repeated in triplicate. 
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zinc concentration reliably using the PAR assay, precautions must be taken to avoid exposure of the 
protein sample to nickel.   
Analysis of the PAR absorption spectrum over the range of 300 to 600 nm (figure 4.2.2-1), shows that 
free PAR has a peak at 414 nm. With addition of increasing zinc acetate concentrations, a second peak 
at 492 nm gradually forms representing the PAR-Zn2+ complex, whereas the 414 nm free PAR peak 
decreases. An example of PAR’s absorption profile in the presence of increasing concentration of 
ZnAc2 is shown in figure 4.2.2-1.  For each measurement of zinc content, a new standard curve was 
generated.  
  
Using the original Ni-NTA purification method, the PAR assay yielded a CtIP-CTD to Zn2+ ratio of 1:1 
over 3 repeats, similar to that reported previously (Sun, 2013). Using the amylose purification 
procedure that excluded exposure to Ni2+ using the same zinc addition on lysis as the original 
purification method a CtIP-CTD to Zn2+ ratio of 2.2:1 over 3 independent repeats was measured, which 
is lower than previously reported (figure 4.2.2-2). A possible explanation for the difference is a 




of zinc standard 
concentrations in complex 
with PAR. Concentration 
range of ZnAc2 from 0 (blue) 
to 100 nM (cyan) ZnAc2.  
Figure 4.2.2-2: 
Determination of zinc 
content for CtIP-CTD. Blue 
circles represent values used 
in the linear fit with 
equation displayed. Grey 
Cross plotted on the line is 
the average ratio of 
absorbance values at 492 
and 414 nm for the CtIP-CTD 
sample (100 µM) plotted on 
the linear fit. 
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Using the new purification procedure, and in contrast to previous results by Meidai Sun (Sun, 2013), 
concentrations of zinc recovered from CTDDM were also at a ratio of 2.4:1 protein to zinc (figure 4.2.2-
.3).  
  
The conclusion from these experiments is that removal of Ni-NTA chromatography from the 
purification protocol has led to a reduction in the total metal content of CtIP-CTD preparations, 
suggesting that part of the metal previously detected was due to nickel contamination. It was further 
observed that DNA binding by CtIP-CTD, when analysed by FP, was dependent on the addition of zinc 
to the sample, suggesting that the zinc content in original CtIP-CTD preparations might be sub-optimal. 
Together, these observations led to exploration of additional strategies to improve zinc incorporation 
in the CtIP-CTD. 
The addition of zinc to bacterial growth media is a well-documented method for the soluble over-
expression of exogenous zinc-binding proteins. A typical approach is to add 250 µM zinc acetate to 
the growth media prior to induction (Graham et al., 2009; Lee et al., 2014; Yamamoto and Ishihama, 
2005). Using zinc-supplemented media increased the levels of Zn2+ ions recovered from CtIP-CTD to 
the level of 1:1 protein to zinc. Surprisingly, CTDDM also showed a similar level of Zn2+ ion incorporation, 
with the addition of zinc to the bacterial media giving a protein to zinc ratio of 1:1 over three repeats 
(figure 4.2.2-4). The level of zinc recovered from CtIP-CTD and CTDDM was the same 1:1 ratio as the 
original purification, however greater than purifying without Ni-NTA chromatography. This further 
supports the presence of contaminant Ni2+ ions bound to the CTD and suggests the C813/C816 
residues mutated to alanine in CTDDM were required for binding these Ni2+ ions. 
 
Figure 4.2.2-3: 
Determination of zinc 
content for CTDDM. Blue 
circles represent values 
used in the linear fit with 
equation displayed. Orange 
cross on the line is the 
average ratio of absorbance 
values at 492 and 414 nm 









Ratio of Protein to zinc 
CTDDM 28.8 13.7 ± 0.2 2:1 
CTDDM – Amylose 
purification 
32.6 31.2 ± 0.7 1:1 
CtIP-CTD – Amylose 
purification 
31.8 29 ± 2 1.1:1 
Figure 4.2.2-4: Determination of zinc content for CtIP-CTD and CTDDM expressed using zinc 
supplemented media. Blue circles represent values used in the linear fit with equation displayed. 
Orange cross on the line is the average ratio of absorbance values at 492 to 414 nm for the CTDDM 
sample. Yellow cross on the line is the average ratio of absorbance values at 492 and 414 nm for 
CTDDM with zinc media, grey cross on the line is the average for CtIP-CTD with zinc media. 







4.2.2.1 Determining the zinc binding residues 
As CTDDM retained the capability to bind zinc at a 1:1 ratio other residues must also be involved and 
were further explored. A total of 6 cysteine or histidine residues (excluding C813A/C816A) with 
potential for zinc binding were selected within the CtIP-CTD by sequence analysis (figure 4.2.2.1) with 
individual point mutations created by overlap extension PCR. 
 
  Figure 4.2.2.1: Schematic drawing of CtIP-CTD zinc binding single point mutations. 
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4.2.2.1.1 Expression and purification of CtIP-CTD point mutants  
For purification of each construct two litres of cells were grown without zinc-supplemented media. 
Using the same protocol as for CtIP-CTD (figure 4.2.1.4-3) protein from clarified lysate was purified 
through sequential steps of: amylose initial capture, overnight dialysis with TEV cleavage and heparin 
chromatography with a 17.5% buffer B step for contamination removal. At this point the purification 
diverged to further remove contamination: protein was concentrated to 1 mL prior to the final 
amylose recapture. The flow-through from this final recapture was applied to a SEC 16/60 Superdex 
75 column and resulting fractions containing CtIP-CTD were identified by SDS-PAGE. The same process 
was used for all six individual point mutants. Figure 4.2.2.1.1 illustrates the final purification stage for 
CTDC835A as a representative example. 
 
  
Figure 4.2.2.1.1: Final stage purification of 
CTDC835A by SEC. Protein was purified according 
to the standard amylose –heparin purification A) 
Protein concentrated to 1 mL (Pre) was passed 
through an amylose column (A-FT) which was 
washed (A-W). Contaminant elution fractions (A-
E) were discarded. The A-FT and A-W fractions 
were pooled for SEC in B. Fractions indicated in 
blue are from SEC in B with fractions in Red 
pooled and concentrated for analysis. B) SEC 
using a Superdex 75 16/60 column of CTDC835A 
analysed by SDS-PAGE in B.  
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4.2.2.1.2 Determination of zinc content for CtIP-CTD point mutants 
Using the PAR assay, as described earlier in this section, the zinc content of each individual CtIP-CTD 
protein mutant was analysed. Protein concentration varied from purification to purification with 
concentrations used denoted in table 4.2.2.1.2-1. As non-zinc supplemented media was used, the 
ratios were expected to be 2:1 protein to zinc. 
Protein Protein concentration 
used/ μM 
Average zinc 
concentration/ μM  
Protein to zinc 
ratio 
CTDC795A 80.0 40 ± 1 2.0 ± 0.5 :1 
CTDH811A 95.3 31 ± 1 3.0 ± 0.1 :1 
CTDC835A 84.7 33 ± 2 2.5 ± 0.1 :1  
CTDH838A 76.8 44.4 ± 0.2  1.7 ± 0.01 :1 
CTDC862A 84.0 44.0 ± 0.7 1.9 ± 0.1 :1 
CTDC875A 59.0 31 ± 4 1.9 ± 0.6 :1 
Table 4.2.2.1.2-1: Protein and zinc concentrations for CtIP-CTD mutants. Zinc concentrations 
were determined through the standard curve in figure 4.2.2.1.2-2.  
Zinc was detected for all 6 single point mutations through observation of a colour change on mixing 
proteinase K-digested protein with PAR. Slight differences can be seen within the ratio of protein to 
zinc compared between the mutants, with CTDH811A having the least zinc present (table 4.2.2.1.2-1 & 
figure 4.2.2.1.2-2). Further analysis will be necessary over multiple purifications to determine any true 
differences between the mutations with zinc supplemented media. However, no single mutation 
tested abolished zinc binding.  
 
  Figure 4.2.2.1.2-2: Determination of zinc content for CtIP-CTD single zinc binding point 
mutations. Blue circles represent values used in the linear fit with equation displayed. Values 
for 5 and 1 5µM were omitted as they did not start at the baseline. Crosses represent the 




4.2.2.2 Expression and purification of CTDABC 
Single point mutations failed to abolish zinc binding of the CtIP-CTD. As there is potential for 
compensation between the different residues, combinations of mutations were generated by overlap 
extension PCR. Although many of these were cloned, due to insufficient time only one of these has 
been expressed. This clone, named CTDABC combines all 6 mutated sites (figure 4.2.2.2-1).  
 
 
The 6 combined point mutations resulted in a large amount of degradation. The standard purification 
process was therefore halted prior to TEV cleavage, and the sample was subjected to sequential steps 
of Hi-Trap heparin chromatography and SEC (figure 4.2.2.2-2).  In both steps, contaminating 
degradation products were observed to co-elute with the target of interest. Due to the inability to 
satisfactorily purify this mutant protein, analysis of zinc content was not undertaken. Further analysis 
of combination mutations is therefore necessary, perhaps with a change of purification approach. 
 
   
Figure 4.2.2.2-2: Purification of CTDABC using amylose and 
heparin chromatography. A) Eluate from amylose initial 
capture (A-E) was diluted to a final NaCl concentration of 
100 mM (diluted), before being applied to a 5 ml Hi-Trap 
Heparin column.  Flow-through (Hep-FT) was analysed to 
confirm target capture. Triangle represents increasing 
buffer B (1 M NaCl) from 10% v/v to 50% v/v over 32 mL 
with MBP-CTDABC indicated. All fractions were pooled and 
concentrated for SEC in B. B) Chromatographic profile of 
MBP-CTDABC purification. Fractions indicated were 
analysed by SDS-PAGE in C. C) Fractions analysed from SEC 
with MBP-CTDABC indicated. 
 
Figure 4.2.2.2-1: Schematic drawing of CTDABC zinc binding 6 combined point mutations  
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4.2.3 Confirmation that CtIP-CTD can form dimers and their analysis.  
During successive purification runs of CtIP-CTD a higher molecular weight peak/shoulder was 
consistently observed on the SEC chromatographic profile (figure 4.2.3.1). Like the NTD, a higher 
molecular weight band was also seen on SDS-PAGE analysis of fractions from SEC of CtIP-CTD and was 
confirmed to be dimeric CTD by MALDI-TOF MS (Appendix supplementary figures 7.5 & 7.6). On 
purification of MBP-fused CTD for protein-protein interaction studies the addition of the 42 kDa MBP 
protein increased the separation of these peaks and allowed for purification and analysis of two 
distinctive populations of the CTD.  
4.2.3.1 Expression and purification of MBP-CTD 
The MBP-CTD construct was expressed in Rosetta™ 2 (DE3) E.coli cells, with soluble protein purified 
by sequential amylose resin and heparin chromatography stages without TEV cleavage. The sample 
was concentrated to 1 mL prior to final polishing by SEC using a Superdex 200 16/60 column (figure 
4.2.3.1). Fractions containing either monomeric or dimeric species of CtIP-CTD were pooled 
separately.  






Figure 4.2.3.1: Purification of two species of MBP fused CtIP-CTD by SEC for mass analysis. 
Protein was purified using the standard procedure with the TEV cleavage stage omitted. A) 
Chromatogram of the MBP-CTD elution profile of Superdex 200 16/60 SEC. Fractions indicated 
were analysed by SDS-PAGE in B. B) SDS-PAGE analysis of protein applied (Load) to the SEC 
column followed by SEC elution fractions. Fractions corresponding to either monomeric (red) or 
dimeric (cyan) species of CtIP-CTD were pooled separately. 
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4.2.3.2 SEC-MALS on two CTD species  
To confirm the molecular weights of the suspected monomeric and dimeric species, SEC-MALS was 
performed. Light scattering is a powerful technique to measure the molecular weight of a native 
protein without relying on protein standards. When a MALS photometer is used in combination with 
SEC, the molecular mass of a protein sample can be determined from analysis of its scattering 
characteristics coupled with accurate determination of its concentration as measured by its refractive 
index. The upstream SEC functions to remove contamination, aggregation, and to fractionate 
polydisperse materials prior to light scattering analysis. MALS has the advantage of being independent 
of protein shape, thus gives a more accurate estimate of protein sizes in their native oligomeric state. 
The molecular masses of CtIP-CTD dimer and monomer were determined using SEC-MALS. Analysis of 
the monomer fraction (figure 4.2.3.1 second peak red fractions) showed a measured value of 59.2 kDa 
(figure 4.2.3.2a). The predicted molecular weight of MBP fused CtIP-CTD is 60.23kDa and so confirms 
the presence of a monomer species as the value was within the range of the instrument. On 
application of the CtIP-CTD dimer fraction (figure 4.2.3.1, first peak cyan fractions) to the SEC-MALS 
instrument two peaks were apparent with baseline separation. Molecular weight analysis of the peaks 
gave weights of 115.8 kDa and 59.1 kDa (figure 4.2.3.2b). The measured value for the higher molecular 
weight species is 1.92x that of the predicted monomeric weight and is within the range of the 





Figure 4.2.3.2: MALS 
analysis of MBP fused 
CtIP-CTD shows 
monomer and dimer. 
Experiment was carried 
out using a 10/300 
Superdex 200 SEC column 
connected to the MALS 
instrumentation. RI = 
refractive index, Ls = light 
scattering, UV = UV from 
the SEV elution, Mass = 
molar mass of the peak. 
A) Analysis of MBP fused 
CtIP-CTD monomer 
fraction highlighted in red 
in figure 4.2.3.1 
measured mass is 59.2 
kDa. Polydispersity is 
1.001 ± 0.126%. B) 
Analysis of MBP fused 
CtIP-CTD dimer, 
highlighted in cyan in 
figure 4.2.3.1 measured 
mass of peak 1 is 115.8 
kDa with a Polydispersity 
of 1.000 ± 0.096%. Peak 2 
is measured at 59.15 kDa 
with a Polydispersity of 
1.000 ± 0.159%. 
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4.2.3.3 Zinc analysis of the dimeric CTD. 
SEC chromatograms of CTD expressed using the new purification strategies showed a higher molecular 
weight peak, corresponding to dimeric CtIP-CTD, persisting even without zinc addition (figure 4.2.1.4-
2). The initial CtIP-CTD amylose purification where zinc was added upon cell lysis (figure 4.2.1.4-2, red 
trace) was pooled as a monomer and dimer fraction. These two species were analysed by PAR assay 
with similar protein monomer: zinc ratios (figure 4.2.3.3-1). In this experiment 50 µM of dimer had a 
35 µM zinc content (2.8:1 protein monomer to zinc), while 100 µM of monomer had 43 µM of zinc 
content (2.4:1 protein to zinc content). 
  
Purification optimisations to increase zinc content using zinc supplemented 2xYT media still gave a 
dimeric peak on SEC analysis. PAR assays were also performed on these samples with the dimeric CTD 
having the same 1:1 monomer protein to zinc ratio as CtIP-CTD (figure 4.2.3.3-2). In this experiment 
17 µM dimeric CTD gave a zinc content of 37.0 µM (0.9:1 monomer CTD to zinc content ratio), while 
33 µM monomeric CTD gave a zinc content of 38.4 µM (0.85:1 protein to zinc content ratio); each zinc 
value is averaged over three repeats.  
 
Figure 4.2.3.3-1: 
Determination of zinc 
content for dimeric CtIP-CTD. 
Blue circles represent values 
used in the linear fit with 
equation displayed. Grey 
cross on the line is the ratio of 
absorbance values at 492 and 
414 nm for the CtIP-CTD 
sample. Red cross on the line 
is the ratio of absorbance 
values at 492 and 414 nm for 
the dimeric CtIP-CTD sample. 
Figure 4.2.3.3-2: 
Determination of zinc 
content for dimeric CtIP-CTD 
expressed using zinc 
supplemented media. Blue 
circles represent values used 
in the linear fit with equation 
displayed. Grey cross on the 
line is the ratio of absorbance 
values at 492 and 414 nm for 
the CtIP-CTD sample. Yellow 
cross on the line is the ratio of 
absorbance values at 492 and 




4.2.3.4 DNA binding of dimeric CtIP-CTD 
Dimeric CTD was also tested in DNA binding assays, with FP results indicating extra zinc was still 
necessary for DNA binding as measured by FP. Figure 4.2.3.4-1 shows a representative trace from two 




The EMSA also confirmed the interaction of the dimeric CtIP-CTD with DNA through the formation of 
a slow migrating species on addition of protein (figure 4.2.3.4-2). This result was repeated both with 
and without growth in zinc-supplemented media, with no striking difference between monomeric and 
dimeric protein. 
 
Figure 4.2.3.4-1: Zinc dependency of FP DNA binding for Dimeric CtIP-CTD. DNA binding with 
linear dsDNA fdx60. Graphical representation of dimeric CtIP-CTD binding curves with buffer 
containing 50 µM ZnAc2 (circles) verses without zinc addition (triangles). Blue traces represent 
CtIP-CTD binding curves with (circles) and without (triangles) 50 µM ZnAc2.  
 
Figure 4.2.3.4-2: Dimeric CtIP-CTD 
binds DNA by EMSA. DNA binding 
with 1 µM dsDNA fdx60. Triangle 
represents decreasing amounts of 
CtIP-CTD or dimeric CtIP-CTD from 
4.8-0.6 µM. Different protein 
concentrations were made by serial 
dilution in both experiments. 
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4.2.3.5 CTDABC and Threonine 847 phosphomimetic still form dimeric species  
On expression of CTDABC a higher molecular weight peak is prominent on the SEC chromatogram 
shown by SDS-PAGE to contain CTDABC. Degradation products were also shown to co-elute. To further 
explore the necessity of zinc for dimer formation, semi-analytical Superdex 200 10/300 SEC runs were 
performed on mixed species of MBP-CTD protein. Addition of a 10-fold excess of EDTA to chelate 
metal ions had no effect on the amount of dimeric MBP-CTD (figure 4.2.3.5-1, P1) although it increased 
the levels of aggregated MBP-CTD and reduced the levels of monomeric MBP-CTD. EDTA has a kd for 
zinc of approx. 10−16 M and is known for its ability to disrupt and aggregate zinc finger proteins such 
as transcription factors (Nyborg and Peersen, 2004). The observation that the dimeric species 
remained unchanged supports zinc being dispensable for dimer formation. 
 
The presence of a dimeric species in CTDABC, MBP-CTD with EDTA, and the similar protein: zinc ratios 
for dimeric and monomeric CtIP-CTD show that zinc is likely dispensable for dimer formation. Within 
the CTD the conserved threonine at position 847 has been shown to be necessary for CtIP’s action in 
DNA repair (Sartori et al., 2007). To assess the necessity of threonine 847 of CtIP in formation of a 
dimeric CtIP-CTD species, residue 847 was mutated to glutamic acid (CTDT847E) to mimic 
phosphorylation (Sartori et al., 2007). Expression and purification of CTDT847E was performed from four 
litres of Rosetta™ 2 (DE3) cells. Upon lysis, zinc was added in accordance with the original protocol. 
Subsequently the amylose purification protocol was followed (figure 4.2.1.4-3), with clarified lysate 
applied to an amylose column to capture CTDT847E before overnight dialysis incubated with TEV 
protease and HiTrap heparin chromatography. On SEC analysis multiple peaks were seen (figure 
4.2.3.5-2a); SDS-PAGE analysis showed CTDT847E to be present across all the peaks (figure 4.2.3.5-2b). 
The first peak contained predominantly contamination products, however, the second major peak 
eluted at the point of a dimeric CtIP-CTD; SDS-PAGE analysis confirmed the presence of the dimeric 
Figure 4.2.3.5-1: Dimeric CtIP-CTD (P1) is 
unaffected by EDTA. Superdex 200 
10/300 SEC was performed 
independently on MBP-CTD both with 
and without the addition of 2mM EDTA to 
the sample prior to application to the 





species. Fractions containing either monomeric or dimeric species of CTDT847E were pooled separately. 
The protein identity was determined by MALDI analysis to contain CtIP, further confirming the 




An EMSA was performed to assess the DNA binding capability of CTDT847E to determine if monomer or 
dimer could still bind to DNA and have any effects therein (figure 4.2.3.5-3). As noted in figure 4.2.3.5-
2b, MBP was still present within the CTDT847E purification and therefore protein concentrations 
measurements were likely overestimations. However, both CTDT847E and dimeric CTDT847E were able to 




Neither changes in zinc nor a phosphomimetic T847 disrupted dimer formation or its ability to bind 
DNA. To further study the appearance of the dimeric species the CTD sequence was probed.   
Figure 4.2.3.5-2: Final stage purification of CTDT847E by SEC. A) Chromatogram of the CTDT847E 
elution profile of Superdex 75 16/60 SEC with fractions analysed by SDS-PAGE in B. B) SDS-Page 
analysis of SEC fractions. Fractions indicated in red were pooled as ‘CTDT847E’ with fractions in 
cyan pooled for ‘dimeric CTDT847E’ and concentrated for further experiments. 
Figure 4.2.3.5-3: CTDT847E binds DNA by EMSA. EMSA with decreasing amounts of CTD from 11-
0.68 µM with 1 µM dsDNA fdx60, resulting in the formation of slow migrating species which 
represent protein-DNA complexes. Different protein concentrations were made by serial dilution 




4.2.4 Presence of a coiled coil region adjacent to CTIP-CTD 
Upon identification of the N-terminal coiled-coil region that was shown to form dimers by Dubin et al. 
in 2004, they speculated there was potential for a further coil-coil at the C-terminus of CtIP. Here it 
was reported that residues 700-775 had a 10% chance of forming a coiled coil (Dubin et al., 2004). 
With the apparent dimerisation of CtIP-CTD the CtIP sequence was submitted to the coiled-coil 
prediction software COILS (Lupas et al., 1991), MARCOILS (Delorenzi and Speed, 2002) and Paircoil2 
(McDonnell et al., 2006) servers to probe the C-terminus for a further coiled-coil domain. These 
servers compare the sequence to an ever-expanding database of known parallel coiled-coils, therefore 
as new coiled-coil sequences are deposited the chance of detecting a divergent coiled-coil becomes 
greater. The COILS prediction highlights the N-terminal domain with the presence of two distinctive 
coiled-coil regions which are already known. The prediction however also highlights a second domain 





Figure 4.2.4-1: COILS prediction for CtIPFL highlights a coiled-coil at both N- and C-termini. Green 
line represents a search window of 14 residues, blue line represents a window of 21 residues, 
with red representing a window of 28 residues. A probability scale is shown on the y-axis with 1.0 
indicating high probability and 0 representing low probability. 
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More recently developed servers MARCOIL and Paircoil2 were also performed with similar results. In 
particular MARCOIL at a 50% threshold predicted residues 703-774 to form a coiled-coil domain. 
MARCOIL also detected the NTD coiled-coil to a 90% threshold. All three of the servers predicted that 
the 769-domain boundary was adjacent to, and overlapping with, a potential coiled-coil region. To 
assess the nature of this predicted coiled-coil domain and its effect on the CTD, two further constructs 
were generated. Here CtIP residues 694 to 775 (dCTD) and residues 694-897 (CTDex) were cloned into 
pMAT11 for expression as His-MBP fusion constructs (figure 4.2.4-2). To aid purification dCTD was 







Figure 4.2.4-2: Schematic drawing of dCTD and CTDex. CtIP residues 694-775 are shown in dark 




4.2.4.1 Purification of dCTD 
As dCTD is upstream of the zinc binding region (769-897) it could be purified using a Ni-NTA column 
procedure as metal binding was not envisaged to be an issue. In addition, the C-terminal Strep-tag 
aided in the removal of contaminants. Two litres of Rosetta™ 2 (DE3) cells expressing dCTD were 
grown using the standard procedure. Following lysis by sonication and clarification, the protein was 
purified using Ni-NTA prior to TEV cleavage. The C-terminal strep tag was then used for isolation of 
the dCTD. Figure 4.2.4.1a illustrates the results of these steps as analysed by SDS-PAGE. Unfortunately, 
a large proportion of dCTD didn’t bind to the Strep-Tactin resin and un-cleaved MBP-dCTD persisted 
in the elution fraction. A final Superdex 75 16/60 SEC column resolved the fully cleaved and un-cleaved 
MBP-dCTD species into two separate elution volumes (figure 4.2.4.1b), as visualised by SDS-PAGE 
(figure 4.2.4.1c). While the first peak contained a mixture of both cleaved and un-cleaved species 
(possibly due to the formation of mixed-species dimers), the second peak contained homogeneous 
cleaved dCTD. Fractions corresponding to this latter peak were therefore pooled for concentration 
and further experimental analysis.  
   
   
Figure 4.2.4.1: Purification of dCTD by Ni-NTA 
and Strep-Tactin capture. A) Initial Ni-NTA 
capture followed by TEV cleavage (TEV) and 
Strep-Tactin capture. Flow through (FT), wash 
(W) and elution (E) fractions are shown for Ni-
NTA (N) and Strep-Tactin (S) capture stages. Ni-
E1&2 were combined for TEV cleavage. SE1 
was used for SEC in B. B) SEC trace for dCTD, 
fractions in blue were analysed by SDS-PAGE in 
C. C) SDS-PAGE analysis of protein loaded onto 
SEC along with elution fractions with MBP-
dCTD and dCTD noted. Fractions in red were 
pooled for concentration and flash freezing. 
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4.2.4.2 Purification of CTDex  
For the purification of CTDex an adapted amylose chromatography and heparin chromatography 
protocol was utilised. Two litres of Rosetta™ 2 (DE3) cells were used with standard media for the 
expression, with cells processed by the standard method without addition of zinc. Clarified lysate was 
applied to an amylose chromatography column and dialysed overnight with TEV protease. On a 
preliminary purification a heparin gradient was used with minimal separation of contaminants. 
Optimisation led to a 40% v/v buffer B step to elute and concentrate cleaved CTDex (24.4 kDa), while 
removing some contaminants (figure 4.2.4.2a). Protein from the first three 2 mL fractions of the 40% 
B elution from heparin chromatography was concentrated to 1 mL prior to a final amylose capture 
stage to remove further MBP and un-cleaved protein (figure 4.2.4.2b). The flow-through and wash 
fraction were applied to a Superdex S75 16/60 SEC column, with resulting fractions analysed by SDS-
PAGE (figure 4.2.4.2c). SEC did not fully resolve the cleaved and un-cleaved CTDex species, so only 
central fractions from the two overlapping elution peaks were taken forward for further experiments. 
Optimisations to the procedure will be necessary for more homogeneous protein purification.  
   
   
Figure 4.2.4.2: Purification of CTDex by 
amylose and heparin chromatography 
methods. A) Initial amylose capture followed 
by TEV cleavage and HiTrap heparin 
chromatography. Across A&B: A stands for 
amylose chromatography, ‘FT’ stands for flow 
through, ‘W’ stands for wash, ‘Hep’ stands for 
heparin. The first three 40% fractions were 
pooled and concentrated for amylose re-
capture in B. B) Amylose re-capture of MBP 
and un-cleaved CTDex. A-FT and A-W were 
pooled (1 mL) for SEC in C. Fractions indicated 
by the blue line are from SEC in C. 
C) SEC of CTDex, fractions were analysed by SDS-PAGE in B. Fractions highlighted in cyan were 




4.2.4.3 SEC analysis of dCTD and CTDex 
SEC-MALS was performed at Diamond Light Source, however, there was insufficient contrast between 
the signal and background noise for data processing. SEC-MALS has yet to be completed using our in-
house instrument due to insufficient resources. From SEC alone information about the size and shape 
of the protein can be determined through globular protein standards.  
dCTD from its amino acid sequence has a molecular weight of 10.8 kDa, however it elutes earlier on a 
Superdex 75 16/60 SEC column than predicted (figure 4.2.4.3-1). From globular molecular weight 
standards, a protein of 17 kDa eluted at 77.3 mL on the same column. As dCTD elutes at 68.6 mL, this 
is a first indication that the protein is oligomeric and/or is not globular. SEC-MALS will be necessary to 




  Figure 4.2.4.3-1: Comparison between dCTD and globular molecular weight standards by SEC. Both 
protein samples were applied to the same Superdex 75 16/60 SEC with the same experimental setup. 
Dashed red line represents Bio-Rad molecular weight standards while the solid blue line represents 
dCTD. Traces were overlaid using the Unicorn™ software using the elution volume. Fractions 
indicated by the blue line and red highlight analysed by SDS-PAGE in figure 4.2.4.1. 
170 
 
Analysis of CTDex using the same method also showed an earlier elution volume than expected. From 
the sequence the molecular weight is 24.38 kDa, thus a dimeric protein would have a molecular weight 
of 48.76 kDa. From SEC analysis the elution volume was 59 mL, earlier than the 44 kDa globular 
molecular weight standard at 62 mL (figure 4.2.4.3-2). As CTDex contains residues corresponding to 
the dCTD and CtIP-CTD globular molecular weights are also likely to overestimate its size, however the 
early elution volume does indicate the potential for oligomerisation. SEC-MALS will be necessary to 
confirm the molecular weight of the both proteins. SEC-SAXS was used to further probe the nature of 






Figure 4.2.4.3-2: Comparison between CTDex and globular molecular weight standards by SEC. Both 
protein samples were applied to the same Superdex 75 16/60 SEC with the same experimental setup. 
Dashed red line represents Bio-Rad molecular weight standards while the solid blue line represents 
CTDex. Traces were overlaid using the Unicorn™ software using the elution volume. Blue and red 




4.2.4.4 Zinc incorporation by CTDex 
CTDex contains the 8-potential zinc-binding residues, therefore it should have the ability to bind zinc. 
Digested CTDex protein was analysed with the PAR reagent as described previously. CTDex protein 
assayed was purified from media without addition of further zinc using the new amylose purification 
method 4.2.1.4-3. Two concentrations of CTDex (CTDex fraction B figure 4.2.4.2) were digested (58 
and 116 µM with respect to monomer molecular weight 24379 Da) with zinc detected through 
wavelength shift in peak absorbance on mixing with the PAR reagent. Analysis of triplicate assays 
showed CTDex to have a protein to zinc ratio of 3.0 (± 0.2):1 protein (monomer) to zinc (figure 4.2.4.4). 
Although this is lower than expected the zinc content is similar to dimeric CtIP-CTD from initial 
purifications - where zinc was only added upon cell lysis. The assay confirmed that CTDex can bind zinc 
without addition of zinc. Further analysis of protein purified from zinc supplemented media, and 
determination of oligomerisation will be necessary to confirm the ratio of CTDex to zinc bound from 
further purifications. 
 
Protein Protein concentration 
used/ μM 
Average zinc 
concentration/ μM  
Protein to zinc 
ratio 
CTDex Peak B 116 35.4 ± 1.5 3.3 ± 0.33 :1 
CTDex Peak B 58 19.5 ± 1.0 3.0 ± 0.2 :1 
Figure 4.2.4.4: Determination of zinc content for CTDex. Blue circles represent values used in the 
linear fit with equation displayed. Orange cross on the line is the ratio of absorbance at 492 to 414 
nm for the CTDex sample at 116 µM. Purple cross on the line is the ratio of absorbance at 492 to 
414 nm for the CTDex sample at 58 µM. Values for 5 and 15 µM were omitted as they did not start 







4.2.5 Low resolution structural analysis of the CtIP C-terminal domain by SEC-SAXS. 
Crystallography of CtIP-CTD has yet to yield any promising avenues for structure determination. Size 
Exclusion Chromatography Small Angle X-Ray Scattering (SEC-SAXS) is a powerful X-ray scattering 
technique that can be used to obtain low resolution structural information about a biological sample 
in solution (Feigin and Svergun, 1989; Rambo and Tainer, 2013). Therefore, it can provide information 
about the shape and size of a protein without the need for crystal formation.  
SEC-SAXS was used to characterise dCTD and CTDex. Normalised Kratky plots of the dCTD and CTDex 
gave preliminary information about their shape. The data for CTDex approximated a bell-shaped 
curve, which is indicative of a globular protein.  Meanwhile, the data for dCTD lacked a defined 
inflection point, thereby indicating that this sample possesses a peptide-like or coiled-coil structure 
(figure 4.2.5-1). 
  
The shape of the Dimensionless Kratky plot for dCTD was very similar to that seen for the NTD in 
chapter 3. Following further processing (figure 4.2.5-2) models were generated to fit the dCTD SAXS 
data. The dCTD model looks long and thin resembling a coiled coil (figure 4.2.5-3a) more similar to the 
NTD rather than to a globular protein. Comparison between the dCTD SAXS model and that of NTD31-
145Strep shows that dCTD can easily be positioned into the longer NTD coiled-coil with little excess 
envelope (figure 4.2.5-4). This supports existing evidence that dCTD exists as a coiled-coil. Comparison 
between the two proteins from an end-on perspective shows there is little extra room for a second 
molecule of dCTD within the NTD envelope further suggesting the protein measured is already 
dimeric. A model to fit the CTDex data shows a similar structure to dCTD at one side with a more 
globular head domain adjacent (figure 4.2.5-3b). These likely represent the coiled-coil and dimeric 

















Figure 4.2.5-2: SEC-SAXS analysis of dCTD and CTDex – Guinier fitting and P(r) distribution. 
Top two panels show Guinier fitting for dCTD and CTDex with RG displayed. Bottom two panels 
show the P(r) distributions for dCTD and CTDex with DMAX values displayed.  
 
Figure 4.2.5-3: Models to fit the SEC-SAXS data for dCTD and CTDex. Overlay of DAMFIT 
models generated using DAMMIF from the SAXS data A) dCTD model in green shows a long 
rather than a globular shape. B) Overlay between the model for the dCTD (yellow) and CTDex 








Figure 4.2.5-4: Models to fit the SEC-SAXS data for dCTD and NTD31-145Strep. DAMFIT models 
generated using DAMMIF from the SAXS data for dCTD (green) and NTD31-145 Strep (Cyan). Models 




4.2.6 The CTD and its interactions with And1  
Within a study by Chen et al. interactions were shown between And1 and CtIP by co-
immunoprecipitation from HEK293T chromatin-free cell extracts (Chen et al., 2017). Deletion studies 
within CtIP highlighted the importance of both the N- and C-terminal domains, with the N-terminal 
interaction with full length And1 confirmed using purified proteins. And1 deletion studies showed 
residues 850-1050 formed the minimal interaction region with CtIP. However, direct interactions 
between And1 residues 850-1050 and CtIP or the CtIP C-terminus and And1 were not reported (Chen 
et al., 2017). For direct interaction between And1 and CtIP pulldown experiments were performed. 
Various And1 constructs (figure 4.2.6) were purified from either insect cells or bacteria with constructs 
provided by Dr Mairi Kilkenny (Kilkenny et al., 2017). An MBP-tagged CTD was purified (figure 4.2.6) 
as bait in pulldown experiments. The cleavage stage within the CTD purification was removed and the 
MBP-CTD fusion protein purified using the new amylose purification procedure to homogeneity. The 
CtIP-CTD ‘monomer’ fraction was used in all pull-down experiments (figure 4.2.1.4-3). 
 
 
4.2.6.1 Purification of full-length And1 
The And1 full length (And1FL) construct was expressed in Sf9 insect cells and harvested 3 days post 
transfection. The soluble protein was purified using sequential Ni-NTA and Heparin affinity 
chromatography steps. Final polishing was performed using a 16/60 Superdex 200 SEC (figure 4.2.6.1). 
Fractions were analysed by SDS-PAGE, with fractions containing purified And1 pooled and 
concentrated for pulldown experiments. 







Figure 4.2.6.1: Purification of And1 expressed in insect cells by Ni-NTA and Hi-Trap heparin. 
A) Initial Ni-NTA purification with lysate, supernatant, Ni-NTA flow through and elution 
fractions shown. Elution fractions 1-3 were pooled for Hi-Trap heparin in B. B) Hi-Trap heparin 
chromatogram, buffer B was 1M NaCl. Fractions correspond to SDS-PAGE in C. C) SDS-PAGE 
analysis of Hi-Trap Heparin fractions with red highlight indicating fractions pooled for SEC in D. 
D) SEC chromatogram of applied And1 protein to the Superdex 200 16/60 column. Fractions 
correspond in SDS-PAGE in E. E) Analysis of SEC fractions: fractions highlighted in red were 





4.2.6.2 Interaction of And1 with CtIP CTD 
To verify the And1FL interactions reported by Chen et al., pull-down experiments using purified CtIP 
MBP-NTD and CtIP MBP-CTD as ‘bait’ vs full length And1FL ‘prey’ were performed. See chapter 2 for 
buffers and protocol. And1FL was found within CtIP-CTD elution fractions but not with CtIP-NTD. 
 
 
Western Blot analysis confirmed the interaction of And1 and CtIP-CTD. No And1FL through virtue of its 
Myc tag could be detected in the presence of CtIP-NTD, thus confirming And1FL does not interact with 
CtIP-NTD. And1FL was unable to independently bind to the amylose resin (figure 4.2.6.2-1). Further 
pull-down experiments with CtIP-CTD were performed to find the And1 interaction domain. 
4.2.6.3 Identification of the And1: CtIP-CTD interaction domain 
To confirm which domains of And1 were necessary for the CtIP-CTD interaction, And1 constructs 
And1316-1129 (no WD domain), And1826-1129 (no WD or SepB domains) and And11-316 (the WD domain) 
Figure 4.2.6.2-1: CtIP-CTD, but 
not CtIP-NTD can retain And1 
by pull-down assay. And1 was 
tested for interaction with 
MBP-tagged CtIP-CTD or NTD 
bound to amylose resin. 
Results are shown by SDS-
PAGE. And1FL was flowed over 
the resin (flow) before 
washing (wash) and eluting 
with 20 mM maltose (elution).  
Presence of each protein 
incubated with the beads is 
indicated by “+”.  
 
Figure 4.2.6.2-2. Western 
blot analysis of CtIP-CTD 
and CtIP-NTD pull-down 
assay. A) Western blot 
using anti Myc tag 
antibody against the 
And1FL Myc tag, lanes 
indicated are from figure 
4.2.6.2-1. B) Pull-down of 




were tested. And1 proteins for these pull-downs were purified and provided by Dr Mairi Kilkenny 
(Kilkenny et al., 2017). The same buffers and protocols were used as for the original And1FL pulldown 
experiment. Figure 4.2.6.3-1 confirms the interaction of CtIP-CTD with And1FL. CtIP-CTD however 
failed to retain And11-316 (figure 4.2.6.3-1 lane 20) and And1826-1129 (figure 4.2.6.3-1 lane 12) on the 
beads showing that the interaction was not through the WD or C-terminal domain of And1 
respectively.  
 
And11-316 was further shown to be dispensable through And1316-1129 being retained on the beads in the 
presence of CtIP-CTD (figure 4.2.6.3-1), highlighting the SepB domain from residues 316-826 as the 
potential interaction site. And11-826 containing the WD and SepB domains was purified from Rosetta™ 
2 (DE3) E. coli for testing against CtIP-CTD. The soluble protein was purified using sequential Ni-NTA 
and Hi Trap Q chromatography as detailed in methods. Figure 4.2.6.3-2 shows the combined elution 
from the Hi Trap Q column as the input for And11-826. Amylose beads containing CtIP-CTD were able to 
retain a band of correct size for And11-826 within the amylose elution while And11-826 could not bind to 
the amylose resin in the absence of CtIP-CTD suggesting an interaction between the two proteins. 
Figure 4.2.6.3-2 also further confirms the interaction of And1FL with CtIP-CTD. 
Figure 4.2.6.3-1: And1 WD1 domain is dispensable for interaction with CtIP-CTD. CtIP-CTD was 
bound to amylose beads And1 constructs And1FL, And1316-1129, And1826-1129 and And11-316 were 
flowed over the resin (flow) in the pull-down experiments before washing (wash) and eluting with 
20 mM maltose (elution). Presence of each protein incubated with the beads is indicated by a “+”. 





While MBP-tagged CtIP-CTD retained And1316-1129 and And11-826 on the amylose beads, And11-316 and 
And1826-1129 could not associate with the CtIP-CTD under the same conditions. This focuses the 
interaction of CtIP with And1’s SepB domain, rather than the WD domain or HMG box at the C-
terminus.  
  
Figure 4.2.6.3-2: CtIP-CTD interacts with 
And1 through its WD1-SepB domain. 
CtIP-CTD was bound to amylose beads 
And1 constructs And1FL, and And11-826 
were the flowed over the resin (flow) in 
the pull-down experiments before 
washing (wash) and eluting with 20 mM 
maltose (elution).  Presence of each 
protein incubated with the beads is 




So far pull-down experiments have narrowed down the interaction between And1 and CtIP to the 
SepB domain of And1 and CTD of CtIP. Therefore, a construct spanning And1 residues 316-826 
(And1316-826) was expressed and purified from bacterial cells. The soluble protein was purified using 
sequential Ni-NTA and Hi Trap Q chromatography, with a SEC 16/60 Superdex 200 gel filtration final 
polishing stage (figure 4.2.6.3-3). Fractions were confirmed by SDS-PAGE to contain And1316-826, 
however it was also noted that And1316-826 had the same molecular mass by SDS-PAGE as MBP fused 
CtIP-CTD (figure 4.2.3.1). Consequently, a direct observation of an interaction using the same pull-
down protocol was not possible (figure 4.2.6.3-4). 




    
Figure 4.2.6.3-3: Final stage purification of And1316-826 by SEC. A) Superdex 16/60 SEC 
chromatogram with fractions corresponding in B. B) fractions analysed by SDS-PAGE from 
SEC in A. Fractions highlighted in red were pooled for experimental analysis.   
Figure 4.2.6.3-4: CtIP-CTD 
pulldown experiment with 
And1316-826. CtIP-CTD was bound to 
amylose beads And1 construct 
And1FL and And1316-826 were the 
flowed over the resin (flow) in the 
pull-down experiments before 
washing (wash) and eluting with 20 
mM maltose (elution). Presence of 
each protein incubated with the 




To overcome this obstacle the protocol was adapted to include a TEV digestion stage post elution of 
protein from the amylose beads (see chapter 2) to cleave the MBP tag from the CtIP-CTD and reveal 
any proteins bound of a similar size. This allowed the MBP tag to isolate CtIP-CTD on the beads for 
interaction studies while later removing the overlapping band. Using this method, the MBP-CTD band 
is degraded into a 42 kDa MBP and 15 kDa CtIP-CTD band along with the 28 kDa band for the TEV 
protease present, (figure 4.2.6.3-5 lane 14). And1FL interaction was confirmed for this pull-down 
experiment with the presence of And1FL not affected by TEV digestion (figure 4.2.6.3-5 lane 5&6). Post 
TEV digestion of the And1316-826 pull down elution a band of 51 kDa corresponding to the molecular 
weight of And1316-826 was now apparent (figure 4.2.6.3-5 lane 11). Western blot analysis using an 
antibody against His-tagged proteins confirmed that the band at 51 kDa (figure 4.2.6.3-5 boxed) was 
not an un-digested MBP tagged CtIP-CTD (figure 4.2.6.3-5 western lane 11). MALDI-TOF mass 
spectrometry was also used to confirm that the band (figure 4.2.6.3-5 boxed) contained And1.  
  
  
Figure 4.2.6.3-5: CtIP-CTD interacts with And1316-826 SepB domain. CtIP-CTD was bound to 
amylose beads, And1 constructs And1FL, and And1316-826 were flowed over the resin (flow) in the 
pull-down experiments before washing (wash) and eluting with 20 mM maltose (elution). Digest is 
post 1-hour incubation with TEV protease with location of MBP, TEV and CtIP-CTD digestion 
products indicated. Presence of each protein incubated with the beads is indicated by a “+”. LHS 
of image shows a western blot analysis of the indicated lanes using an anti-his antibody to detect 




4.3 Conclusions and future work 
Sequence homology within the C-terminal region of human CtIP is highly conserved across a wide 
range of eukaryotic species. This, along with the drastic phenotypes apparent in Seckel syndrome, 
suggests a highly important role in CtIP function. The results presented here have provided insights 
into this region. Secondary structure analysis of CtIP predicts a coiled-coil motif near the C-terminus, 
juxtaposed to the functionally conserved homology domain. Chromatography techniques have been 
exploited to investigate the oligomeric state of the broader C-terminal region, including analytical SEC 
(using several different conditions), SEC-MALS and SEC-SAXS. The results of these techniques all 
support the existence of a dimeric species.  SEC-SAXS generated an elongated envelope for this region, 
supporting the presence of a coiled-coil upstream of the CtIP Sae2 homology domain at the C-
terminus.  Future work should include further SEC-MALS and AUC experiments with dCTD and CTDex 
to confirm the oligomeric state. 
Further to this, these domains are proposed as regions of interest for crystallographic study. The dCTD 
is of particular interest as its predicted coiled-coil structure is likely to be the most crystallographically 
tractable component of this region. Protein purification for the dCTD currently produces 
homogeneous protein for one of the two species. An additional step to remove any un-cleaved MBP-
tagged protein would allow both species to be analysed by SEC-MALS to determine the target for 
crystallisation. For CTDex, a change of approach may be necessary; addition of a C-terminal strep-tag 
might aid purification of homogeneous protein. 
The C-terminal region contains 8 putative zinc-binding Cys/His residues.  The ability of these residues 
to bind zinc was assessed in this study with no single residue abolishing zinc binding. Further 
mutational analyses will be required to determine the contribution of each residue to zinc-protein 
complex formation. Alternative methods for zinc incorporation during protein purification have also 
brought into question the residues involved in zinc binding. Zinc was found to be important for the 
stabilisation of monomeric species of the CTD.  Notably, protein aggregation was observed when 
either metal chelators were added, or zinc supplementation was omitted during purification.  Since 
putative zinc-binding residues are broadly distributed across the domain, it is plausible that zinc 
coordination stabilises weak structural elements within the whole region.  However, dimeric species 
of the CTD do not show the same sensitivity to zinc loss, indicating that dimerisation helps to stabilise 
the domain. 
Biophysical studies have revealed that CtIP-CTD has an affinity for DNA in the low micromolar range, 
with a minimal interaction length of 20 to 25 bp. While this is not considered a high-affinity interaction, 
it may be modulated by dimerisation and/or post-translational modification of the CTD. It is also 
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plausible that the CTD undergoes induced folding upon binding to other protein factors, to further 
increase its affinity for DNA. Further DNA-binding experiments will be required to elucidate the effect 
of dimerisation, zinc and phosphorylation on this DNA-CtIP interaction. 
To probe CtIP’s involvement with the replication fork the interaction between the replication fork-
associated protein And1 and CtIP was explored. This interaction had been previously reported through 
co-immunoprecipitation analysis (Chen et al., 2017). However, here alternative domains have been 
identified using purified And1 and purified CtIP proteins with an interaction between And1316-826 and 
CtIP-CTD shown within this thesis. The different interaction sites determined between the two studies 
supports existence of alternate forms of CtIP, with interactions and conformations within the protein 
affecting the C-terminal domain. This would explain the differences seen between CtIP-CTD expressed 
alone verses removal of the CtIP-CTD or CtIP-NTD by Chen et al.  
As the crystal structure of And1 residues 424-824 has been determined (Kilkenny et al., 2017), the 
binding of the CtIP-CTD to And1316-826 provides a potential avenue for determination of a CtIP-And1 
protein complex crystal structure. Future work within this project is necessary to identify the And1-
CtIP interaction motif though the overarching aim will be to crystallise and determine the structure of 
the complex. Methods such as Hydrogen-Deuterium Exchange (HDX) may be used to probe the 
interaction surfaces between And1 and CtIP, helping to guide crystallisation efforts. Interactions 
between other repair proteins (such as MRN) and the protein constructs described in this chapter 











Chapter 5, CtIP Full-Length 
5.1 Introduction 
CtIP is a protein fundamental to life with ubiquitous cellular expression and a multitude of different 
roles from transcription to DNA repair. Apart from several short motifs that are characterised as 
protein-protein interaction sites and a large array of reported post translational modifications, the 
only known structural element of the protein is a coiled-coil domain at the N-terminus of CtIP (Dubin 
et al., 2004; Fusco et al., 1998). Later structural studies have demonstrated the presence of a 
tetramerisation domain preceding and joined to the coiled-coil region. The impact of abolishing 
tetramerisation on HR repair is known through cellular assays, showing a strong defect on DNA-end 
resection (Davies et al., 2015).  
Functional studies of CtIP have mainly been limited to cell-based investigations due to the difficulty of 
recombinant protein purification. Where research groups have expressed CtIP (Anand et al., 2016; 
Liao et al., 2016; Makharashvili et al., 2014; Sartori et al., 2007; Wang et al., 2014) this has been mainly 
for radiation-based gel assays with no biophysical or structural analysis of full length CtIP published to 
date. Structure prediction from the protein sequence can provide an avenue for biophysical 
characterisation of sub domains, however for CtIP this is limited to its N- and C-terminus. Therefore, 
a large portion (~600 amino acids or 66%) of the protein remains unexplored. With potential for N-
terminal modifications to affect the C-terminal of the protein, research into CtIP as an intact 
recombinant protein is therefore paramount. In order to characterise structurally human CtIP, I set 
out to express and purify the full-length protein. This chapter reports the successful production of 






5.2.1 E. coli expressed CtIPFL 
E. coli is the workhorse of recombinant protein expression and is the expression system of choice due 
to its low cost, ease of manipulation and high protein yields. Since C-terminal and N-terminal CtIPFL 
constructs had been shown to require the MBP tag for expression and solubility, CtIPFL was cloned in 
frame with an MBP tag as a first expression test using Image cDNA clone 4830693. PCR of the CtIPFL 
ORF required annealing temperature optimisation to remove contaminants (figure 5.2.1.1b). The 
CtIPFL open reading frame was cloned into pMAT11 using restriction sites SalI and NcoI, generating a 
His6MBP tagged CtIP construct.  
5.2.1.1 Bacterial protein expression and purification of Human CtIPFL 
Expression trials of the CtIPFL construct were carried out using the Rosetta™2 (DE3) strain.  Figure 
5.2.1.1a shows the result of the Ni-NTA purification from 2 litres of cells. No protein band attributable 
to the 139 kDa His6MBP-CtIPFL was visible by SDS-PAGE or by Anti-His Western blot (figure 5.2.1.1c). 
As the bacterial expression was not successful, an alternative expression system was required.  
  
 
Figure 5.2.1.1: Cloning and expression trial of CtIPFL expressed in E. coli. Image clone 4830693 
was amplified, cloned and expressed in Rosetta™ 2 (DE3) bacterial cells. A) Result of Ni-NTA 
affinity purification. ‘FT’ stands for flow-through. Combined elution fractions 1-3 were 
analysed by Western blot in C. B) PCR product from optimised CtIPFL PCR reaction, 70°C was 
found to be the optimum annealing temperature. C) Western blot analysis of Ni-NTA elution 
fractions using an anti-His tag antibody that can detect His-MBP tagged CtIPFL. 
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5.2.2 Insect-cell expression and purification of CtIPFL 
Baculovirus expression in insect cells is a well-established system that is suitable for expressing large 
amounts of eukaryotic protein, and has been previously deployed with success by other research 
groups to produce recombinant CtIPFL (Makharashvili et al., 2014). The Flag-tagged CtIPFL construct 
donated by Tanya Paull was used for baculovirus generation.  
5.2.2.1 CtIPFL expression test 
Following p2 virus generation, a small-scale expression test was performed infecting 50 mL of Sf9 cells 
at 2x106 cells per mL. At four time intervals (+1 day, +2days, +3days, +4 days) 1 mL of cells were 
removed for expression testing. Cells were pelleted and suspended in lysis buffer: 20 mM Tris pH 8, 
300 mM NaCl, 0.5 mM TCEP, 10% v/v glycerol and SigmaFAST™ protease inhibitor tablets EDTA free. 
Total lysate and supernatant of each time point were analysed by Western blot using an Anti-Flag 
antibody to detect the Flag-tagged CtIPFL protein. Expression of CtIPFL was detected from +2 days 
onwards, together with evidence of degradation products (figure 5.2.2.1). From this experiment it was 
therefore determined that cells should be harvested at +2 days to ensure a maximum CtIPFL yield and 
minimise the formation of degradation products. 
  
 
5.2.2.2 CtIPFL protein purification 
500 mL of Sf9 cells infected with Flag-tagged CtIPFL baculovirus were grown and harvested at +2 days. 
Filtered cell lysate supernatant was first passed over a 1 mL anti-Flag tag resin column, washed, and 
the retained Flag-tagged CtIPFL eluted with Flag-peptide buffer (figure 5.2.2.2a). Fractions were 
analysed by SDS-PAGE and pooled accordingly; the CtIPFL was then concentrated to 0.5 mL and applied 
Figure 5.2.2.1: Western blot 
of CtIPFL Sf9 expression test 
using Anti-flag antibody. 
Samples corresponding to 
total protein (T) and 
Supernatant (S) from clarified 
lysate are shown on the 
Western blot. ‘Control’ is the 




to a Superdex 200 10/300 SEC column pre-equilibrated into buffer containing 20 mM Tris pH 8, 300 
mM NaCl, 0.5mM TCEP and 10% v/v glycerol. Eluted fractions containing CtIPFL as shown by SDS-PAGE 
were pooled and concentrated to 400 µL. Protein was snap frozen with liquid nitrogen in 40 µL 
aliquots. The bands from SDS-PAGE analysis (figure 5.2.2.2b) were identified by MALDI-TOF mass 





The concentration of purified and concentrated CtIPFL was measured as 0.7 mg/mL or 6.75 µM 
(monomer), using a theoretical extinction coefficient of 41715 M-1. Given the presence of a 
contaminant species as HSP70 and of CtIPFL degradation products, the concentration value is likely to 
represents an over-estimate of the true concentration of CtIPFL in the sample. 
Figure 5.2.2.2: CtIPFL purification from 
Sf9 insect cells infected with CtIPFL Flag 
tagged baculovirus. A) SDS-PAGE 
analysis of CtIPFL purification by Anti-
flag affinity chromatography (F) with 
flow-through (FT), wash (W) and elution 
(E) fractions shown. B) SDS-PAGE 
analysis of eluted fractions from size-
exclusion chromatography of affinity-
purified CtIPFL. Pre: protein loaded onto 
the column. C) Chromatographic profile 
of CtIPFL elution from the SEC column. 
Fractions in red were pooled and 
concentrated for experimental analysis. 
The second peak in the chromatogram 
corresponds to eluted Flag peptide.  
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5.2.2.3 CtIPFL DNA binding 
Human CtIP and its fission-yeast orthologue S. pombe Ctp1 have been shown to possess DNA binding 
ability, residing within their conserved C-terminal domains (Andres et al., 2015; Davies et al., 2015). 
Therefore, the DNA-binding ability of recombinant human CtIPFL was tested by EMSA alongside that 





Clear differences in DNA binding behaviour between CtIPFL and CtIP-CTD were apparent. The CtIPFL-
DNA complex migrated as a tight band, unlike the CtIP-CTD-DNA species that showed a more diffuse 
pattern in the gel, a possible indication that this complex is unstable during electrophoresis. In 
contrast, CtIP-CTD was able to shift almost all the DNA probe, although the inability of CtIPFL to achieve 
a similarly complete bandshift might be due to an overestimation of its protein concentration. The 
observed differences in the electrophoretic mobility behaviour of the protein-DNA complexes formed 
by CtIPFL and its CTD prompted me to explore the role of CtIP oligomerisation in DNA binding.  
5.2.2.4 L27E CtIPFL protein purification 
The mutation of leucine residue 27 to glutamic acid (L27E) has been shown to abrogate 
tetramerisation (Davies et al., 2015). Therefore, if tetramerisation of CtIPFL is important for DNA 
binding, a L27E CtIP mutant should have reduced or no DNA binding ability. To generate the L27E 
mutation on CtIPFL the Quikchange mutagenesis protocol was used on the CtIPFL Flag-tagged pACEBac1 
construct. After DNA sequence confirmation of the L27E mutation, a L27E CtIPFL bacmid and 
baculovirus were generated. L27E CtIPFL was expressed and purified in the same way as the wild-type 
protein (figure 5.2.2.4).  
Figure 5.2.2.3: DNA binding of insect expressed CtIPFL by EMSA. Left-hand side: EMSA of 1 µM 
40 bp dsDNA in the presence of CtIPFL at concentrations of 6 µM, 3 µM, 1.5 µM, 0.75 µM, and 
0.375 µM. Right-hand side: EMSA of 1 µM 40 bp dsDNA in the presence of CtIP-CTD at 
concentrations of 12 µM, 6 µM, 3 µM, 1.5 µM and 0.75 µM. The position in the gel of the free 







The CtIPL27E protein eluted in a wider peak and at a later volume (8.0 mL) than the wild-type protein 
(7.2 mL), in agreement with the expected reduction in oligomerisation status. The L27E CtIPFL sample 
achieved a similar degree of purity as the wild-type protein and was concentrated to 0.7 mg/mL or 
6.75 µM (monomer).  
5.2.2.5 CtIPL27E DNA binding 
The EMSA was used for side-by-side comparison of L27E CtIPFL and the CtIP-CTD, using the same assay 
as in the previous EMSAs of CtIPFL. The DNA substrate was a 200 bp fluorescently-labelled dsDNA at a 
final concentration of 1 µM.   
Figure 5.2.2.4: Purification of L27E 
CtIPFL from insect cells. A) SDS-PAGE 
analysis of L27E CtIPFL purification by 
Anti-Flag affinity chromatography (F), 
with flow-through (FT), wash (W) and 
elution (E) fractions shown. B) SDS-
PAGE analysis of eluted fractions from 
SEC of affinity-purified L27E CtIPFL. Pre: 
loaded protein onto the column. C) 
Chromatographic profile of L27E CtIPFL 
elution from the SEC column. Fractions 
in red were pooled and concentrated 
for experimental analysis. The second 
peak in the chromatogram 









The EMSA shows that the L27E CtIPFL-DNA complex shows a similar electrophoretic behaviour to that 
of CtIPFL (figure 5.2.2.5). Interestingly, in this experiment CtIPL27E achieves full bandshift of the DNA 
probe, suggesting a higher affinity for dsDNA than the wild-type protein. This might be due to the 
differences in overestimation of protein concentration between CtIPFL and L27E CtIPFL. The observed 
binding of CtIPL27E to DNA indicates that tetramerisation is not necessary for interaction with DNA. 
  
Figure 5.2.2.5: DNA binding of L27E CtIPFL by EMSA. Left-hand side - EMSA of 1 µM 200 bp 
dsDNA in the presence of L27E CtIPFL at concentrations of 6 µM, 3 µM, 1.5 µM, 0.75 µM, and 
0.375 µM. Right-hand side: EMSA of 1 µM 200 bp dsDNA in the presence of CtIP-CTD at 
concentrations of 12 µM, 6 µM, 3 µM, 1.5 µM and 0.75 µM. The position in the gel of the free 





5.2.2.6 Expression and purification of Mre11-Rad50-Nbs1 (MRN) 
The direct interaction of CtIP with the MRN complex is necessary for DNA-end resection in preparation 
for homologous recombination (Anand et al., 2016; San Filippo et al., 2008; Sartori et al., 2007). To 
explore this critical interaction, I set out to prepare purified MRN. The MRN complex was expressed 
and purified from Sf9 cells infected with individual Mre11, Rad50 and Nbs1 viruses. The complex was 
initially purified from filtered cell lysate supernatant by fast-flow heparin chromatography, followed 
by Anti-Flag affinity chromatography to capture the complex using Mre11’s Flag tag and a final step 
of Hi-Trap S ion-exchange chromatography (figure 5.2.2.6a). The identity of the purified MRN 
components was confirmed by MALDI-TOF MS to be Rad50 (155 kDa), Nbs1 (85 kDa) and Mre11 (81 
kDa). Analysis of the protein by SDS-PAGE showed stoichiometric quantities of Mre11 and Rad50 
however sub-stoichiometric levels of Nbs1. Nevertheless the purified protein was shown to possess 
manganese-dependent nuclease activity on a PhiX174 circular single-stranded virion DNA substrate 
using the published nuclease activity assay (Sartori et al., 2007) (figure 5.2.2.5b). 
  
Figure 5.2.2.6: Purification of Mre11-Rad50-Nbs1 from insect cells. A) SDS-PAGE analysis of 
MRN purification by Anti-Flag affinity chromatography. B) Nuclease gel assay of MRN 
performed in accordance to Satori et al 2007 using purified protein from A. The assay was 
conducted with 40ng of MRN, 500ng of PhiX174 circular single-stranded virion DNA substrate 
and 5 mM MgCl2 or 5 mM MnCl2. 
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5.2.2.7 CtIPFL Protein purification optimisation 
At this point a change of approach was necessary to increase initial capture and gain sufficient protein 
for analysis. For this, the purification tag was changed to the twin-Strep tag sequence to allow 
purification using the Strep-Tactin resin. This system was chosen as it has a greater binding capacity 
per mL along with the ability to use more stringent conditions to remove contamination. This would 
also allow pull-down experiments to be performed with the MRN complex. 
5.2.2.7.1 Cloning of twin-Strep CtIP 
The sequence corresponding to Human CtIP was PCR-amplified from the original flag tagged CtIPFL 
construct variant x3 and subcloned into both pACEBac1 for insect cell expression and pACEMam1 for 
mammalian expression. Positive clones were identified through restriction digest and DNA 
sequencing. Further insertion of the Twin-Strep tag was achieved to generate an N-terminally Strep 
tagged CtIPFL. Clones were tested by BstBI cleavage that had been engineered into the tag, followed 






5.2.2.7.2 Twin Strep CtIPFL initial purification. 
One litre of Sf9 cells were infected with the new virus and harvested at +2 days. Soluble protein was 
diluted to 100 mM NaCl for heparin binding and filtered before application to the column via a sample 
pump. Protein was eluted in a sharp peak with 70% v/v buffer B (1 M NaCl). This 5 mL elution was 
subsequently bound to a 1 mL Hi-Trap Strep-Tactin column, washed, eluted and fractions analysed by 
SDS-PAGE at each stage. Western blot analysis was used to determine possible effects on protein 
solubility of buffer salt concentration and the efficacy of the heparin and Strep-Tactin purification 
steps (figure 5.2.2.7.2). 100 mM NaCl had little apparent effect on CtIP solubility, however a large 
amount of CtIP protein could be detected within the heparin flow through (Hep-FT). Western blot of 
the Strep elution only contains CtIPFL, conversely on SDS-PAGE analysis (figure 5.2.2.7.2b) many 




Figure 5.2.2.7.2: Purification of CtIPFL twin strep tagged protein using Hi-Trap heparin and 
Strep-Tactin resin. A) Western blot analysis of initial purification stages shows little change in 
protein solubility with 300 mM (super), 100 mM (su-100) or 200 mM (su-200) NaCl 
concentrations. Over both images Hi-Trap heparin (hep) and Strep-Tactin (S) with flow-through 
(FT), wash (W) and elution (E) purification fractions are shown. Little CtIPFL is detected in the 
Strep flow through with only CtIPFL detected by Western Blot B) SDS-PAGE analysis of Strep-




5.2.2.7.3 Twin Strep CtIPFL ammonium sulphate precipitation 
Ammonium sulphate precipitation is a classical method for initial purification of proteins by salting 
out (Wiley, 1998). To determine if this method could remove CtIP degradation products, powdered 
ammonium sulphate was added to filtered cell lysate supernatant and precipitated protein removed 
by centrifugation. Fractions were dialysed into standard buffer to allow analysis of retained CtIPFL at 
each stage by SDS-PAGE and Western blot using the anti-Strep antibody (figure 5.2.2.7.3). CtIPFL 
protein was detected within the 20% w/v ammonium sulphate fraction and was impossible to be 





Figure 5.2.2.7.3: Anti-strep Western blot analysis of 
ammonium sulphate precipitation fractions. Fractions 
are sequential from a one litre insect cell purification of 
twin-strep CtIPFL. “Su” and “super” stand for 
supernatant, “Pe” stands for the insoluble proteins 
removed by centrifugation with numbers indicating the 
percentage of ammonium sulphate. Fractions were 
dialysed into standard buffer overnight to allow SDS-
PAGE and Western blot analysis. CtIPFL and its 
degradation products were detected within the 
insoluble pellet fractions. 
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5.2.2.7.4 Direct capture of Twin Strep CtIPFL  
Two litres of Sf9 cells infected with twin-Strep CtIPFL baculovirus were gown and harvested at +2 days. 
Benzonase® was added to half of the cell preparation with filtered cell lysate supernatant passed over 
two individual 1 mL Strep-Tactin columns. It was apparent that the Benzonase® treated sample flowed 
through the column faster by gravity flow. The column was washed with the retained CtIPFL protein 
eluted with d-desthiobiotin elution buffer. Fractions were analysed by SDS-PAGE with a considerable 
amount of degradation products co-eluting (figure 5.2.2.7.4).  
  
Although CtIPFL was purified using the insect cell baculovirus system the protein was unstable with an 
increase in CtIPFL degradation products detected by SDS-PAGE. This instability is likely due to the 
unknown complexity of the human CtIP unstructured region. Thus, an alternative human expression 
system was chosen for further expression of twin-Strep CtIPFL. 
  
Figure 5.2.2.7.4: Insect expressed CtIPFL strep 
capture with and without Benzonase®. 
Protein was expressed using the baculovirus 
expression system with the preparation split 
into two and purified identically. The Strep-
Tactin resin (S), Flow-through (FT), Wash (W) 
and Elution (E) are shown. 
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5.2.3 Human Embryonic Kidney 293F expressed Full Length CtIP 
Production of recombinant CtIPFL was changed to the Human Embryonic Kidney 293F suspension cell 
line to increase the likelihood that the protein was active, stable, correctly modified, and true to the 
real human protein; this should then give the most reliable results. Maintenance of the HEK293F cell 
line and tissue culture facility was performed by Dr Neil Rzechorzek and Vincentius Aji Jatikusumo. 
5.2.3.1 Protein purification of CtIPFL optimisation 
A small-scale expression test was performed infecting 50ml of HEK293F cells at 1X106 per mL with the 
CtIP Twin Strep pACEmam1 expression construct. At three time intervals (+1 day, +2 days, +3 days) 1 
mL of cells were removed for expression testing. Cells were pelleted and suspended in lysis buffer: 20 
mM Tris pH 8, 300 mM NaCl, 0.5% v/v Tween 20, 10% v/v glycerol and protease inhibitor tablets (EDTA-
Free). Total lysate and supernatant of each time point were analysed by Western blot using an Anti-
Strep antibody to detect the Strep-tagged CtIPFL protein. Expression of CtIPFL was detected from +1 
days onwards, together with evidence of degradation products (figure 5.2.3.1-1a). From this 
experiment it was therefore determined that cells should be harvested at +2 days to ensure a 
maximum CtIPFL yield and minimise the formation of degradation products. 400 mL of HEK293F cells 
at 1X106 per mL with the CtIP Twin Strep pACEmam1 expression construct was harvested at +2 days 
using the same procedure however protein was absent from the soluble fraction by anti-Strep 
Western blot (figure 5.2.3.1-1b). 
  
  
Figure 5.2.3.1-1: Western blot of 50 
mL and 400 mL CtIPFL HEK293F 
expression tests using Anti-Strep 
antibody. “D” stands for day, “T” for 
total lysate and “S” for clarified lysate 
supernatant for both images. A) Time 
trial expression test with 50ml of cells. 
Day2 (D2) was chosen for subsequent 
harvesting of HEK293F cells in B. B) 
400 mL expression of CtIPFL in 
HEK293F cells. Most of the protein 
was shown to be insoluble.  
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A further 400 mL of HEK293F cells expressing the CtIPFL construct were prepared, however, 0.5 mM 
TCEP was added to the cell re-suspension buffer. This was shown to improve solubility of CtIP by Anti-
Strep Western blot analysis. Filtered cell lysate supernatant was applied to a 1 mL Strep-Tactin column, 
washed, eluted and fractions analysed by SDS-PAGE (figure 5.2.3.1-2). CtIPFL was detected within the 





It has been recently reported that addition of valproic acid can enhance recombinant protein 
production in transiently infected cell lines (Backliwal et al., 2008; Wulhfard et al., 2010). A further 
expression time trial was repeated with final concentration 4 mM valproic acid added to the cell 
media. The same procedure as detailed previously was performed with 1 mL samples taken at one day 
intervals until +5 days. Total lysate and supernatant were analysed by anti-Strep Western blot (figure 
5.2.3.1-3). 
Figure 5.2.3.1-2: HEK293F expressed CtIPFL purification using Strep-Tactin resin. A) SDS-
PAGE analysis of CtIPFL purification by Strep-Tactin chromatography (S) with flow-through 
(FT), wash (W) and elution (E) fractions shown. B) Anti-Strep-tag Western blot, CtIPFL can be 




Addition of valproic acid increased soluble protein yield with optimal cell harvesting determined to be 
+4 days. HEK293F cells not transfected gave a contamination band above 51 kDa detectable by Anti-
Strep Western blot. However, the band was not present on Strep-Tactin elution of CtIPFL so was no 
longer pursued (figure 5.2.3.1-3). 
  
Figure 5.2.3.1-3: Western blot 
of CtIPFL HEK293F valproic 
acid expression test using 
Anti-Strep antibody. Samples 
corresponding to total protein 
(T) and supernatant (S) from 
clarified lysate are shown on 
the Western blot. ‘Pre’ were 
cells not transfected with the 
CtIPFL construct, the band at 




The addition of 0.5 mM TCEP on cell lysis improved solubility. Further optimisations were tested 
through small-scale analysis of valproic acid treated cells. Increasing Tris concentration to 50 mM had 
a greater yield of protein from Strep-Tactin elution with Benzonase® increasing the speed of gravity 
flow chromatography without reducing yield (figure 5.2.3.1-4).  
  
Purification optimisations were combined for a 400ml HEK293F expression test of Strep-tagged CtIPFL 
grown in the presence of 4mM valproic and harvested at +4 days. Cells were pelleted and suspended 
in lysis buffer: 50 mM Tris pH 8, 100 mM NaCl, 0.5 mM TCEP, 0.5% v/v Tween 20, 10% v/v glycerol, 2.5 
units of Benzonase® and SigmaFAST™ EDTA-Free protease inhibitors. Filtered cell lysate supernatant 
was first passed over a 1 mL Hi-Trap Strep-Tactin column, washed and the retained CtIPFL eluted. 
Fractions were analysed by SDS-PAGE and pooled accordingly; the early eluting CtIPFL was applied in 
two 500 µL applications to a Superdex 200 10/300 SEC column pre-equilibrated into buffer containing 
50 mM Tris pH 8, 300 mM NaCl, 0.5mM TCEP and 10% v/v glycerol. Eluted fractions containing CtIPFL 
as shown by SDS-PAGE were pooled and concentrated to 0.52 mg/mL 5.6 µM in 500 µL (figure 5.2.3.1-
5. 
  
Figure 5.2.3.1-4: 50 mL HEK293F CtIPFL 
expression test with valproic acid and Strep-
Tactin capture. CtIPFL was detectable by 
Coomassie Brilliant blue stain on SDS-PAGE 
analysis indicated by the arrow. Lane 2 was a 
control preparation using 20 mM Tris and 100 
mM NaCl. CtIPFL could not be detected in Strep-
Tactin elution with addition of zinc or Mung 









Figure 5.2.3.1-5: HEK293F expressed CtIPFL Purification using 
Strep-Tactin resin and SEC. A) SDS-PAGE analysis of CtIPFL 
purification by Strep-Tactin affinity chromatography (S) with 
flow-through (FT), wash (W) and elution fractions 
corresponding to the chromatogram in B. B) Chromatographic 
profile of CtIPFL elution from the Strep-Tactin column. 
Fractions highlighted in red were pooled for SEC. C) Superdex 
200 10/300 SEC of CtIPFL, two runs were performed with one 
shown. Fractions from run 1 were analysed by SDS-PAGE in D. 
D) SDS-PAGE analysis of eluted fractions from size-exclusion 
chromatography of affinity-purified CtIPFL. Pre: protein loaded 
onto the column. Fractions highlighted in red pooled and 
concentrated for analysis.  
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5.2.3.2 Dextran Blue void volume calculation for the Superdex 200 10/300 SEC column. 
CtIPFL has been shown to elute from SEC with an estimated size of 766 kDa, almost double its molecular 
weight (Davies et al., 2015). As 766 kDa is above the gel matrix exclusion limit for a Superdex 200 SEC 
column the volume of buffer surrounding the beads, termed void volume, was determined. Blue 
dextran has a weight of 2 mega Daltons so cannot flow through the gel matrix, its elution volume can 
therefore be interpreted as the void volume. Figure 5.2.3.2 shows the two SEC chromatograms 
overlaid with the blue dextran peak (7.1 mL) eluting earlier than CtIPFL (7.6 mL). Thus, showing the 
bulk of CtIPFL is flowing through the gel matrix rather than the void of the column. The CtIPFL peak is 
however broad and overlaps with blue dextran indicating there is a mixture of species with some too 






Figure 5.2.3.2: Superdex 200 10/300 SEC of CtIPFL (blue) overlaid with Dextran blue (red). Y-axis 
correspond to the two peaks and have been adjusted to show full peak comparison.   
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5.2.3.3 DNA binding  
The EMSA was further used to assess the DNA binding affinity of HEK293F expressed CtIP. A 60bp 
fluorescently-labelled dsDNA or ssDNA substrate at a final concentration of 100 nM was used with 
CtIPFL protein concentration from 5 µM to 0.31 µM.  The addition of CtIP results in formation of a slow 
migrating species representing a protein-DNA complex. Increasing concentrations shift the 





Figure 5.2.3.3-1: Binding of CtIPFL to 60 bp dsDNA 
and ssDNA by EMSA. Triangle represents 
decreasing estimated concentrations of CtIP from 
5.0 µM to 0.31 µM with 100 nM DNA. No major 
differences seen between dsDNA and ssDNA. 
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To deduce the minimum length of DNA necessary for the CtIP-DNA interaction, further EMSAs were 
performed using the same procedure with progressively shorter dsDNA substrate. Initial experiments 
showed DNA binding to 40 bp dsDNA with minimal signs of DNA binding for substrates of 20 bp dsDNA 
and below. The length of substrates was reduced by 5 bp dsDNA iteratively with similar amounts of 
binding shown from 40 bp to 25 bp dsDNA. The DNA binding of CtIP to 20 bp is greatly impaired with 
no binding at low concentrations and a large reduction at 5.0 µM. These results indicate the minimum 
length requirement of DNA for CtIP binding to be between 25 bp and 20 bp (figure 5.2.3.3-2). This is 






minimum DNA length for 
CtIPFL interaction by EMSA. 
Top panel- triangle 
represents decreasing 
estimated concentrations 
of CtIP from 5.0 µM down 
to 0.31 µM. Left to right: 
EMSAs with 60 bp, 40 bp, 
20 bp and 10 bp 
fluorescently labelled 1 µM 
dsDNA. Bottom panel – 
triangle represents 
decreasing CtIP 
concentrations from 5.0µM 
to 0.62 µM. left to right, 40 
bp, 35 bp, 30 bp, 25 bp and 
20 bp 100 nM fluorescently 
labelled dsDNA. Addition of 
CtIP results in the 
formation of a slower 






The CtIP interaction with MRN has been reported to generate a nick 5’ to the DSB on the 3’ DNA strand 
(Anand et al., 2016). To test if this nick changes the DNA binding affinity of CtIP, 60 bp substrates were 
generated with a nick or 2 bp deletion on either the 3’ or 5’ strand. No differences were seen between 
the four different substrates each producing a similar amount of slower migrating DNA-CtIP complexes 
(figure 5.2.3.3-3). Conversely, there was a greater CtIP-DNA affinity for the linear 60 bp dsDNA 








Figure 5.2.3.3-3: Interaction of CtIPFL with nicked or 2bp deleted fluorescent DNA by EMSA. 
Triangle represents decreasing estimated CtIPFL concentrations from 2.5 µM to 0.62 µM. Left to 
right: 60 bp fluorescently labelled dsDNA, 60 bp fluorescently-labelled dsDNA with 5’ strand 
nick, 5’ strand 2 bp deletion, 3’ strand nick, 3’ strand 2 bp deletion. Addition of CtIP results in 
the formation of a slower migrating species which represents protein-DNA complexes. No 
major differences were seen in relation to each different substrate over the three repeats. All 




Resection of a DNA DSB by MRN and CtIP results in a 3’ DNA tail, necessary for homology directed DSB 
repair. To test if CtIP can bind to a single stranded DNA adjacent to a double stranded DNA, four further 
DNA substrates were generated. As the minimum interaction length was determined to be around 20 
bp, two different lengths of ssDNA were generated: 24 bp and 16 bp. No differences were seen 









Figure 5.2.3.3-4: Interaction of CtIP with 5’ or 3’ ssDNA tails on fluorescent DNA by EMSA. 
Triangle represents decreasing estimated CtIP concentrations from 5.0 µM to 0.62 µM. From 
left to right: 60 bp fluorescently labelled ds DNA, 60 bp fluorescently labelled DNA: with 5’ 
strand 24 bp ssDNA, 5’ strand 16 bp ssDNA, 3’ strand 16 bp ssDNA, with 3’ strand 24 bp ssDNA. 
Substrates are represented on the right-hand side. Addition of CtIP results in the formation of a 
slower migrating species which represents protein-DNA complexes. No major differences were 
seen in relation to each different resected substrate over the three repeats. All DNA substrates 





5.2.3.4 Nuclease activity 
The nuclease activity of HEK293F-expressed CtIPFL was analysed using the protocol of Sartori et al. 
2007. Either 200 or 350 ng of twin-Strep CtIPFL expressed in HEK293F cells was incubated with the 
PhiX174 substrate with either 5mM magnesium or manganese, analysed by gel electrophoresis and 
stained with Syber™ Gold. No nuclease activity was reported with either metal with identical results 
as addition of buffer (figure 5.2.3.4). The activity of HEK293F expressed CtIP with MRN could not be 




Figure 5.2.3.4: HEK293F expressed CtIPFL 
does not have nuclease activity. 
PhiX174 DNA substrate was incubated 
with either 350 ng (++) or 200 ng (+) of 
CtIPFL in 5 mM MgCl2 or MnCl2 run on an 
agarose gel and stained with SYBR Gold. 
Nuclease control was 200 ng of 





5.2.3.5 Measuring HEK293F expressed CtIPFL stability  
HEK293F-expressed CtIPFL was observed to have a greater stability at room temperature compared to 
insect cell expressed CtIPFL protein (Data not shown). This is likely due to the differences in post 
translational modifications between the two expression systems, or the presence of contaminant 
proteases within the insect cell purification. To quantify the CtIPFL stability a thermal shift assay was 
performed with a melt curve produced and melt peak temperature of 42.5°C recorded (figure 5.2.3.5). 
The value obtained is an ensemble of CtIPFL, its degradation products, and HSP70. As heat shock 
proteins are known to have high melt temperatures and remain stable at 50° (Boswell-Casteel et al., 





Further purification optimisation was performed with each iterative preparation of CtIPFL to increase 
yields. This led to a reverse flow elution from the Strep-Tactin column and increasing the volume of 
starting cell culture.  
 
  
Figure 5.2.3.5: Thermal melt peak and melt curve for HEK293F expressed CtIPFL. From the binding 
of SYPRO® Orange to unfolded protein the fluorescence increases and is measured in relative 
fluorescence units. Two concentrations of CtIPFL were used: 8.36 µM and 4.79 µM. 
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5.2.4 Cryo-EM of HEK293F Full Length CtIP 
So far only small peptides and short domains of CtIP have been crystallised and the structure 
determined with CtIP predicted to have a large ~600 amino acid region of unstructured protein. Cryo-
EM avoids the need for protein crystals but is typically restricted to large protein domains and 
complexes (>100 kDa). The Twin-Strep tagged CtIP has a molecular weight of 106.3 kDa, however 
following the CtIP tetramerisation the complex has a mass of 425 kDa which makes it a candidate for 
Cryo-EM to elucidate the structure of the full-length protein.  
5.2.4.1 CtIPFL protein purification for Cryo-EM.  
The CtIPFL Twin-Strep construct was expressed in 800 mL of HEK293F cells, with the filtered soluble 
protein applied to a 1 mL HiTrap Strep-Tactin column in three 10 mL applications. The column was 
washed, and flow reversed with an additional wash in reverse flow before the retained Strep-tagged 
CtIPFL was eluted. The reversal of the column decreased the elution volume and increased protein 
concentration (figure 5.2.4.1). Fractions were analysed by SDS-PAGE and pooled accordingly. 500 µL 
of protein was buffer exchanged using a Nap5 column to remove glycerol, with the peak 200 µL elution 
fraction at 0.9 mg/mL or 8.46 µM (monomer). A further 500 µL was applied to a Superdex 200 10/300 
SEC column equilibrated into the standard buffer, the peak elution fraction gave a CtIPFL concentration 
of 0.24 mg/mL or 2.25µM (monomer). Both were used for preparation of Cryo-EM grids. 
All grid manipulations were performed by Dr Neil Rzechorzek. The grids used were from Batch 









Figure 5.2.4.1: HEK293F 
expressed CtIPFL Purification 
using Strep-Tactin and SEC 
for Cryo-EM. CtIP protein 
purification from 800 mL of 
HEK293F cells expressing 
Twin-Strep tagged CtIP. A) 
Chromatographic profile of 
CtIPFL elution from the 1ml 
Hi-Trap Strep-Tactin column. 
Fractions in red were pooled 
with 500 µL used for SEC in 
B, 500 µL used for Nap5 
buffer exchange with SDS-
PAGE analysis of peak elution 
shown in C. B) 
Chromatographic profile of 
CtIPFL elution from the SEC 
column. Peak fraction in cyan 
was used for Cryo-EM 
Protein highlighted in red 
was pooled for further 
analysis. Red trace is Dextran 
Blue applied to the same 
column after CtIPFL had 
eluted. This is to calculate 
the void volume of the 
column and is detailed in 
section 5.2.3.2. C) SDS-PAGE 
analysis of fractions from the 
Strep-Tactin column and SEC.  
RHS of gel shows the 
fractions used for Cryo-EM. 
Nap5 F3 was the peak 
fraction from the Nap5 
elution which was used at 





5.2.4.2 Cryo-EM Data collection 
Grids containing CtIPFL were analysed using the Titan Krios G2 Transmission Electron Microscope 
(TEM), 300 keV, at the Nano Science department, University of Cambridge. The microscope was 
prepared by Dr Dima Chirgadze with the Falcon 3 detector on integration mode and controlled by Dr 
Jamie Blaza. It was noted that many squares per grid had dark black centres, indicating a non-optimal 
glow discharge. Large areas covered in thick ice proved problematic to image. Only a selection of 
squares had optimum ice thickness for image collection (figure 5.2.4.2-1).  
  
Where imaging was possible protein appeared as dark dense with non-vitreous ice particles present 
across all micrographs. Across a series of 15 micrographs recorded 4 grid squares showed a 
recognisable structure which looked to be a filament. These filaments are shown in figure 5.2.4.2-3 
with a representative complete micrograph shown in figure 5.2.4.2-2. Since the number of filaments 
per hole and the number of holes appropriate for screening were minimal further screening with 
optimised settings will be necessary. Filaments were not present in SEC filtered protein samples, likely 




EM Atlas image from 
SEC purified protein. 
Numbers indicate 







Figure 5.2.4.2-2: CtIPFL Cryo-EM Titan Krios G2 microscope image. Representative micrograph of 
Nap5 buffer exchanged protein applied to a QuantiFoil R 1.2/1.3 Cu300 grid. Non-vitreous ice can 
be seen as large dark circles. Various other particles can be seen, some of which are likely to be 
CtIPFL protein, such as filaments with an example in a green oval. 
Figure 5.2.4.2-3: CtIPFL 
Cryo-EM, filament image 
gallery. Images span 4 
grid squares from Nap5 




5.2.4.3 CtIP Superose 6 SEC 
CtIPFL protein elutes on a Superdex 200 close to the column exclusion limit and filaments have been 
seen in Cryo-EM micrographs. To separate the CtIP species a Superose 6 Increase SEC column was 
used. This column has a separation range for globular proteins of 5 kDa to 5 MDa and therefore should 
be able to separate different oligomers of CtIP. The CtIPFL Twin-Strep construct was expressed in 800 
mL of HEK293F cells with the soluble protein filtered and applied to a 1 mL Hi-Trap Strep-Tactin column 
via Superloop. The column was washed with lysis buffer and flow reversed with an additional wash in 
reverse flow into the standard buffer (figure 5.2.4.3-1). Protein was eluted from the column with 
fractions containing CtIPFL concentrated to 10.52 mg/mL in 70 µL. 





The concentrated protein was centrifuged at 14,000 RCF 4°C with no change in concentration or 
appearance. To prepare the SEC column after equilibration sodium hydroxide was applied to clean the 
column. 60 µL of concentrated CtIPFL at 10.52 mg/mL was applied to the Superose 6 column and eluate 
fractionated in 50 µL fractions. Fractions were analysed by SDS-PAGE with 20 µL of each fraction and 
5 µL of the concentrated sample loaded; CtIPFL was detectable by Coomassie blue stain using the 
standard procedure (figure 5.2.4.3-2). 
Figure 5.2.4.3-1: Purification of CtIPFL from 800ml of HEK293F cells using Strep-Tactin resin. A) 
Chromatographic profile of CtIPFL elution from the Strep-Tactin column. Fractions indicated are 
analysed by SDS-PAGE in B. Fractions in red were pooled for concentrating down to 70 µL for SEC 
analysis. B) Initial capture of protein by Strep-Tactin (S) resin with flow-through (FT) wash (W) 






CtIPFL can be detected across all the fractions with multiple CtIP containing peaks present indicated by 
numbers (figure 5.2.4.3-2B). No separation of individual degradation products can be seen. Each of 
the peaks 3-6 contains CtIPFL and degraded protein, the co-migration of these degradation products 
shows they are forming a complex with CtIPFL. Peaks 1&2 however mainly contain CtIPFL and a sub-
stoichiometric level of Hsp70 protein. The elution point of the first two peaks indicates they are 
forming larger mega-Dalton complexes rather than the tetrameric 425 kDa CtIPFL complex. Although 
column pressure did not change over the run, washing the column with sodium hydroxide at the end 
of the experiment eluted further protein from the column. As the column was washed before the run, 
this is likely to be CtIP that could not pass through the column or bound to the Superose 6 increase 
matrix.  
  
Figure 5.2.4.3-2: Superose 6 3.2/300 
Increase SEC of CtIPFL from Strep-Tactin 
purification. Protein was initially purified 
in figure 5.2.4.3-1. A) Superose 6 3.2/300 
Increase SEC chromatogram showing 
multiple peaks. B) SDS-PAGE analysis of 
fractions indicated in A. CtIP can be seen 




5.2.4.4 Analytical ultra-Centrifugation (AUC) analysis of CtIPFL 
Analytical Ultra Centrifugation (AUC) was performed to further analyse the different forms of CtIPFL. 
This technique is one of the classical methods to characterise different aspects of proteins in solution 
including gross shape, weight and protein self-association (Brown et al., 2008; Cole et al., 2008).  
The CtIPFL Twin-Strep construct was expressed in 800 mL of HEK293F cells with the soluble protein 
filtered and applied to a 1 mL Hi-Trap Strep-Tactin column via Superloop. The column was washed, in 
both forward and reverse flow before the retained Strep-tagged was CtIPFL eluted. Fractions were 
analysed by SDS-PAGE and pooled accordingly; the CtIPFL was then dialysed overnight into the 
standard buffer (figure 5.2.4.4a/b). Three samples were analysed by AUC at 100%, 50% and 25% 
protein concentration (figure 5.2.4.4a). The data were fitted using a continuous c(S) distribution with 
a frictional ratio (f/f0) of 2.006, with various distributions of protein due to the non-homogeneous 
sample. Figure 5.2.4.4 shows the interferometry from the AUC experiment with panel D showing the 
distribution from 5S to 15S of different sedimentation values for the multimeric CtIP species. As C-
terminal degradation products of CtIP can still form a tetramer there are a large array of different 
species within the sample, therefore a fixed molecular weight could not be calculated. Peak 1 
corresponds to 45 kDa and is likely an underestimate of HSP70 present within the sample due to the 
high bulk frictional ratio and globular nature of HSP70. Peak 2 corresponds to between 200-240 kDa 
which is much larger than monomeric CtIP at 106 kDa, supporting formation of an oligomeric species 
with a distribution of degradation products. The sharp peak towards the end of the sedimentation 
coefficient graph represents larger species with sedimentation values between 20-50S. This indicates 









Figure 5.2.4.4: CtIPFL analysis 
by Analytical Ultra 
Centrifugation. CtIP protein 
purification from 800 mL of 
HEK293F cells expressing 
Twin-Strep tagged CtIP. A) 
Initial 1 mL HiTrap Strep-
Tactin capture. “S” stands for 
Strep, “FT” for flow through, 
“W” for wash. Fractions in 
red pooled for dialysis 
overnight into the standard 
buffer. 100%, 50% and 25% 
were analysed by AUC with 
dilutions made using the 
dialysis buffer. B) Strep-Tactin 
chromatogram analysed by 
SDS-PAGE in A. C) Upper 
panel: data fitted to the 
continuous distribution c(S) 
Lamm equation model. Lower 
panel: the residual overlay 
species shows the error of fit 
for each data set. 
D) The sedimentation coefficient distribution of all species up to 20S. Peak 1 corresponds to a 
weight of 45 kDa with peak 2 corresponding to between 200-240 kDa. Further species were seen 




5.3 Conclusions and future work 
In vitro biochemical studies of full length human CtIP protein have been impeded by the arduous task 
of purifying recombinant protein. First attempts to purify CtIPFL using the E. coli expression system 
gave a multitude of degradation products as shown by Western Blot analysis. CtIPFL expression has 
however been achieved in both the baculovirus and HEK293F expression systems, with CtIPFL protein 
purified to above 60% purity for biochemical analysis. Tetramerisation plays a role in the purity 
limitations, as C-terminal degradation products co-purify through the N-terminal oligomerisation. This 
has been shown by Western Blot analysis with no major difference between the two systems. Heat 
shock protein 70 (HSP70) has been shown to co-purify with CtIP at a sub-stoichiometric ratio as a 
further source of contamination. Nevertheless, the bulk purified protein has been shown to be soluble 
and non-aggregated with passage through the beads of both Superdex 200 and Superose 6 SEC 
columns. Preliminary thermal melt analysis has also determined an unfolding temperature of 42.5°C 
from the purified HEK293F protein. As heat shock proteins can be stable at above 50°C (Boswell-
Casteel et al., 2015), this indicates the presence of stable folded CtIPFL domains.  
Further analysis of CtIPFL in size determination have shown multiple species to be present. These have 
ranged from dimeric, tetrameric and further oligomeric species with evidence for filament formation 
seen in both Cryo-EM and AUC analysis. From Cryo-EM single particles are difficult to be seen, 
probably due to the predicted unstructured regions of CtIP, however filaments are reproducibly 
present within micrographs indicating a higher oligomeric state. AUC further confirms the presence of 
higher oligomers. The main bulk of protein (S5-S10) however gave a molecular weight between 200-
240 kDa. This indicates two important features: first, this is greater than a monomer or dimeric 
molecular weight and therefore oligomers are formed; second, this is lower than the expected CtIPFL 
tetrameric weight indicating that intact CtIPFL is more likely to be within the filament at higher 
sedimentation values. This is further supported by Superose 6 SEC with CtIPFL eluting earlier with 
minimal co-elution of degradation products, with composite oligomers containing CtIPFL eluting at 
various volumes. A high frictional coefficient was also determined through AUC, which is higher than 
that of the N-terminal domain alone at 1.8 (Sun, 2013), providing further evidence that CtIP has an 
elongated nature.  
Biochemical studies have revealed CtIPFL and the tetrameric mutant L27E CtIPFL can bind dsDNA, with 
a greater affinity than the CtIP C-terminal domain alone. Determination of a precise DNA binding 
affinity has yet to be achievable due to the inability to determine the absolute CtIPFL concentration. 
Future optimisations will be necessary for this to be achievable.  Further DNA binding experiments 
with CtIPFL have shown affinity to be irrespective of breaks in the phosphodiester back bone 
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juxtaposed to the 5’ or 3’ strand end or the presence of ssDNA tracks on either strand mimicking 
resected DNA. This could be accounted for by the length of the total DNA as there is still sufficient 
dsDNA for a CtIP interaction. Future work within this project would involve shorter DNA constructs to 
determine any effect of the ssDNA tails or gaps in the DNA. To confirm CtIPFL-DNA complex formation 
fluorescence polarisation (FP) could be used. The quantity of CtIPFL protein necessary for such 
experiments however is the limiting factor. Preliminary studies using the technique have shown CtIP 
to interact with the 96 well plate and therefore will require optimisation. 
Alternative methods of purification optimisation, chromatography and experimental technique will be 
necessary for absolute determination of DNA binding affinity and the different oligomeric states 
present of CtIPFL. These optimisations will also enable selective Cryo-EM of the different species. 
Future work within this area will be to apply the different fractions of CtIPFL from Superose 6 SEC and 
analyse any changes in protein seen across the elution profile. With the aim of this project area to 
determine a structure of CtIPFL by Cryo-EM. Purification of the Mre11-Rad50-Nbs1 complex has been 
successfully achieved with homogenous protein purified that possessed nuclease activity. This will 
allow for future studies between HEK293F expressed CtIPFL and the MRN complex. The overarching 
aim of this project will be to determine the structural changes brought about by different CtIP-MRN 
interactions through biophysical and structural methods. The starting building blocks for these future 
projects however have been set out within this chapter for structural analysis and conclusive 









Chapter 6: Discussion  
The studies presented in this thesis characterise structural and biophysical features of the two 
evolutionarily conserved regions (NTD and CTD) and the full-length human CtIP protein. The NTD is 
known to be required for the action of DNA-end resection, with deletion studies within the domain 
abolishing Nbs1 binding and activation of the G2/M checkpoint. However, studies of the domain have 
been limited to structural determination of the tetramerisation residues 18-52 and biophysical 
measurements (Davies et al., 2015). Here X-ray crystal structure determination of residues 31-136 
with two cysteine-to-alanine mutations has provided an insight into the domain; confirming the 
formation of an elongated parallel coiled coil by both crystallography and SEC-SAXS. My structure 
agrees with the observation that the coiled-coil domain is separated at the zinc binding site, with 
discontinuation of the coiled-coil into a pair of parallel alpha helices. As the NTD is known to 
coordinate zinc through the two cysteines, it is likely that the alanine mutations encourage the alpha 
helical formation in this region with a local change in conformation. Nevertheless, the coiled-coil is 
juxtaposed to this zinc-binding region limiting any conformational changes. SEC-SAXS measurements 
have been consistent between the wild type and double mutant proteins in agreement that any 
differences in this region are minimal. Previous models using light scattering postulated the NTD to 
form a four-helix bundle comprising two coiled-coils. However, the results presented here confirm the 
N-terminal domain forms an elongated coiled-coil. Analysis of the full-length CtIP protein by AUC 
further supports a long rod-shaped protein and an elongated structure.  
X-ray diffraction of the wild type NTD was insufficient for structure determination, but the diffraction 
pattern was suggestive of a partial fibrous nature of the crystals. Fibre formation was also seen for 
CtIP full-length protein by Cryo-EM, with large molecular weight species on AUC and Superose 6 SEC. 
However, the precise mechanisms for this filament formation and the biological relevance is unknown. 
While CtIP Is regulated by a consortium of post translational modifications, filament formation may 
show a further method to regulate the protein through storage within a higher oligomeric state. This 
would function to protect the protein from degradation and enable a fast, non-transcriptional, 
response to DNA DSBs by disassembly of the filament. 
Oligomerisation of CtIP at the NTD is well established for both human CtIP and the Sae2/Ctp1 
orthologues. While dimerisation of the CTD has been shown necessary for interaction with LMO4, 
oligomerisation of the CTD remains poorly understood. Within my thesis I have consistently shown 
the formation of a higher molecular weight species on purification of the CTD. Chromatography 
techniques have been exploited to investigate the oligomeric state of the broader C-terminal region 
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supporting the existence of a dimeric species. While secondary structure analysis of CtIP predicted a 
coiled-coil motif near the C-terminus juxtaposed to the functionally-conserved homology domain. 
SEC-SAXS scattering analysis of this region showed a rod like structure with an elongated envelope 
generated, supporting the presence of a coiled-coil upstream of the CtIP Sae2 homology domain.  
Both NTD and CTD possess zinc-binding regions, however the function of these two-separate zinc-
binding domains is unknown. Mutation of the zinc-binding motif to alanine residues is known to 
abolish zinc binding within the NTD. However, the mutation showed little change to the protein 
structure by SEC-SAXS and enabled structure determination. Conversely, mutation of a single or pair 
of cysteine residues within the CTD failed to abolish zinc binding with increased degradation products 
when 6/8 of the purported residues were mutated. The DNA binding ability of the CTD has also been 
further explored by FP. Using FP, a zinc dependency has been shown, indicating that zinc could be 
involved in structural arrangement of this domain. Conversely, zinc is dispensable for DNA binding by 
EMSA and is not required for dimer formation. Both monomer and dimer of the CtIP-CTD have shown 
a low micromolar affinity to DNA. The DNA binding ability has been translated to that of the full-length 
CtIP protein with a greater affinity for DNA than the CTD, of both tetrameric CtIP and dimeric L27E 
CtIP. This points towards further factors within CtIP increasing DNA binding at its C-termini. Both full-
length CtIP and its CTD were able to interact with the same minimal length of DNA, a value which is 
comparable to that obtained for the CtIP orthologue Ctp1 (Andres et al., 2015). Analysis of full-length 
CtIP’s ability to bind DNA showed no preference for DNA with a break in the phosphodiester backbone 
or the presence of a single stranded DNA. The observation that both monomer and dimer of the CTD 
bind DNA to a similar extent indicates only one may be interacting with DNA with the other able to 
form protein-protein interactions such as that with And1. The different interaction region presented 
here between And1 and CtIP further suggests that regions outside of the C-terminus can modulate 
the binding within the CTD which remains to be explored.  
Functionally CtIP is now well established to play a critical role in DNA DSB end resection in association 
with the MRN complex. The current MRN model supports two functionally distinct complex 
formations, one for DNA end resection and one for DNA tethering (figure 1.5.3.2-3). Substantial 
evidence supports the ability of the MRN complex to bridge DNA ends. A similar DNA bridging action 
has been reported for the CtIP orthologue Ctp1, which has been shown to bind and tether two DNA 
strands (Andres et al., 2015). Collectively the results presented here have revealed that CtIP has many 
features that would enable a similar overall architecture to MRN and Cpt1 to be achieved (figure 6). It 
is therefore proposed that alongside a potential CtIP DNA tethering structure, CtIP can synergise post 
translational modifications to change its structure resulting in different affects dependent on the 
modifications. This would enable the various modifications to change the interaction partners and 
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modulate DNA binding affinity. The findings presented within this thesis provide the foundation and 
the molecular building blocks required to determine the detailed mechanism of CtIP functioning in 
complex with MRN in DNA double strand break repair and further structural determination. 
 
Figure 6: Model of CtIP in comparison with the MRN complex. A) CtIP tetramer formation is 
mediated by a 4 helix bundle, this extends into a parallel coiled-coil domain separated into two 
sections by a zinc binding site. The crystal structures of the 18-136 region are shown above the 
schematic representation. The middle domain of CtIP is predicted to be largely unstructured 
however overall the protein forms a long structure. A further coiled-coil domain precedes the 
conserved C-terminal region which has been shown to form a dimer, likely through this coiled-coil. 
The C-terminal domain can bind DNA, zinc, and contains various interaction motifs for proteins 
such as And1 and NBS1. This domain may function as an interaction scaffold to bring about 
further proteins to the MRN-CtIP complex to elicit repair. Post translational modification sites 
such as phosphorylation may mediate changes to DNA binding, folding or protein recruitment. B) 
The structure of Mre11-Rad50 shows the DNA tethering state which through the Rad50 coiled-coil 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































7.2 Optimisation 1 
  
Supplementary figure 7.2: Optimisation 1 - 96 well condition screen. 
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7.3 Optimisation 18 NaSCN 
 
 
 Supplementary figure 7.3: Optimisation 18 - 96 well condition screen. 
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7.4 Incorporation of double alanine mutation in CTDDM 
 
Supplementary figure 7.4: MALDI analysis intact mass of CtIP-CTD vs CTDDM. Confirmation 
that the CTDDM contains two alanine substitutions. 
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Supplementary figure 7.5-1: MALDI-TOF confirmation that CtIP-CTD can exist as a dimer in 
SDS-PAGE. The same profile means that it is the same protein, consistent with band 1 being a 








Antibody Manufacturer Catalogue number Species 
Anti-Myc tag Sigma  06-549 Rabbit 
Anti-His tag Sigma  H1029 mouse 
Anti-Flag M2 
monoclonal 
Sigma  F1804 Mouse 
Anti-Strep tag II RayBiotech  168-10750 Rabbit 








Supplementary figure 7.5-2: SEC on dimer fraction shows both monomer and dimer peaks. 
Superdex 200 10/300 SEC on CTD fraction confirmed to contain monomer and dimer. Two peaks 
correspond to weights for dimer and monomer (mono) respectively. A) SEC trace, fractions 
highlighted were analysed by SDS-PAGE. B) Fraction loaded onto SEC column. C) Silver stain gel 













Supplementary figure 7.7: Sequence information for Twin-Strep tag insertion into CtIPFL. 
DNA sequence is shown with restriction sites displayed. Below is the CtIPFL open reading 
frame with protein translation and features shown. Underneath is the sequencing trace file 
confirming the sequence is correct. CtIPFL sequence was inserted into the plasmid by BamHI 
restriction insertion followed by insertion of the Twin-Strep tag by SalI restriction insertion. 
BstBI site was included for identification of tag insertion.  
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7.8 dCTD and CTDex molecular weight standards 
  
Supplementary figure 7.8: Globular molecular weight standards on 16/60 Superdex 75 SEC 
column. Protein samples dCTD, CTDex and bio-rad standards (Cat no. 1511901) were run 
sequentially on the same Superdex 75 16/60 SEC column with the same experimental setup. 
Elution Values for the standards were taken from the 280nm peaks using the Unicorn™ 
software and plotted in Excel verses their known log10 molecular weight. A straight line fit 
with equation shown was subsequently used to calculate the weight of dCTD and CTDex 
from their elution volumes to be 33.7 kDa and 92.8 kDa respectively.  
The molecular weight of dCTD is higher than expected for a dimeric species, indicating either 
formation of a higher oligomeric state or a more elongated rod shape to the protein. CTDex 
also has a higher than expected weight for a dimeric species, further indicating part of the 
protein is elongated or formation of a higher oligomeric state. 
231 
 
7.9  Morpheus® crystallisation conditions 
 ID Conc Units Salt Conc Units Buffer pH Conc Units  precipitant 
A1 0.06 M Divalents 0.1 M Buffer   1 6.5 50 % v/v   Mix 1 
A2 0.06 M Divalents 0.1 M Buffer   1 6.5 50 % v/v   Mix 2 
A3 0.06 M Divalents 0.1 M Buffer   1 6.5 50 % v/v   Mix 3 
A4 0.06 M Divalents 0.1 M Buffer   1 6.5 50 % v/v   Mix 4 
A5 0.06 M Divalents 0.1 M Buffer   2 7.5 50 % v/v   Mix 1 
A6 0.06 M Divalents 0.1 M Buffer   2 7.5 50 % v/v   Mix 2 
A7 0.06 M Divalents 0.1 M Buffer   2 7.5 50 % v/v   Mix 3 
A8 0.06 M Divalents 0.1 M Buffer   2 7.5 50 % v/v   Mix 4 
A9 0.06 M Divalents 0.1 M Buffer   3 8.5 50 % v/v   Mix 1 
A10 0.06 M Divalents 0.1 M Buffer   3 8.5 50 % v/v   Mix 2 
A11 0.06 M Divalents 0.1 M Buffer   3 8.5 50 % v/v   Mix 3 
A12 0.06 M Divalents 0.1 M Buffer   3 8.5 50 % v/v   Mix 4 
B1 0.09 M Halogens 0.1 M Buffer   1 6.5 50 % v/v   Mix 1 
B2 0.09 M Halogens 0.1 M Buffer   1 6.5 50 % v/v   Mix 2 
B3 0.09 M Halogens 0.1 M Buffer   1 6.5 50 % v/v   Mix 3 
B4 0.09 M Halogens 0.1 M Buffer   1 6.5 50 % v/v   Mix 4 
B5 0.09 M Halogens 0.1 M Buffer   2 7.5 50 % v/v   Mix 1 
B6 0.09 M Halogens 0.1 M Buffer   2 7.5 50 % v/v   Mix 2 
B7 0.09 M Halogens 0.1 M Buffer   2 7.5 50 % v/v   Mix 3 
B8 0.09 M Halogens 0.1 M Buffer   2 7.5 50 % v/v   Mix 4 
B9 0.09 M Halogens 0.1 M Buffer   3 8.5 50 % v/v   Mix 1 
B10 0.09 M Halogens 0.1 M Buffer   3 8.5 50 % v/v   Mix 2 
B11 0.09 M Halogens 0.1 M Buffer   3 8.5 50 % v/v   Mix 3 
B12 0.09 M Halogens 0.1 M Buffer   3 8.5 50 % v/v   Mix 4 
C1 0.09 M NPS 0.1 M Buffer   1 6.5 50 % v/v   Mix 1 
C2 0.09 M NPS 0.1 M Buffer   1 6.5 50 % v/v   Mix 2 
C3 0.09 M NPS 0.1 M Buffer   1 6.5 50 % v/v   Mix 3 
C4 0.09 M NPS 0.1 M Buffer   1 6.5 50 % v/v   Mix 4 
C5 0.09 M NPS 0.1 M Buffer   2 7.5 50 % v/v   Mix 1 
C6 0.09 M NPS 0.1 M Buffer   2 7.5 50 % v/v   Mix 2 
C7 0.09 M NPS 0.1 M Buffer   2 7.5 50 % v/v   Mix 3 
C8 0.09 M NPS 0.1 M Buffer   2 7.5 50 % v/v   Mix 4 
C9 0.09 M NPS 0.1 M Buffer   3 8.5 50 % v/v   Mix 1 
C10 0.09 M NPS 0.1 M Buffer   3 8.5 50 % v/v   Mix 2 
C11 0.09 M NPS 0.1 M Buffer   3 8.5 50 % v/v   Mix 3 
C12 0.09 M NPS 0.1 M Buffer   3 8.5 50 % v/v   Mix 4 
D1 0.12 M Alcohols 0.1 M Buffer   1 6.5 50 % v/v   Mix 1 
D2 0.12 M Alcohols 0.1 M Buffer   1 6.5 50 % v/v   Mix 2 
D3 0.12 M Alcohols 0.1 M Buffer   1 6.5 50 % v/v   Mix 3 
D4 0.12 M Alcohols 0.1 M Buffer   1 6.5 50 % v/v   Mix 4 
D5 0.12 M Alcohols 0.1 M Buffer   2 7.5 50 % v/v   Mix 1 
D6 0.12 M Alcohols 0.1 M Buffer   2 7.5 50 % v/v   Mix 2 
D7 0.12 M Alcohols 0.1 M Buffer   2 7.5 50 % v/v   Mix 3 
D8 0.12 M Alcohols 0.1 M Buffer   2 7.5 50 % v/v   Mix 4 
D9 0.12 M Alcohols 0.1 M Buffer   3 8.5 50 % v/v   Mix 1 
D10 0.12 M Alcohols 0.1 M Buffer   3 8.5 50 % v/v   Mix 2 
D11 0.12 M Alcohols 0.1 M Buffer   3 8.5 50 % v/v   Mix 3 
D12 0.12 M Alcohols 0.1 M Buffer   3 8.5 50 % v/v   Mix 4 
E1 0.12 M Ethylene glycols 0.1 M Buffer   1 6.5 50 % v/v   Mix 1 
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 ID Conc Units Salt Conc Units Buffer pH Conc Units  precipitant 
E2 0.12 M Ethylene glycols 0.1 M Buffer   1 6.5 50 % v/v   Mix 2 
E3 0.12 M Ethylene glycols 0.1 M Buffer   1 6.5 50 % v/v   Mix 3 
E4 0.12 M Ethylene glycols 0.1 M Buffer   1 6.5 50 % v/v   Mix 4 
E5 0.12 M Ethylene glycols 0.1 M Buffer   2 7.5 50 % v/v   Mix 1 
E6 0.12 M Ethylene glycols 0.1 M Buffer   2 7.5 50 % v/v   Mix 2 
E7 0.12 M Ethylene glycols 0.1 M Buffer   2 7.5 50 % v/v   Mix 3 
E8 0.12 M Ethylene glycols 0.1 M Buffer   2 7.5 50 % v/v   Mix 4 
E9 0.12 M Ethylene glycols 0.1 M Buffer   3 8.5 50 % v/v   Mix 1 
E10 0.12 M Ethylene glycols 0.1 M Buffer   3 8.5 50 % v/v   Mix 2 
E11 0.12 M Ethylene glycols 0.1 M Buffer   3 8.5 50 % v/v   Mix 3 
E12 0.12 M Ethylene glycols 0.1 M Buffer   3 8.5 50 % v/v   Mix 4 
F1 0.12 M Monosaccharides 0.1 M Buffer   1 6.5 50 % v/v   Mix 1 
F2 0.12 M Monosaccharides 0.1 M Buffer   1 6.5 50 % v/v   Mix 2 
F3 0.12 M Monosaccharides 0.1 M Buffer   1 6.5 50 % v/v   Mix 3 
F4 0.12 M Monosaccharides 0.1 M Buffer   1 6.5 50 % v/v   Mix 4 
F5 0.12 M Monosaccharides 0.1 M Buffer   2 7.5 50 % v/v   Mix 1 
F6 0.12 M Monosaccharides 0.1 M Buffer   2 7.5 50 % v/v   Mix 2 
F7 0.12 M Monosaccharides 0.1 M Buffer   2 7.5 50 % v/v   Mix 3 
F8 0.12 M Monosaccharides 0.1 M Buffer   2 7.5 50 % v/v   Mix 4 
F9 0.12 M Monosaccharides 0.1 M Buffer   3 8.5 50 % v/v   Mix 1 
F10 0.12 M Monosaccharides 0.1 M Buffer   3 8.5 50 % v/v   Mix 2 
F11 0.12 M Monosaccharides 0.1 M Buffer   3 8.5 50 % v/v   Mix 3 
F12 0.12 M Monosaccharides 0.1 M Buffer   3 8.5 50 % v/v   Mix 4 
G1 0.1 M Carboxylic acids 0.1 M Buffer   1 6.5 50 % v/v   Mix 1 
G2 0.1 M Carboxylic acids 0.1 M Buffer   1 6.5 50 % v/v   Mix 2 
G3 0.1 M Carboxylic acids 0.1 M Buffer   1 6.5 50 % v/v   Mix 3 
G4 0.1 M Carboxylic acids 0.1 M Buffer   1 6.5 50 % v/v   Mix 4 
G5 0.1 M Carboxylic acids 0.1 M Buffer   2 7.5 50 % v/v   Mix 1 
G6 0.1 M Carboxylic acids 0.1 M Buffer   2 7.5 50 % v/v   Mix 2 
G7 0.1 M Carboxylic acids 0.1 M Buffer   2 7.5 50 % v/v   Mix 3 
G8 0.1 M Carboxylic acids 0.1 M Buffer   2 7.5 50 % v/v   Mix 4 
G9 0.1 M Carboxylic acids 0.1 M Buffer   3 8.5 50 % v/v   Mix 1 
G10 0.1 M Carboxylic acids 0.1 M Buffer   3 8.5 50 % v/v   Mix 2 
G11 0.1 M Carboxylic acids 0.1 M Buffer   3 8.5 50 % v/v   Mix 3 
G12 0.1 M Carboxylic acids 0.1 M Buffer   3 8.5 50 % v/v   Mix 4 
H1 0.1 M Amino acids 0.1 M Buffer   1 6.5 50 % v/v   Mix 1 
H2 0.1 M Amino acids 0.1 M Buffer   1 6.5 50 % v/v   Mix 2 
H3 0.1 M Amino acids 0.1 M Buffer   1 6.5 50 % v/v   Mix 3 
H4 0.1 M Amino acids 0.1 M Buffer   1 6.5 50 % v/v   Mix 4 
H5 0.1 M Amino acids 0.1 M Buffer   2 7.5 50 % v/v   Mix 1 
H6 0.1 M Amino acids 0.1 M Buffer   2 7.5 50 % v/v   Mix 2 
H7 0.1 M Amino acids 0.1 M Buffer   2 7.5 50 % v/v   Mix 3 
H8 0.1 M Amino acids 0.1 M Buffer   2 7.5 50 % v/v   Mix 4 
H9 0.1 M Amino acids 0.1 M Buffer   3 8.5 50 % v/v   Mix 1 
H10 0.1 M Amino acids 0.1 M Buffer   3 8.5 50 % v/v   Mix 2 
H11 0.1 M Amino acids 0.1 M Buffer   3 8.5 50 % v/v   Mix 3 
H12 0.1 M Amino acids 0.1 M Buffer   3 8.5 50 % v/v   Mix 4 





‘Salt’ Composition  
Divalents  0.3M Magnesium chloride hexahydrate; 0.3M Calcium chloride 
dihydrate 
Halogens  0.3M Sodium fluoride; 0.3M Sodium bromide; 0.3M Sodium iodide 
NPS (Nitrate Phosphate 
Sulfate) 
0.3M Sodium nitrate, 0.3 Sodium phosphate dibasic, 0.3M Ammonium 
sulfate 
Alcohols  0.2M 1,6-Hexanediol; 0.2M 1-Butanol; 0.2M 1,2-Propanediol; 0.2M 2- 
Propanol; 0.2M 1,4-Butanediol; 0.2M 1,3-Propanediol 
Ethylene glycols  0.3M Diethylene glycol; 0.3M Triethylene-glycol; 0.3M Tetraethylene 
glycol; 0.3M Pentaethylene glycol 
Monosaccharides  0.2M D-Glucose; 0.2M D-Mannose; 0.2M D-Galactose; 0.2M L-Fucose; 
0.2M D-Xylose; 0.2M N-Acetyl-D-Glucosamine 
Carboxylic acids  0.2M Sodium formate; 0.2M Ammonium acetate; 0.2M Sodium citrate 
tribasic dihydrate; 0.2M Sodium potassium tartrate tetrahydrate; 0.2M 
Sodium oxamate 
Amino acids  0.2M L-Na-Glutamate; 0.2M Alanine (racemic); 0.2M Glycine; 0.2M 
Lysine HCl (racemic); 0.2M Serine (racemic) 
Supplementary figure 7.8-2: Mixes of additives in Morpheus® commercial screen. 
 
Mix name  Conc. pH @ 20C Composition 
Buffer System 1 1.0 M 6.5 Imidazole; MES 
monohydrate (acid) 
Buffer System 2 1.0 M 7.5 Sodium HEPES; MOPS 
(acid) 
Buffer System 3 1.0 M 8.5 Tris (base); BICINE 
Supplementary figure 7.8-3: Buffer systems in Morpheus® commercial screen 
 
Mix name Composition 
Precipitant Mix 1 40% v/v PEG 500* MME; 20 % w/v PEG 20000 
Precipitant Mix 2 40% v/v Ethylene glycol; 20 % w/v PEG 8000 
Precipitant Mix 3 40% v/v Glycerol; 20% w/v PEG 4000 
Precipitant Mix 4 25% v/v MPD; 25% PEG 1000; 25% w/v PEG 3350 








Appendix 2, Primers  
N-terminal domain 
Residue Primer Enzyme 
Fwd CtIP 1 CATGCCATGGC AACATCTCGGGAAGCAGCTG NcoI 
Fwd CtIP 28 CATGCCATGGGCAAAGAATGTCATGATAGAGAAGTACAA NcoI 
Fwd CtIP 29 CATGCCATGGGCGAATGTCATGATAGAGAAGTACAAGG NcoI 
Fwd CtIP 30 CATGCCATGGGCTGTCATGATAGAGAAGTACAAGGTTTAC NcoI 
Fwd CtIP 31 CATGCCATGGGCCATGATAGAGAAGTACAAGGTTTACAAG NcoI 
Fwd CtIP 32 CATGCCATGGGCGATAGAGAAGTACAAGGTTTACAAGTAAAA
G 
NcoI 
Fwd CtIP 33  CATGCCATGGGCAGAGAAGTACAAGGTTTACAAGTAAAAGT NcoI 
Fwd CtIP 34 CATGCCATGGGCGAAGTACAAGGTTTACAAGTAAAAGTAACC NcoI 
Fwd CtIP 35 CATGCCATGGGCGTACAAGGTTTACAAGTAAAAGTAACCAAGC NcoI 
Fwd CtIP 36 CATGCCATGGGCCAAGGTTTACAAGTAAAAGTAACCAAGCTAA
AAC 
NcoI 
Fwd CtIP 37 CATGCCATGGGCGGTTTACAAGTAAAAGTAACCAAGCTAAAAC
AG 
NcoI 
Fwd CtIP 38 CATGCCATGGGCTTACAAGTAAAAGTAACCAAGCTAAAACAGG
A 
NcoI 






Fwd CtIP 93 CATGCCATGGGCGCAGTAACTGAAGAACATATGC NcoI 
Rev CtIP 145 CGCTCGAGCTAATCATTCTCAATTTTCTGCTG XhoI 






N-terminal domain mutation primers  
Mutation Primer 
Cluster 1 KKQ Fwd GAACATATGCGGGCCGCAGCGCAAGAGTTTGA 
Cluster 1 KKQ Rev CTGAAGAACATATGCGGGCCGCAGCGCAAGAGTTTGAAAATATCC 
Cluster 2 KQE Fwd TTACAAGTAAAAGTAACCAAGCTAGCAGCGGCCCGAATCTTAGAT 
GCACAAA 
Cluster 2 KQE Rev GTAACCAAGCTAGCAGCGGCCCGAATCTTAGATG 
Cluster 3 EQK Fwd GAATACTCTACAGGCCGCGAATGCAAAGCTTTCTG 





C-terminal domain  
Primer Sequence Enzyme 
Fwd CtIP 694 CTAGTACCATGGGCTTGGTTAGTGAAACCGTTC NcoI 









C-terminal domain mutation primers  









































































Sequencing Primers  
Primer Sequence 
CtIP internal 1 TTCTAGTAGCTGACACTTATGACCAAAG 
CtIP internal 2 CTCCCTTCTGCTCTTGTTTC 
MalE  GGTCGTCAGACTGTCGATGAAGCC 
T7 terminator GCTAGTTATTGCTCAGCGG 
SV40 Rev CCTCTACAAATGTGGTATGG 
PolH Fwd AAATGATAACCATCTCGC 








Appendix 3, Construct abbreviations 
CtIP N-terminal domain 
CtIP residues 1-897 CtIPFL 
CtIP residues 1-897 L27E CtIPL27E 
CtIP residues 1-145 NTD1-145 
CtIP residues 18-145 NTD18-145 
CtIP residues 18-145 N-terminal MBP fusion MBP-NTD18-145 
CtIP residues 28-145 NTD28-145 
CtIP residues 29-145 NTD29-145 
CtIP residues 30-145 NTD30-145 
CtIP residues 31-145 NTD31-145 
CtIP residues 32-145 NTD32-145 
CtIP residues 33-145 NTD33-145 
CtIP residues 34-145 NTD34-145 
CtIP residues 35-145 NTD35-145 
CtIP residues 36-145 NTD36-145 
CtIP residues 37-145 NTD37-145 
CtIP residues 38-145 NTD38-145 
CtIP residues 28-145 C-terminal Strep tag NTD28-145-Strep 
CtIP residues 29-145 C-terminal Strep tag NTD29-145-Strep 
CtIP residues 30-145 C-terminal Strep tag NTD30-145-Strep 
CtIP residues 31-145 C-terminal Strep tag NTD31-145-Strep 
CtIP residues 32-145 C-terminal Strep tag NTD32-145-Strep 
CtIP residues 33-145 C-terminal Strep tag NTD33-145-Strep 
CtIP residues 34-145 C-terminal Strep tag NTD34-145-Strep 
CtIP residues 35-145 C-terminal Strep tag NTD35-145-Strep 
CtIP residues 36-145 C-terminal Strep tag NTD36-145-Strep 
CtIP residues 37-145 C-terminal Strep tag NTD37-145-Strep 
CtIP residues 38-145 C-terminal Strep tag NTD38-145-Strep 
CtIP residues 30-145 N-terminal MBP fusion C-
terminal Strep tag 
MBP-NTD30-145-Strep 
CtIP residues 31-145 C89A C92A C-terminal 
strep tag 
NTD31-145DM-Strep 
CtIP residues 31-145 K107A K108A Q109A - 
Cluster 1 - C-terminal strep tag 
NTD31-145C1-Strep  
CtIP residues 31-145 K52A Q53A E54A - Cluster 
2 - C-terminal strep tag 
NTD31-145C2-Strep 
CtIP residues 31-145 E135A Q136A K138A - 
Cluster 3 - C-terminal strep tag 
NTD31-145C3-Strep  
CtIP residues 31-88 C-terminal strep tag NTD31-88-Strep 





CtIP C-terminal domain  
CtIP residues 769-897 CtIP-CTD 
MBP fused CtIP residues 769-897 MBP-CTD 
CtIP residues 694-775 dCTD 
CtIP residues 694-897 CTDex 
CtIP residues 769-897 C813A C816A CTDDM 
CtIP residues 769-897 H795A CTDH795A 
CtIP residues 769-897 H811A CTDH811A 
CtIP residues 769-897 C813A CTDC813A 
CtIP residues 769-897 C816A CTDC816A 
CtIP residues 769-897 C835A CTDC835A 
CtIP residues 769-897 H383A CTDH383A 
CtIP residues 769-897 C862A CTDC862A 
CtIP residues 769-897 C875A CTDC875A 
CtIP residues 769-897 H795A, H811A, C835A, 
H838A, C862A, C875A 
CTDABC 
CtIP residues 769-897 T847E CTDT847E 
 
And1  
And1 residues 1-1129 And1FL 
And1 residues 826-1129 And1826-1129 
And1 residues 316-1129 And1316-1129 
And1 residues 1-316 And11-316 
And1 residues 1-826 And11-826 
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